Micrornas and methods of their use

ABSTRACT

Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5′-end and/or 3′-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the divisional of U.S. patent application Ser. No. 16/082,852, filed Sep. 6, 2018, which is the § 371 U.S. National Stage of International Application No. PCT/US2017/021178, filed Mar. 7, 2017, which was published in English under PCT Article 21(2), which in turn claims the benefit of U.S. Provisional Application No. 62/304,844, filed Mar. 7, 2016, which is incorporated herein by reference in its entirety.

FIELD

This disclosure relates to treatment and/or diagnosis of cancer, particularly methods utilizing microRNAs.

SEQUENCE LISTING INCORPORATION BY REFERENCE

The Sequence Listing is submitted as an XML file in the form of the file named “4239-96229-08_Sequence_Listing” (940,718 bytes), which was created on Apr. 14, 2023, which is incorporated by reference herein.

BACKGROUND

Deregulation of microRNA (miR) expression has emerged as a potentially important contributory driver of aberrantly expressed mRNAs that mediate the complex malignant phenotypes of cancers (Stahlhut and Slack, Genome Med. 5:111, 2013). It is less clear which miRs co-regulate critical mRNA targets within diverse pathways and gene programs that coordinate the malignant phenotype. Since a single miR may simultaneously target multiple mRNAs, miR-based therapeutics may help mitigate intrinsic or acquired resistance observed using more selective small molecule or biologic therapies targeting a single oncogene or pathway in cancer.

SUMMARY

Disclosed herein are miRNAs that have increased or decreased expression in cancers. The disclosed miRNAs or mimics and/or mimetics thereof can be utilized in methods of treating and/or diagnosing a subject with cancer (such as a malignant tumor).

Disclosed herein are methods of treating a subject with cancer. The methods include administering to a subject one or more miRNA nucleic acids (or mimics or mimetics thereof) with altered expression in a tumor. In some examples, the methods include administering to a subject with cancer an effective amount of an miR-30 nucleic acid, an miR-26a-5p nucleic acid, an miR-26b-5p nucleic acid, an miR-145-5p nucleic acid, an miR-338-3p nucleic acid, an miR-375 nucleic acid, an miR-29 nucleic acid, an miR-27 nucleic acid, an miR-101 nucleic acid, a mimic or mimetic thereof, an miR complementary to any one of miR-30, miR-26a-5p, miR-26b-5p, miR145-5p, miR-338-3p, miR-375, or a combination of any two or more thereof. In particular examples, the subject has a squamous cell carcinoma, such as head and neck squamous cell carcinoma (HNSCC). In additional examples, the methods include administering to the subject an effective amount of at least one of the miRNA nucleic acids listed in any one of Table 1, Table 3, Table 4, Table 5, Table 18, Table 20, Table 21, and Table 23, a mimic or mimetic thereof, a complementary oligonucleotide, or a combination of any two or more thereof. In some examples, the miRNA nucleic acids are administered as duplex miRNA nucleic acids and/or are included in a vector. In some examples, the miRNA nucleic acid and/or mimic or mimetic thereof decreases expression of one or more mRNAs listed in Tables 6 to 14.

Also disclosed herein are compositions including one or more miRNA nucleic acids, such as at least one of the miRNAs listed in any one of Table 1, Table 3, Table 4, Table 5, Table 18, Table 20, Table 21, and Table 23. In some examples, the miRNA nucleic acids are modified miRNAs, for example, an miRNA nucleic acid including one or more sequence modifications, modified nucleotides, and/or a 5′-end and/or 3′-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid, including, but not limited to the modified miRNAs provided herein as SEQ ID NOs: 37-61. In other examples, the modified miRNA nucleic acid includes the miRNA nucleic acids provided herein as SEQ ID NOs: 62-67. In still further examples, the modified miRNA nucleic acid includes the miRNA nucleic acids provided herein as SEQ ID NOs: 73-158. In some examples, the miRNA nucleic acids include duplex miRNA nucleic acids and/or are included in a vector.

Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs listed in any one of Tables 1, 3, 4, 5, 18, and 20 in a sample from the subject and comparing the expression in the sample from the subject to a control. In some examples, an altered amount of miRNA expression compared to the control indicates that the subject has a tumor. In some examples, the methods include detecting expression of one or more of an miR-30 nucleic acid, an miR-26a-5p nucleic acid, an miR-26b-5p nucleic acid, an miR-145-5p nucleic acid, an miR-338-3p nucleic acid, or an miR-375 nucleic acid and determining that the subject has a tumor (including, but not limited to, a squamous cell carcinoma tumor) if expression of one or more of the miRNAs is decreased compared to the control. In some embodiments, the methods further include administering one or more miRNA nucleic acids to the subject, such as one or more of an miR-30 nucleic acid, an miR-26a-5p nucleic acid, an miR-26b-5p nucleic acid, an miR-145-5p nucleic acid, an miR-338-3p nucleic acid, an miR-375 nucleic acid, or a mimic or mimetic thereof.

The foregoing and other features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram showing exemplary methods for screening and validation of miR-30 expression and function in HNSCC.

FIGS. 2A and 2B are a pair of graphs showing 33 miRNAs that were identified as differentially expressed by SAMseq in both TCGA (FIG. 2A) and USMC (FIG. 2B) HNSCC tumor cohorts when compared with mucosa controls. For each, left: fold-change of median expression between tumor and mucosa, presented by linear scale. Right: box and whisker plot of median expression distribution of mucosa and tumor as log 10 RPM. Medians are represented by thick black lines in the middle, bars represent 25^(th) and 75^(th) percentile, and outliers are displayed as individual points. FDR≤0.05.

FIGS. 2C and 2D are a pair of graphs showing decreased expression of nine miRNAs in TCGA (FIG. 2C) and UMSC (FIG. 2D) HNSCC cohorts. Fold-change of median expression between tumor and mucosa controls is displayed on the left of each graph. Box and whisker plots of median expression distribution of mucosa and tumor are presented on the right of each graph as log₁₀ RPM (reads per million base pairs). Medians are represented by the thick black lines in the middle, bars represent 25^(th) and 75^(th) percentile, outliers are displayed as individual points.

FIGS. 3A-3D are a series of graphs showing the effect of miRNAs with decreased expression on HNSCC proliferation. MicroRNAs displayed anti-proliferative activity in an in vitro genome wide RNAi screening in the HNSCC cell line UM-SCC-1. Scatter plots display differentially expressed microRNAs (log₂ tumor vs. mucosa in y axis) vs. statistical distribution for proliferation score (Median Absolute Deviation (MAD)) using TCGA (FIG. 3A) and UMSC (FIG. 3B) expression data. The box in the lower left portion of the plot denotes microRNA expression ratios (y axis) that are repressed with anti-proliferative activity in RNAi screening (x axis). miR-30-5p family members are marked in red. FIG. 3C is a graph showing anti-proliferative of miRNA mimics 96 hours after transfection in UM-SCC-1, presented as percentage of miRNA mimic control. FIG. 3D shows expression of hsa-miR-30-5p family members in mucosa and tumor specimens from the TCGA cohort. Bars represent SEM and * denotes (q<0.2 samseq tools). miR-30a-5p and miR-30e-5p are the highest expressed family members in mucosa specimens and display the greatest reduction in tumor specimens.

FIG. 4 is a series of panels showing expression of miR-30a-5p (log₁₀ RPM, x axis) vs. mRNA expression (log₁₀ RSEM (RNA-Seq by Expectation Maximization), y axis) from the HNSCC TCGA dataset, and filtered for mRNAs containing predicted miR-30 binding sites. Linear regression scatterplots are presented for the indicated mRNAs with p values.

FIG. 5 is a pair of graphs showing qRT-PCR measurement of selected miR-30 target genes in UM-SCC-46 cells transfected with miR negative control (neg Con), miR-30a, or anti-miR-30a control oligonucleotide for 72 hr. All data represent the mean of three independent experiments and error bars represent SEM. *p-value<0.05 by student's T-test.

FIGS. 6A-6E are a series of panels showing validation of miR-30a predicted targets in HNSCC cell lines. FIG. 6A shows base pairing of miR-30a (SEQ ID NO: 1) with 3′ UTR of target mRNAs EGFR (SEQ ID NO: 68), IGFIR (SEQ ID NO: 69), MET (SEQ ID NO: 70), and IRS-1 (SEQ ID NO: 71), predicted by Mfold (available on the World Wide Web at unafold.rna.albany.edu/?q=mfold). Bases in red depict binding of seed sequence. Underlined bases in mRNA were deleted in mutant 3′ UTR control reporters. FIG. 6B shows relative luciferase activity measured 48 hours after co-transfection of UM-SCC-46 cells with miR30a or anti-30a and vector containing wild type 3′ UTR (left) or mutant 3′ UTR (right) cloned behind a Renilla luciferase gene. A positive control vector (Pos Con) containing 5×miR-30 binding sites and a negative GAPDH 3′ UTR control are also displayed. All data represent the mean of three independent experiments and error bars represent SEM. (*) Denotes p-value<0.05 by student's T-test. FIGS. 6C and 6D are images of Western blots showing expression of miR-30 targets (FIG. 6C) and phosphorylation of downstream signaling molecules (FIG. 6D) using whole cell lysates from human oral keratinocytes (HOK) or UM-SCC-46 cells 72 hours after transfection with miR-30a, anti-30a, or negative control miR (NC) oligonucleotides. FIG. 6E is a graph showing protein levels of miR-30-5p targets analyzed from triplicate experiments.

FIGS. 7A-7I are a series of panels showing effect of a miR-30a mimic on HNSCC cell proliferation, colony formation, cisplatin sensitivity, and cell viability. FIG. 7A is a graph showing proliferation measured by XTT assay in 6 replicates at day 5 following transfection with control (NC) or miR-30a mimic across primary human oral keratinocytes (HOK) and ten HNSCC cell lines. FIG. 7B is a graph showing basal level of miR-30a expression measured by qRT-PCR in HOK cells and ten HNSCC cell line when in log growth phase. The relative miR-30a expression level was normalized to the mean expression of the cell lines.

FIG. 7C is a graph showing colony formation assay of UM-SCC-46 cells following 48 h transfection with miR-30a or anti-miR30a oligonucleotides. Colonies were counted in three wells and repeated in three independent experiments. FIG. 7D is a graph showing UM-SCC-46 cells transfected with miR-30a-5p mimic for 48 hrs, and treated with 2 μM cisplatin for 3 h and then washed. Cell density was measured by XTT assay 72 h after cisplatin treatment. The mean of at least three experiments ±SEM, * denotes p<0.05 by a Student's t-test.

FIG. 7E is a graph of colony formation UM-SCC-46 cells following 48 hours transfection with miR30a and anti-miR-30a oligonucleotides. Colonies were counted in three wells and repeated in three independent experiments. FIG. 7F is a graph showing cell density of UM-SCC-46 cells transfected with miR-30a mimic for 48 hours and treated with 2 μM cisplatin for three hours and then washed away. Cell density was measured by XTT assay 72 hours after cisplatin treatment. All data represents the mean of at least three experiments and error bars represent SEM. FIG. 7G is a graph showing cell viability of UM-SCC-46 cells transfected with control (Neg con), miR-30a, or anti-miR-30a duplex. *p-value<0.05 by student's T-test.

FIG. 7H is a digital image showing representative images of colony formation assays with control, miR-30a-5p, or anti-30a transfections. FIG. 7I is a pair of graphs showing proliferation in UM-SCC-46 cells by an XTT assay in 6 replicates at days 0, 1, 3 and 5 following transfection with control, miR-30a-5p, or its anti-miR, or in combination with cisplatin treatment at the IC50 dose.

FIGS. 8A-8D are a series of panels showing effect of miR-30a on HNSCC cell motility and invasiveness. UM-SCC-1 (left) and UM-SCC-6 cells (right) were transfected with miR-30a or anti-miR oligonucleotides for 48 hours before wound creation. Cell migration was followed until wound closure in controls. Representative light microscopy images (100×) for wound healing are presented (FIG. 8A). UM-SCC-1, left, time 0; right, time 20 hr. UM-SCC-6, left, time 0; right, time 60 hr. Cell migration over time was quantified (FIG. 8B). FIG. 8C is representative light microscopy images of invasion membranes (100×) for UM-SCC-1. FIG. 8D is a graph of relative quantitation of invading cells for UM-SCC-1 (left) and UM-SCC-46 (right). All data represents the mean of at least three experiments and error bars represent SEM. (*) Denotes p-value<0.05 by student's T-test.

FIGS. 9A-9E are a series of panels showing effect of miR-30a-5p mimic on in vivo HNSCC xenograft tumors. FIG. 9A is a series of images of tumors and organs from athymic nu/nu female mice intramuscularly injected with UM-SCC-46 cells. The tumors were grown to ˜300 mm³, then the mice were injected intravenously (IV) with 100 μg (˜5 mg/kg) of complexed FITC-labeled control oligonucleotide or control vehicle. 24 hours after injection, mice were sacrificed for tumor and organ harvest. FIG. 9B is a graph of tumor growth in mice bearing UM-SCC-46 xenograft tumors ˜150 mm³ injected IV with nine doses of 60 μg (˜3 mg/kg) of complexed miR-30a mimic packaged in nanoparticles (miR-30a-scL) or control on Monday, Wednesday, and Friday (MWF) for 3 weeks. The graph displays mean tumor volume for each group and error bars represent SEM. Representative images of tumor size at the end of treatment on day 24 are shown in FIG. 9C for a control and miR-30a-scL treated mouse (top) and mouse weight during treatment (bottom). FIG. 9D shows Kaplan-Meier survival analysis between mice treated with control or miR-30a-scL. FIG. 9E shows mean tumor volume in mice with HPV+UM-SCC-47 xenograft tumors grown to ˜150 mm³, and injected IV with four doses of 60 μg miR-30a-scL or control on MWF schedule. 24 hours after the last treatment, mice were sacrificed and tumor tissue collected for molecular analysis. Error bars represent SEM, and (*) Denotes p-value<0.05 by student's T-test.

FIG. 10A is a graph showing quantitative real-time PCR of miR-30a-5p target mRNAs in mice implanted with UM-SCC-46 xenograft tumors and injected i.v. with four doses of 60 μg of control miR-ScL or miR-30a-ScL on MWF schedule. Data represent the mean of 3 animals, error bars represent SEM, and (*) denotes p-value<0.05 by student's T-test.

FIG. 10B is a series of digital images showing immunofluorescent staining of EGFR and MET in frozen sections harvested from xenograft tumors after control miR-scL or miR-30a-scL treatment. Scale bars, 20 μm. FIG. 10C is a pair of graphs showing mean florescence intensity quantified from six independent 40×fields in UM-SCC-46 (left) and UM-SCC-47 (right) cells. Error bars represent ±SEM, (*) denotes p<0.05 by a student's t-test.

FIG. 10D is a pathway diagram connecting miR30 targeted molecules with reported interactions and function in relation to proliferation and migration by Ingenuity Pathway Analysis. Molecules shown in red are miR-30a-5p target genes with inverse relationship to miR-30a expression. Molecules shown in blue are those exhibiting binding or signaling interactions connecting with the molecules in red.

FIG. 10E is representative digital images and quantification of UM-SCC-46 xenograft tumors stained for Ki-67 by immunohistochemistry. Values represent mean intensity quantified from six independent 20×fields and error bars represent ±SEM, (*) denotes p<0.05 by a student's t-test. FIG. 10F shows representative images of UM-SCC-47 xenograft tumors stained by immunofluorescence for miR-30 target genes EGFR or MET.

FIGS. 11A-11F are a series of panels showing association of copy number variation (CNV), methylation, and expression of miR-30 family members with HNSCC clinical features. FIGS. 11A and 11B are Interactive Genome Viewer (IGV, Broad Institute) plots displaying frequency of homozygous and heterozygous deletions on chromosome locations that overlap with MIR30A/C2 (FIG. 11A) and MIR30E/C1 (FIG. 11B) genes. Blue represents reduced copy number and red represents increased copy number. Samples are ordered based on values for CNV. FIGS. 11C and 11D show HNSCC samples from TCGA (n=260) displayed in columns and sorted by DNA methylation of miR30A promoter (FIG. 11C) or CNV or miR30E (FIG. 11D). Clinical features (colored bars, top four rows) and genetic characteristics (heat maps, bottom three rows) are assorted accordingly. A significant correlation between CNV and expression of miR-30e-5p (FIG. 11E) and methylation and low expression of miR-30a-5p (FIG. 11F) was observed. Low expression of miR-30a-5p was significantly correlated with tumors occurring in the oral cavity, and low expression of miR-30e-5p was significantly correlated with HPV negative tumors occurring in the larynx.

FIGS. 11G and 11H are a pair of graphs showing survival analysis for miR-30a-5p (FIG. 11G) and miR-30e-5p (FIG. 11H) segregated into high and low by median expression. Kaplan-Meier plots and log rank test p-values comparing disease specific survival.

FIGS. 12A and 12B are a series of Kaplan-Meier survival plots showing lower expression of miR-30e correlated with lower overall survival (FIG. 12A, left), CNV loss of the MIR30E loci correlated with lower overall survival (FIG. 12A, middle), and survival analysis for tumors expressing low or high levels of miR-30e-5p occurring in oropharynx revealed a survival difference, whereby high expression of miR-30e-5p predicted better prognosis (FIG. 12A, right) and lower expression of miR-26a-5p (FIG. 12B, top) and miR-26b-5p (FIG. 12B, bottom) correlated with lower overall survival.

FIG. 13 is a graph showing cell viability of non-HNSCC cancer cell lines transfected with miR-30a, measured by XTT assay. Data represent mean of 6 replicates and error bars represent SEM. *, p<0.05

FIGS. 14A-14B are a series of panels showing effect of a modified miR-30a oligonucleotide on a UMSCC-46 xenograft model. FIG. 14A shows tumor growth in control mice, mice treated with radiation therapy (RT), mice treated with miR-30a-scl, and mice treated with miR-30a-006-scl and radiation therapy (M006-scl+RT). FIG. 14B is a Kaplan-Meier survival plot in control, radiation treated (RT), M-miR-006 (M-006), M-006 plus radiation, and cisplatin treated mice.

FIG. 15 is a graph showing the effect of an miR combination treatment on cell density of the indicated cell lines. The cells were transfected with a combination of miR-30a-014 (G11+P12 stands), miR-145, miR-26a, and miR-375. Data represent the mean of 6 replicates, and error bars represent SD.

FIGS. 16A-16D are graphs showing the effect of individual miRNAs or pairs of miRNAs on cell density of UM-SCC108 cells (FIG. 16A), UM-SCC-22B cells (FIG. 16B), UM-SCC-47 cells (FIG. 16C), and UM-SCC-1G cells (FIG. 16D). NT, non-transfected; NC, negative control; 145, miR-145-5p; 375, miR-375; m16, M-miR30a-016; 26a, miR-26a-5p; 30a, miR-30a-5p.

FIGS. 17A and 17B are graphs showing cell viability in UM-SCC-1 (FIG. 17A) or UM-SCC-46 (FIG. 17B) cells transfected with miR-27-5p or miR-26b-1-5p duplexes. Data represent the mean of six replicates. Error bars represent SEM. *p<0.05 by student's T test.

FIG. 18 is a series of digital images showing stability of miR-30a and modified mimics (M-006, M-018, and M-019) in serum over the course of 48 hours.

FIG. 19 is a graph showing the effect of miRNA pairs on cell density of UM-SCC-46 cells. NT, non-transfected; NC, negative control; miRNA pairs are as shown in Tables 19 and 22. Error bars represent SD.

SEQUENCE LISTING

Any nucleic acid and amino acid sequences listed herein or in the accompanying Sequence Listing are shown using standard letter abbreviations for nucleotide bases and amino acids, as defined in 37 C.F.R. § 1.822. In at least some cases, only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.

-   -   SEQ ID NOs: 1-36 are the nucleotide sequences of exemplary         mature miRNAs.     -   SEQ ID NOs: 37-53 are modified miR-30a guide strand nucleotide         sequences.     -   SEQ ID NOs: 54-61 are modified miR-30a passenger strand         nucleotide sequences.     -   SEQ ID NOs: 62 and 63 are modified miR-375 guide and passenger         strands, respectively.     -   SEQ ID NOs: 64 and 65 are modified miR-26a-5p guide and         passenger strands, respectively.     -   SEQ ID NOs: 66 and 67 are modified miR-145-5p guide and         passenger strands, respectively.     -   SEQ ID NO: 68 is an epidermal growth factor receptor (EGFR) 3′         untranslated region (UTR) nucleotide sequence.     -   SEQ ID NO: 69 is an insulin growth factor-1 receptor (IGFR1) 3′         UTR nucleotide sequence.     -   SEQ ID NO: 70 is a MET 3′ UTR nucleotide sequence.     -   SEQ ID NO: 71 is an insulin receptor substrate 1 (IRS-1) 3′ UTR         nucleotide sequence.     -   SEQ ID NO: 72 is an exemplary miR-30a passenger strand         nucleotide sequence.     -   SEQ ID NOs: 73-92 are additional exemplary modified miR-30a         guide and passenger strands.     -   SEQ ID NOs: 93-104 are additional exemplary modified miR-375         guide and passenger strands.     -   SEQ ID NOs: 105-115 are additional exemplary modified miR-26         guide and passenger strands.     -   SEQ ID NOs: 116-125 are additional exemplary modified miR-145-5p         guide and passenger strands.     -   SEQ ID NOs: 126-135 are additional exemplary modified miR-101         guide and passenger strands.     -   SEQ ID NOs: 136-146 are additional exemplary modified miR-29         guide and passenger strands.     -   SEQ ID NOs: 147-158 are additional exemplary modified miR-27         guide and passenger strands.

DETAILED DESCRIPTION

Genome-wide expression profiling studies have demonstrated broad deregulation and heterogeneity in mRNA and miR expression in primary tumors and cell lines. This underscores the complexity and challenge in identifying miRs and mRNAs of critical importance in the malignant phenotype and therapeutic resistance, from among hundreds of candidates. However, until the recent publication of the head and neck and pan-cancer analyses from The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas Network Nature 517:576-582, 2015; Hoadley et al., Cell 158:929-944, 2014), comprehensive data from multiple platforms has not been available from such a large dataset to compare and identify the most significantly altered miRs, inversely expressed mRNAs, and contribution of genomic alterations driving their expression.

Alternatively, functional screens employing miR libraries have identified miRs contributing to different features of the malignant phenotype in HNSCC (Lindenbergh-van der Plas et al., Clin. Cancer Res. 19:5647-5657, 2013). However, prioritization has been difficult and many candidate miRs identified by expression profiling of tumors or in vitro screens often do not translate to therapeutic activity in vivo. Thus far, few tumor suppressive miRs driven by genetic and epigenetic alterations have been identified through integrated genomic and functional analyses. Even fewer miRs have been shown to regulate diverse mRNA programs, and implicated in the malignant phenotype, clinical features, or therapeutic resistance of HNSCC.

Disclosed herein are miRs that can be utilized to treat or inhibit cancer (for example, cancer where expression of one or more miRNAs is altered) and/or for diagnosis of cancer in a subject. To identify miRs of potential regulatory, biologic, and/or therapeutic importance in cancer, the inventors employed an integrated approach that combined structural and functional genomic analyses. The inventors compared analysis of expression of miRs and inversely correlated mRNAs from TCGA and a validation data set of HNSCC tumors, with functional screening for anti-proliferative miRs in vitro. Integration of data from TCGA from 279 HNSCC tumor specimens and the functional screen of a 781 miR library uncovered nine under-expressed and inhibitory miRs, of which four were members of the miR-30-5p family. In particular, the inventors determined that decreased miR-30a expression is inversely related to overexpression of a program of growth factor receptor, signaling and metastatic mRNAs implicated in the biology and clinical features of HNSCC. As disclosed herein, the role of miR-30-5p in tumor suppression was confirmed in regulation of several classical oncogenes centering on growth factor receptor tyrosine kinases, signaling, and metastasis. Finally, disclosed herein are synthetic miR-30a-5p mimic formulations which can delay tumor growth when delivered in xenograft tumor models of HNSCC.

I. Abbreviations

-   -   CNV copy number variation     -   HNSCC head and neck squamous cell carcinoma     -   miRNA or miR microRNA     -   RPM reads per million base pairs     -   RSEM RNA-Seq by Expectation Maximization     -   SCC squamous cell carcinoma     -   TCGA The Cancer Genome Atlas     -   XTT sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis         (4-methoxy-6-nitro) benzene sulfonic acid hydrate

II Terms

Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes VII, published by Oxford University Press, 2000 (ISBN 019879276X); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Publishers, 1994 (ISBN 0632021829); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by Wiley, John & Sons, Inc., 1995 (ISBN 0471186341); and other similar references.

As used herein, the singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Also, as used herein, the term “comprises” means “includes.” Hence “comprising A or B” means including A, B, or A and B. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including explanations of terms, will control. The materials, methods and examples are illustrative only and not intended to be limiting.

In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:

-   -   Altered expression: An alteration in expression of a miR nucleic         acid refers to a change or difference, such as an increase or         decrease, in the level of the miR nucleic acid that is         detectable in a biological sample, for example relative to a         control. An “alteration” in expression includes an increase in         expression (up-regulation) or a decrease in expression         (down-regulation). In some examples, the difference is relative         to a control or reference value, such as an amount of microRNA         expression in a sample from a healthy control subject or a         population of healthy control subjects.     -   Cancer: A malignant neoplasm (e.g., a tumor) that has undergone         characteristic anaplasia with loss of differentiation, increased         rate of growth, invasion of surrounding tissue, and is capable         of metastasis. Metastatic cancer is a cancer at one or more         sites in the body other than the site of origin of the original         (primary) cancer from which the metastatic cancer is derived. In         some examples, cancer is a condition in which expression of one         or more miRNAs is altered (for example, increased or decreased)         in the neoplasm, compared to normal or healthy tissue of the         same tissue type. Exemplary cancers include but are not limited         to squamous cell carcinomas (such as HNSCC).     -   Control: A “control” refers to a sample or standard used for         comparison with a test sample, such as a sample obtained from a         healthy subject (or a population of healthy subjects). In some         embodiments, the control is a sample obtained from a healthy         subject (or a population of healthy subjects) or non-malignant         tissue from the same subject and of the same histologic type as         the cancer (also referred to herein as a “normal” control). In         some embodiments, the control is a historical control or         standard value (e.g., a previously tested control sample or         group of samples that represent baseline or normal values, such         as baseline or normal values in a healthy subject). In some         examples the control is a standard value representing the         average value (or average range of values) obtained from a         plurality of samples (such as an average value or range of         values of expression of one or more miR nucleic acids from         normal subjects).     -   Effective amount: An amount of an agent (such as one or more         miRNAs) that is sufficient to produce a desired response, such         as reducing or inhibiting one or more signs or symptoms         associated with a condition or disease. In some examples, an         “effective amount” is an amount that treats or inhibits one or         more signs or symptoms of a tumor. In some examples, an         “effective amount” is a therapeutically effective amount in         which the agent alone or with one or more additional therapies,         induces the desired response, such as a decrease in size of a         tumor in a subject, number of tumors in a subject, size or         number of tumor metastases in a subject, and/or an increase in         survival of a subject (such as disease-free survival,         metastasis-free survival, or overall survival).     -   Isolated: An “isolated” biological component (such as a nucleic         acid molecule, protein, or cell) has been substantially         separated or purified away from other biological components (for         example, in the cell or tissue of an organism, or the organism         itself, in which the component naturally occurs, such as other         chromosomal and extra-chromosomal DNA and RNA, proteins and         cells). Nucleic acid molecules and proteins that have been         “isolated” include those purified by standard purification         methods. The term also embraces nucleic acid molecules         (including microRNAs) and proteins prepared by recombinant         expression in a host cell as well as chemically synthesized         nucleic acid molecules and proteins.     -   microRNA (miRNA): Single-stranded, small non-coding RNA         molecules that regulate gene expression. miRNAs are generally         about 16-27 nucleotides in length. miRNAs typically modulate         gene expression (e.g., increase or decrease translation) by         promoting cleavage of target mRNAs or by blocking translation of         the cellular transcript. miRNAs are processed from primary         transcripts known as pri-miRNA to short stem-loop structures         called precursor (pre)-miRNA and finally to functional, mature         miRNA. Mature miRNA molecules are partially complementary to one         or more messenger RNA molecules, and their primary function is         to down-regulate gene expression. As utilized herein, “miR         nucleic acid” or “miRNA nucleic acid” refers to any of a         pri-miRNA, a pre-miRNA, an miRNA duplex, or a mature miRNA.     -   miRNA sequences are publicly available. For example, miRBase         (mirbase.org) includes a searchable database of annotated miRNA         sequences. miRNA sequences are also available through other         databases known to one of ordinary skill in the art, including         the National Center for Biotechnology Information (ncbi.nlm         nih.gov). One of ordinary skill in the art can also identify         targets for specific miRNAs utilizing public databases and         algorithms, for example at MicroCosm Targets         (ebi.ac.uk/enright-srv/microcosm/htdocs/targets/), TargetScan         (targetscan.org), and PicTar (pictar.mdc-berlin.de). Based on         miRNA sequences from one organism (such as mouse), one of         ordinary skill in the art can utilize the available databases to         determine a corresponding miRNA from another organism (such as         human).     -   miRNA Mimic or Mimetic: An miRNA mimetic includes an miRNA has         the same sequence as the native or wild type miRNA, but has a         modified backbone, a modified base, and/or a 5′ or 3′ end         modification. In some examples an miRNA mimetic is may less         susceptible to degradation or nuclease activity. An miRNA mimic         is an miRNA with at least one sequence modification and having         75% or higher sequence identity to a native or wild type miRNA         and that also binds to the same mRNA(s) with similar affinity as         the wild type or native miRNA. The disclosed miRNAs may also be         both an miRNA mimetic and an miRNA mimic, for example, an miRNA         with at least one sequence modification (e.g., 75% or higher         sequence identity) to a wild type miRNA, and also having a         modified backbone, base, and/or end modification.     -   Sample (or biological sample): A specimen containing DNA, RNA         (including mRNA), protein, or combinations thereof, in some         examples, obtained from a subject. Examples include, but are not         limited to, peripheral blood, urine, saliva, tissue biopsy, fine         needle aspirate, surgical specimen, and autopsy material. In         some examples, a sample includes a tumor sample, such as a         fresh, frozen, or fixed tumor sample.     -   Subject: Living multi-cellular vertebrate organisms, a category         that includes human and non-human mammals (such as laboratory or         veterinary subjects).     -   Vector: A nucleic acid molecule allowing insertion of foreign         nucleic acid without disrupting the ability of the vector to         replicate and/or integrate in a host cell. A vector can include         nucleic acid sequences that permit it to replicate in a host         cell, such as an origin of replication. A vector can also         include one or more selectable marker genes and/or other genetic         elements. An expression vector is a vector that contains the         necessary regulatory sequences to allow transcription and         translation of the inserted nucleic acid(s). In some embodiments         herein, the vector is a plasmid vector. In other embodiments,         the vector is a viral vector.

III. miRNAs

Disclosed herein are miRNAs that are differentially regulated in cancers, including but not limited to squamous cell tumors. These miRNAs can be utilized in methods for treating tumors, and may also be used in diagnostic methods. Also disclosed are modified miRNAs that can also be utilized in compositions and methods of treatment.

miRNAs are small non-coding RNA molecules that regulate gene expression. Mature miRNAs are generally about 17-25 nucleotides in length. miRNAs typically modulate gene expression (e.g., increase or decrease translation) by promoting cleavage of target mRNAs or by blocking translation of the cellular transcript. miRNAs are processed from primary transcripts known as “pri-miRNA” to short stem-loop structures called “precursor (pre)-miRNA.” The pre-miRNA is processed to an miRNA duplex and finally to functional, mature single-stranded miRNA. During processing of the miRNA duplex, one strand (referred to as the “passenger” strand) is degraded, while the other strand (the “guide” strand) is the mature miRNA molecule.

Mature miRNA molecules are partially complementary to one or more messenger RNA molecules, and their primary function is to down-regulate gene expression. As disclosed herein, an miRNA nucleic acid includes precursor miRNAs, as well processed or mature miRNA nucleic acids. For example, an miRNA nucleic acid may be a pri-miRNA, a pre-miRNA, an miRNA duplex, or a mature miRNA nucleic acid.

miRNA sequences are publicly available. One of ordinary skill in the art can identify miRNA precursors, as well as processed or mature miRNAs, for example, utilizing publicly available databases. For example, miRBase (mirbase.org) includes a searchable database of annotated miRNA sequences. miRNA sequences are also available through other databases known to one of ordinary skill in the art, including the National Center for Biotechnology Information (ncbi.nlm.nih.gov). One of ordinary skill in the art can also identify targets for specific miRNAs utilizing public databases and algorithms, for example at MicroCosm Targets (ebi.ac.uk/enright-srv/microcosm/htdocs/targets/), TargetScan (targetscan.org), and PicTar (pictar.mdc-berlin.de). Based on miRNA sequences from one organism (such as mouse), one of ordinary skill in the art can utilize the available databases to determine a corresponding miRNA from another organism (such as human).

In some examples, microRNA functions by activating cleavage or destabilization of a target mRNA or non-coding RNA, which can be detected by RT-PCR, is situ hybridization, FRET, northern blot, or sequencing. It may also function by inhibiting translation of a target mRNA into a protein, which may be detected by Western blot, immune blotting, florescence polarization assay, enzyme activity assay, FRET, immunofluorescence, immunohistochemistry, ELISA, or mass spectrometry. The resulting change in expression of targeted mRNAs or non-coding RNA may result in repression of a number of cancer relevant phenotypes including cell proliferation, resisting cell death, pro-inflammatory processes, increased migration and invasion, angiogenesis, evasion of immune destruction, replicative immortality, decreased genome stability, deregulated cellular energetics, and/or deregulation of epigenetic processes which effect tumor growth and progression.

In some examples, the miRNA nucleic acids of use in the compositions and methods disclosed herein include the mature miRNAs listed in Table 1. In other examples, the miRNA nucleic acids include those with at least 75% sequence identity to those listed in Table 1 (e.g., miRNA mimics), as long as such modified miRNAs retain one or more functions of the unmodified miRNA. For example, the miRNA nucleic acid includes or consists of a nucleic acid sequence at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% 99%, or 100% identical to the nucleic acid sequence of one of the miRNAs listed in Table 1. Additional miRNA nucleic acids of use in the disclosed compositions and methods include the modified miRNAs (including guide and/or passenger strands) shown in Tables 18, 20, 21, and 23, or miRNAs with at least 75% sequence identity (for example, at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to those shown in Tables 18, 20, 21, and 23 (e.g., miRNA mimetics and/or mimics), as long as such modified miRNAs retain one or more functions of the unmodified miRNA. In some examples, the miRNAs with at least 75% sequence identity to those shown in Table 1, Table 18, Table 20, Table 21, or Table 23 include at least one (such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) non-naturally occurring nucleotide.

TABLE 1 Exemplary mature human miRNAs differentially expressed in tumors SEQ ID Human miRNA Sequence NO: hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG  1 hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU  2 hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC  3 hsa-miR-30d-5p UGUAAACAUCCCCGACUGGAAG  4 hsa-miR-30e-5p UGUAAACAUCCUUGACUGGAAG  5 hsa-miR-30a-3p CUUUCAGUCGGAUGUUUGCAGC  6 hsa-miR-30b-3p CUGGGAGGUGGAUGUUUACUUC  7 hsa-miR-30c-1-3p CUGGGAGAGGGUUGUUUACUCC  8 hsa-miR-30c-2-3p CUGGGAGAAGGCUGUUUACUCU  9 hsa-miR-30d-3p CUUUCAGUCAGAUGUUUGCUGC 10 hsa-miR-30e-3p CUUUCAGUCGGAUGUUUACAGC 11 hsa-miR-26a-5p UUCAAGUAAUCCAGGAUAGGCU 12 hsa-miR-26a-1-3p CCUAUUCUUGGUUACUUGCACG 13 hsa-miR-26a-2-3p CCUAUUCUUGAUUACUUGUUUC 14 hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU 15 hsa-miR-26b-3p CCUGUUCUCCAUUACUUGGCUC 16 hsa-miR-375 UUUGUUCGUUCGGCUCGCGUGA 17 hsa-miR-145-5p GUCCAGUUUUCCCAGGAAUCCCU 18 hsa-miR-145-3p GGAUUCCUGGAAAUACUGUUCU 19 hsa-miR-338-5p AACAAUAUCCUGGUGCUGAGUG 20 hsa-miR-338-3p UCCAGCAUCAGUGAUUUUGUUG 21 hsa-miR-205-5p UCCUUCAUUCCACCGGAGUCUG 22 hsa-miR-205-3p GAUUUCAGUGGAGUGAAGUUC 23 hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 24 hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU 25 hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA 26 hsa-miR-29a-5p ACUGAUUUCUUUUGGUGUUCAG 27 hsa-miR-29b-1-5p GCUGGUUUCAUAUGGUGGUUUAGA 28 hsa-miR-29b-2-5p CUGGUUUCACAUGGUGGCUUAG 29 hsa-miR-29c-5p UGACCGAUUUCUCCUGGUGUUC 30 hsa-miR-27a-5p AGGGCUUAGCUGCUUGUGAGCA 31 hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC 32 hsa-miR-27b-5p AGAGCUUAGCUGAUUGGUGAAC 33 hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC 34 hsa-miR-101-5p CAGUUAUCACAGUGCUGAUGCU 35 hsa-miR-101-3p UACAGUACUGUGAUAACUGAA 36

In additional examples, an miRNA nucleic acid includes an miRNA nucleic acid that is slightly longer or shorter than the nucleotide sequence of any one of the miRNA nucleic acids disclosed herein (such as SEQ ID NOs: 1-67 or 72 or 73-158), as long as the miRNA nucleic acid retains a function of the particular miRNA, such as hybridization to an miRNA target sequence or formation of an miRNA duplex. For example, an miRNA nucleic acid can include a few nucleotide deletions or additions at the 5′- or 3′-end of the nucleotide sequence of an miRNA described herein, such as addition or deletion of 1, 2, 3, 4, or more nucleotides from the 5′- or 3′-end, or combinations thereof (such as a deletion from one end and an addition to the other end). In particular examples, modified miRNAs described herein include addition of one or more nucleotides at the 3′ end, such as addition of one or more nucleotides (for example, 1, 2, 3, or more nucleotides) at the 3′ end of an miRNA passenger strand.

Also provided by the present disclosure are miRNAs that include variations to the miRNA sequence (such as a variation of the sequence shown in any of SEQ ID NOs: 1-67 or 72 or 73-158), as long as such modified miRNAs retain one or more functions of the unmodified miRNA. In some examples, the modifications provide increased stability of a guide strand-passenger strand duplex. In some examples, the modifications include substitutions at one or more nucleotides (such as 1, 2, 3, 4, 5, or more nucleotides) in an miRNA. In particular examples, the modifications include substitution of one or more of positions 1, 6, and 20 of an miR-30 passenger strand (such as miR-30a-5p).

Also provided are miRNA mimetics, such as miRNA nucleic acids that include one or more modified nucleotides or nucleic acid analogs. In some embodiments, the isolated miRNA includes at least one nucleobase modification, for example to increase nuclease resistance, enhance half-life and/or improve efficacy. Nucleobase modifications suitable for application to microRNAs are well known in the art (see, for example, U.S. Patent Application Publication Nos. 2010/0298407; 2007/0213292; 2006/0287260; 2006/0035254; 2006/0008822; and 2005/0288244).

In some examples (for example, to increase nuclease resistance and/or binding affinity to a target nucleic acid molecule), an miRNA of the disclosure includes 2′-O-methyl, 2′-fluorine, 2′-O-methoxyethyl, 2′-O-aminopropyl, 2′-amino sugar modifications and/or phosphorothioate linkages. Inclusion of locked nucleic acids (LNA), ethylene nucleic acids (ENA) (e.g., 2′-4′-ethylene-bridged nucleic acids) and certain nucleobase modifications can also increase binding affinity to the target. The inclusion of pyranose sugars in the oligonucleotide backbone can also decrease endonucleolytic cleavage. Additional modifications include morpholinos, peptide nucleic acids (PNA), unlocked nucleic acids (UNA), α-L-LNA, 4′-C-hydroxymethyl-DNA, 2′-N-adamantylmethylcarbonyl-2′-amino-LNA, 2′-N-pyren-1-ylmethyl-2′-amino-LNA, E2′-aminoethyl, 2′-guanidinoethyl, 2′-cyanoethyl, 2′-aminopropyl, oxetane-LNA, 2′,4′-carbocyclic-LNA-locked nucleic acid, 2′,4′-carbocyclic-ENA-locked nucleic acid, 2′-deoxy-2′-N,4′-C-ethylene-LNA, altritol nucleic acid, hexitol nucleic acid, 2′-aminoethoxymethyl, and 2′-aminopropoxymethyl.

Additional miRNA mimetics include miRNAs with modified backbones or non-natural internucleoside linkages. Oligomers having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. Modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone are generally referred to in the art as nucleobase oligomers. Nucleobase oligomers that have modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. Various salts, mixed salts and free acid forms are also included.

miRNAs having modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

In other examples, the modified miRNAs (e.g., miRNA mimetics) include one or more substituted sugar moieties. Such modifications include 2′-O-methyl, 2′-methoxyethoxy, 2′-dimethylaminooxyethoxy, 2′-aminopropoxy, and 2′-fluoro modifications. Modifications may also be made at other positions on an oligonucleotide or other nucleobase oligomer, particularly the 3′ position of the sugar on the 3′ terminal nucleotide. Nucleobase oligomers may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

In further examples, a modified miRNA (e.g., an miRNA mimetic) includes a modification at the 5′ or 3′ end. Such modifications include a primary amino group (for example, with a carbon spacer, such as amino-C3, amino-C6, or amino-C12) at the 5′ end of the miRNA. Additional end modifications include UNAs, methylphosphonate, phosphithorate, an inverted base, or an N-methyl-G cap.

In other embodiments, the miRNA includes two or more modifications, such as two or more modifications selected from a base substitution, a modification at an internucleoside linkage, a modified sugar, or a modification at the 5′ and/or 3′ end. For duplex miRNA molecules, the modification(s) may be present on the guide strand, the passenger strand, or both.

In some examples, the modified (e.g., mimic or mimetic) miRNA nucleic acids disclosed herein include a 5′ end amino modification, such as a 5′-amino C6 modification (such as a 5′-amino C6 modified passenger strand). In other examples, the modified (e.g., mimic or mimetic) miRNA nucleic acid includes one or more nucleotides (such as 1, 2, 3, 4, 5, 6, 7, 8, or more nucleotides) with a 2′ modification (such as 2′-O-Me). The 2′ modified nucleotides may be internal to the miRNA (none of the modifications are on the 5′ or 3′ end nucleotide) or may include the 5′ and/or 3′ end nucleotides. In some examples, an miRNA guide strand includes one or more nucleotides (such as 3-10, 4-9, or 5-8 nucleotides) having a 2′ modification. In specific examples, a guide strand includes 2′ modifications on one or more internal nucleotides, and in some examples, not on a 5′ or 3′ end nucleotide. In other examples, an miRNA passenger stand includes one or more nucleotides (such as 3-10, 4-8, or 5-7 nucleotides) having a 2′ modification. In specific examples, a passenger strand includes 2′ modifications on a 5′ or 3′ end nucleotide, but may also include 2′ modification of one or more internal nucleotides. In particular, non-limiting examples, modified miRNAs include those shown in Tables 18, 20, 21, and 23, below.

In some embodiments, the disclosed miRNA nucleic acids or modified (e.g., mimetic or mimic) miRNA nucleic acids are associated with a detectable label. In some examples, the miRNA nucleic acid is conjugated to a fluorescent label (such as fluorescein isothiocyanate, coumarin, Cy3, Cy5, Cy7, or Alexa Fluor® dyes), a hapten (such as digoxigenin or Myc), or a radioactive label. In other embodiments, the miRNA nucleic acid is associated with a peptide or protein (for example, to facilitate targeted delivery), such as tat, MACV GP1, folate receptor, or penetratin. One of skill in the art can select additional detectable labels or peptides depending on the particular circumstances.

IV. Methods and Compositions for Treating or Inhibiting Cancer

Disclosed herein are miRNAs that are differentially expressed in tumors. These miRNAs can be utilized in methods to treat or inhibit cancer in a subject. Thus, disclosed herein are methods of treating or inhibiting cancer in a subject that include administering to the subject an effective amount of one or more miRNAs. In particular examples, the methods include administering to a subject with cancer one or more miRNAs that are down-regulated in a tumor to a subject with a tumor (such as a squamous cell carcinoma).

In some embodiments, the methods include administering to a subject with a tumor an effective amount of at least one isolated miR-30 nucleic acid (such as a miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, or miR-30e-5p nucleic acid) or a mimic or mimetic thereof, or a vector encoding the miR-30 nucleic acid or a mimic or mimetic thereof. Specific non-limiting examples of miR-30 nucleic acids includes SEQ ID NOs: 1-11 and 66 disclosed herein. In additional examples, the methods include administering to a subject with a tumor an effective amount of a variant or modified (e.g., a mimic or mimetic) miR-30 nucleic acid. The modified miR-30 nucleic acid may be administered as an miR-30 duplex including a guide strand and a passenger strand, for example selected from SEQ ID NOs: 37-61 and 73-92. In particular non-limiting examples, a modified miR-30 nucleic acid includes an miR-30 duplex including SEQ ID NOs: 41 and 55, an miR-30 duplex including SEQ ID NOs: 42 and 56, an miR-30 duplex including SEQ ID NOs: 42 and 57, an miR-30 duplex including SEQ ID NOs: 50 and 61, an miR-30 duplex including SEQ ID NOs: 73 and 61, or an miRNA duplex including SEQ ID NOs: 74 and 61. Additional examples of modified miR-30 duplexes include those in Tables 19 and 22, below.

In further embodiments, the methods include administering to a subject with a tumor an effective amount of one or more of an isolated miR-30 (such as a miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, and/or miR-30e-5p), miR-26a-5p, miR-26b-5p, miR-375, miR-145-5p, miR-338-3p, miR-27, miR-29, or miR-101 nucleic acid, a mimic or mimetic of any thereof, or a combination of any two or more thereof, including one or more duplex miR nucleic acids or vectors encoding the miR nucleic acid(s). The modified miR nucleic acid may be administered as an miR duplex including a guide strand and a passenger strand, for example selected from SEQ ID NOs: 62-67 and 93-158.

In particular examples, the methods include administering to a subject with a tumor an effective amount of a combination of miR-30, miR-145, miR-26a, and miR-375 nucleic acids. In a specific non-limiting example, the methods include administering to the subject a combination of miR-30a-014 (SEQ ID NOs: 41 and 55), miR-145, miR-26a, and miR-375. In further examples, the methods include administering at least 2 (for example, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more) miRNAs from any one of Tables 1, 3, 4, 5, 18, 20, 21, and 23 (such as 2-10, 4-20, 6-30, 10-50, or more). The miRNAs may be administered as single-stranded miR nucleic acids, duplex miR nucleic acids (such as a duplex of a guide strand and a passenger strand), or vectors including miR nucleic acids.

In other examples, the methods include administering to a subject with a tumor an effective amount of two or more miR-30, miR-145, miR-375, and miR-26a nucleic acids. In some examples, the methods include administering to the subject an miR-30 nucleic acid (such as an miR-30a-5p nucleic acid or a modified miR-30a nucleic acid, such as those in Tables 18, 19, and 21) and an miR-145 nucleic acid. In other examples, the methods include administering to the subject an miR-145 nucleic acid and an miR-375 nucleic acid. In further examples, the methods include administering to the subject an miR-30 nucleic acid (such as an miR-30a-5p nucleic acid or a modified miR-30a nucleic acid, such as those in Tables 18 and 19) and an miR-375 nucleic acid. In some examples, the methods include administering to the subject an miR-145 nucleic acid and an miR-26a nucleic acid. In additional examples, the methods include administering to the subject an miR-26a nucleic acid and an miR-375 nucleic acid. In other examples, the methods include administering to the subject an miR-30 nucleic acid (such as an miR-30a-5p nucleic acid or a modified miR-30a nucleic acid, such as those in Tables 18 and 19) and an miR-26a nucleic acid.

The disclosed methods can be used to treat or inhibit a cancer in a subject. Exemplary cancers include Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Cancer in Adrenocortical carcinoma, AIDS-Related Cancers (e.g., Kaposi Sarcoma, AIDS-Related Lymphoma, Primary CNS Lymphoma), Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer (e.g., Ewing Sarcoma Family of Tumors, Osteosarcoma and Malignant Fibrous Histiocytoma), Brain Tumor (e.g., Astrocytomas, Brain Stem, Glioma, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Tumors, Central Nervous System Germ Cell Tumors, Craniopharyngioma, Ependymoma), Breast Cancer, Bronchial Tumors. Burkitt Lymphoma, Carcinoid Tumor, Cardiac (Heart) Tumors, Central Nervous System (e.g., Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumors, Germ Cell Tumor, Lymphoma, Primary), Cervical Cancer, Cholangiocarcinoma, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Neoplasms, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Ductal Carcinoma In Situ (DCIS), Endometrial Cancer, Ependymoma, Esophageal Cancer, Esthesioneuroblastoma, Ewing Sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Eye Cancer (e.g., Intraocular Melanoma, Retinoblastoma), Fallopian Tube Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), Germ Cell Tumor (e.g., Extracranial, Extragonadal, Ovarian. Testicular), Gestational Trophoblastic Disease. Glioma. Hairy Cell Leukemia, Head and Neck Cancer. Heart Cancer, Hepatocellular Cancer, Hodgkin Lymphoma, Hypopharyngeal Cancer, Islet Cell Tumors, Pancreatic Neuroendocrine Tumors, Kaposi Sarcoma, Kidney (e.g., Renal Cell, Wilms Tumor). Langerhans Cell Histiocytosis, Laryngeal Cancer, Hairy Cell Leukemia, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer (e.g., Non-Small Cell, Small Cell), Lymphoma (e.g., AIDS-Related, Burkitt, Cutaneous T-Cell, Hodgkin, Non-Hodgkin, Primary Central Nervous System), Waldenstrom Macroglobulinemia, Merkel Cell Carcinoma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Myelogenous Leukemia. Multiple Myeloma, Myeloproliferative Neoplasms, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma. Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer. Oral Cancer, Oropharyngeal Cancer, Ovarian Cancer (e.g., Epithelial, Germ Cell Tumor, Low Malignant Potential Tumor), Pancreatic Cancer, Pancreatic Neuroendocrine Tumors (Islet Cell Tumors), Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma. Pleuropulmonary Blastoma, Primary Central Nervous System (CNS) Lymphoma, Primary Peritoneal Cancer. Prostate Cancer, Rectal Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas (e.g., Ewing Sarcoma, Kaposi, Osteosarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Uterine Sarcoma. Vascular Tumors), Sdzary Syndrome, Skin Cancer (e.g., Melanoma, Merkel Cell Carcinoma. Nonmelanoma), Small Intestine Cancer, Squamous Cell Carcinoma, Stomach Cancer, T-Cell Lymphoma, Cutaneous, Testicular Cancer, Throat Cancer, Thymoma and Thymic Carcinoma, Thyroid Cancer, Unknown Primary Carcinoma. Unusual Cancers of Childhood, Urethral Cancer, Uterine Cancer, Uterine Sarcoma. Vaginal Cancer, Vascular Tumors, Vulvar Cancer, or Wilms Tumor.

In some non-limiting embodiments, the methods include treating or inhibiting a squamous cell carcinoma (SCC), such as head and neck squamous cell carcinoma, lung squamous cell carcinoma, or cervical squamous cell carcinoma. SCC is a cancer of the carcinoma type that may occur in many different organs, including the skin, lips, mouth, esophagus, urinary bladder, prostate, lungs, vagina, and cervix. It is a malignant tumor of squamous epithelium (epithelium that shows squamous cell differentiation). In some examples, the tumor is a HNSCC, for example, oral squamous carcinoma (such as tumors of the lip, tongue, hard palate, floor of mouth, or buccal mucosa), oropharyngeal squamous carcinoma (such as tumors of the soft palate, base of the tongue, or tonsillar region), hypopharyngeal squamous carcinoma (such as tumors of the pyriform sinus, posterior pharyngeal wall, or postcricoid region), nasopharyngeal squamous carcinoma (such as tumors of the maxillary antrum), or laryngeal squamous carcinoma. In other examples, the tumor is a lung SCC or cervical SCC. In further examples, the tumor is a squamous cell carcinoma of the thyroid, esophageal SCC, squamous cell carcinoma of the skin, squamous cell carcinoma of the breast, or squamous cell carcinoma of the urinary bladder.

In further non-limiting embodiments, the methods include treating or inhibiting cervical adenocarcinoma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, or pancreatic carcinoma.

In some embodiments, a subject is administered an effective amount of a composition including one or more miRNAs or modified miRNAs disclosed herein. Pharmaceutical compositions that include one or more of the miRNAs disclosed herein (such as 2, 3, 4, 5, or more miRNAs) can be formulated with an appropriate solid or liquid carrier, depending upon the particular mode of administration chosen. The pharmaceutically acceptable carriers and excipients useful in this disclosure are conventional. See, e.g., Remington: The Science and Practice of Pharmacy, The University of the Sciences in Philadelphia, Editor, Lippincott, Williams, & Wilkins, Philadelphia, PA, 21^(st) Edition (2005). For instance, parenteral formulations usually include injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, pH buffering agents, or the like, for example sodium acetate or sorbitan monolaurate. Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations.

One skilled in the art can readily determine an effective amount of a disclosed miR nucleic acid (or combination of miR nucleic acids) to be administered to a subject, for example, taking into account factors such as the type of tumor being treated, the extent of disease progression, the age, health and sex of the subject, the size (e.g., weight and/or height) of the subject, and the route of administration. For example, the effective amount can be based on the approximate body weight of a subject to be treated. Such effective amounts can be administered by any suitable route. In some examples, an effective amount of an miR nucleic acid (or combination of miR nucleic acids) administered to a subject ranges from about 5 μg/kg to about 100 mg/kg of body weight, such as about 100 μg/kg to about 10 mg/kg, about 1 mg/kg to about 25 mg/kg, about 20 mg/kg to about 40 mg/kg, about 30 mg/kg to about 50 mg/kg, or about 40 mg/kg to about 100 mg/kg. In one non-limiting example, the amount administered is about 5 mg/kg of an miR nucleic acid (or a combination of miR nucleic acids).

In some embodiments, the compositions are administered in unit dosage form, for example, suitable for individual administration of particular doses. In some examples, a unit dosage contains from about 1 mg to about 5 g of one or more miR nucleic acid molecules (such as about 5 mg to about 50 mg, about 10 mg to about 200 mg, about 100 mg to about 2.5 g, about 250 mg to about 1 g, or about 500 mg to about 5 g). In some examples, a unit dosage contains about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1 g, 1.5 g, 2 g, 2.5 g, 3 g, 4 g, or 5 g of one or more miR nucleic acids.

One skilled in the art can also readily determine an appropriate dosage regimen for the administration of a disclosed miR nucleic acid (or combination of miR nucleic acids) to a subject. For example, the miR nucleic acid(s) can be administered to the subject once (e.g., as a single injection or deposition) or in repeated doses. In some examples, the miR nucleic acid (or combination of miR nucleic acids) is administered once or twice daily, twice per week, three times per week, weekly, biweekly, or monthly for an extended period of time as needed to achieve a desired therapeutic outcome (such as a decrease in one or more signs or symptoms of a tumor). In other examples, the miR nucleic acid(s) are administered in a continuous manner (for example using a pump, implant, or continuous release formulation).

Therapeutic agents can be administered to a subject in need of treatment using any suitable means known in the art. Methods of administration include, but are not limited to, intraductal, intradermal, intramuscular, intraperitoneal, parenteral, intravenous, subcutaneous, vaginal, rectal, intranasal, inhalation, oral, or by gene gun. Intranasal administration refers to delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid. Administration of the compositions by inhalant can be through the nose or mouth via delivery by spraying or droplet mechanisms. Delivery can be directly to any area of the respiratory system via intubation. Parenteral administration is generally achieved by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets. Administration can be systemic or local. In particular, non-limiting examples, administration is intravenous. In other examples, administration is subcutaneous, intramuscular, or intraperitoneal. One of skill in the art can select an appropriate route of administration, depending on the therapeutic agent(s), the condition being treated, the health and treatment history of the subject, and other relevant clinical factors.

Therapeutic agents can be administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present disclosure.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.

Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base-addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

In some embodiments, liposomes are used to deliver a disclosed miR nucleic acid or combination of miR nucleic acids to a subject. Liposomes can also increase the blood half-life of the gene products. Suitable liposomes for use in the compositions and methods disclosed herein can be formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of several factors, such as the desired liposome size and half-life of the liposomes in the blood stream. In a particular example, liposomes are formed with one or more disclosed miR nucleic acids and cationic lipids, such as dioleoyltrimethylammonium phosphate (DOTAP) and dioleoylphosphatidylethanolamine (DOPE).

A variety of methods are known in the art for preparing liposomes (see, for example, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467, 1980; and U.S. Pat. Nos. 4,235,871; 4,501,728; 4,837,028; and 5,019,369). In some embodiments, polymers can be used to deliver a miR nucleic acid to a subject. Cationic lipids and polymers that can be used to deliver therapeutic RNA molecules have been described (see, for example, Zhang et al., J Control Release. 123(1):1-10, 2007; Vorhies et al., Methods Mol. Biol. 480:11-29, 2009; and U.S. Patent Application Publication No. 2009/0306194). In some examples, the liposome further includes a molecule that increases targeting of the complex to a tumor, for example a molecule that binds to the transferrin receptor (such as an anti-transferrin receptor antibody or a fragment thereof). In one example, the liposome includes an anti-transferrin receptor single chain antibody fragment (see for example, Pirollo et al., Hum. Gene Ther. 17:117-124, 2006; Pirollo et al., Cancer Res. 67:2938-2943, 2007). Additional targeting molecules include folate receptor, EGFR, MET, ROR1, GLUT1, Cadherin, CD44, PSMA, and MAGE. Polypeptide carriers can also be used to administer an miR nucleic acid to a subject (see, for example, Rahbek et al., J. Gene Med. 10:81-93, 2008). One of skill in the art can identify additional targeting molecules or polypeptide carriers.

In some embodiments, the method includes administering a vector encoding one or more of the disclosed miRNA nucleic acids or a mimic or mimetic thereof (such as any of SEQ ID NOs: 1-67 and 72, 73-158, or a mimic and/or mimetic thereof). Vectors for use in the disclosed methods can be of non-viral (for example, plasmids) or viral (for example, adenovirus, adeno-associated virus, retrovirus, herpes virus, vaccinia virus) origin. Suitable vectors, such as gene therapy vectors, are well known in the art.

In some examples, the miRNA nucleic acid is expressed from recombinant circular or linear DNA plasmids using any suitable promoter. Suitable promoters for expressing RNA from a plasmid include, for example, the U6 or H1 RNA pol III promoter sequences, a cytomegalovirus promoter, an SV40 promoter or metallothionein promoter. Selection of other suitable promoters is within the skill in the art. The recombinant plasmids can also comprise inducible or regulatable promoters for expression of the miR gene products.

In one non-limiting embodiment, the miRNA nucleic acid is expressed as an RNA precursor molecule from a plasmid, and the precursor molecule is processed into a functional or mature miRNA within the target cell. Selection of plasmids suitable for expressing the miRNAs, methods for inserting nucleic acid sequences into the plasmid to express the gene products, and methods of delivering the recombinant plasmid to the cells of interest are within the skill in the art (see, for example, Zeng et al., Mol. Cell 9:1327-1333, 2002; Tuschl, Nat. Biotechnol., 20:446-448, 2002; Brummelkarnp et al., Science 296:550-553, 2002; Miyagishi et al., Nat. Biotechnol. 20:497-500, 2002; Paddison et al., Genes Dev. 16:948-958, 2002; Lee et al., Nat. Biotechnol. 20:500-505, 2002; and Paul et al., Nat. Biotechnol. 20:505-508, 2002).

The present disclosure also includes methods of treating a subject with combinations of one or more of the miRNA nucleic acids in combination with one or more other agents useful in the treatment of a cancer. For example, the compounds of this disclosure can be administered in combination with effective doses of one or more tumor therapies, including but not limited to, surgery, chemotherapeutic agent(s), radiation, gene therapy, hormone therapy, immunotherapy, and antisense oligonucleotide therapy. A skilled clinician can select an appropriate combination of therapies based on the type of tumor being treated, the subject's clinical history, overall condition, and other factors. The term “administration in combination” or “co-administration” refers to both concurrent and sequential administration of the active agents or therapies.

Chemotherapeutic agents include, but are not limited to alkylating agents, such as nitrogen mustards (for example, chlorambucil, chlormethine, cyclophosphamide, ifosfamide, and melphalan), nitrosoureas (for example, carmustine, fotemustine, lomustine, and streptozocin), platinum compounds (for example, carboplatin, cisplatin, oxaliplatin, and BBR3464), busulfan, dacarbazine, mechlorethamine, procarbazine, temozolomide, thiotepa, and uramustine; antimetabolites, such as folic acid (for example, methotrexate, pemetrexed, and raltitrexed), purine (for example, cladribine, clofarabine, fludarabine, mercaptopurine, and thioguanine), pyrimidine (for example, capecitabine), cytarabine, fluorouracil, and gemcitabine; plant alkaloids, such as podophyllum (for example, etoposide, and teniposide), taxane (for example, docetaxel and paclitaxel), vinca (for example, vinblastine, vincristine, vindesine, and vinorelbine); cytotoxic/antitumor antibiotics, such as anthracycline family members (for example, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin), bleomycin, hydroxyurea, and mitomycin; topoisomerase inhibitors, such as topotecan and irinotecan; monoclonal antibodies, such as alemtuzumab, bevacizumab, cetuximab, gemtuzumab, rituximab, panitumumab, and trastuzumab; photosensitizers, such as aminolevulinic acid, methyl aminolevulinate, porfimer sodium, and verteporfin; and other agents, such as alitretinoin, altretamine, amsacrine, anagrelide, arsenic trioxide, asparaginase, bexarotene, bortezomib, celecoxib, denileukin diftitox, erlotinib, estramustine, gefitinib, hydroxycarbamide, imatinib, pentostatin, masoprocol, mitotane, pegaspargase, and tretinoin.

In a particular example, if the subject has HNSCC, the chemotherapeutic agent includes cisplatin, carboplatin, cetuximab, bevacizumab, erlotinib, bleomycin, paclitaxel/carboplatin or a combination of two or more thereof. In another example, if the subject has lung SCC, the chemotherapeutic agent includes cisplatin or carboplatin, alone or in combination with etoposide, gemcitabine, paclitaxel, vinorelbine, topotecan, or irinotecan. One of skill in the art can select appropriate additional treatments (such as chemotherapy) based on factors such as the type of cancer, the stage of cancer, molecular profile of the cancer, and the health and treatment history of the subject.

V. Methods of Diagnosing Tumors

Disclosed herein are methods of diagnosing a tumor in a subject. In some examples, the methods include identifying a tumor in a subject by detecting a change in amount of one or more miRNAs (such as an increase or decrease) in a sample from the subject, for example compared to a control. In some examples, the methods further include administering a treatment to a subject diagnosed as having a tumor. In one example, the subject is diagnosed as having a tumor that expresses a decreased amount of one or more miRNAs (for example as compared to a control) and a composition including an effective amount of the one or more miRNAs with decreased expression is administered to the subject.

Samples used in the methods described herein, such as a tissue or other biological sample, can be prepared using any method known in the art. Samples include any solid or fluid sample obtained from, excreted by or secreted by a subject. For example, a sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, bile, ascites, saliva, cerebrospinal fluid, aqueous or vitreous humor, or any bodily secretion, a transudate, an exudate (for example, fluid obtained from an abscess or any other site of infection or inflammation), or fluid obtained from a joint (for example, a normal joint or a joint affected by disease). A sample can also be a sample obtained from any organ or tissue (including a biopsy or autopsy specimen, such as a tumor biopsy) or can include a cell (whether a primary cell or cultured cell) or medium conditioned by any cell, tissue or organ. In particular embodiments, the sample includes a tumor sample or a blood sample. The samples can be obtained from subjects for routine screening or from subjects that are suspected of having a disorder, such as a tumor.

In some embodiments, the methods include detecting an amount of one or more of miR-30 (such as miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, or miR-30e-5p), miR-26a-5p, miR-26b-5p, miR-145-5p, miR-338-3p, miR-375, miR-27, miR-29, or miR-101 in a sample from a subject (such as a tumor sample from the subject). In other embodiments, the methods include detecting an amount of one or more miRNAs listed in Tables 1, 3, 4, 5, 18, and 20, below. In particular examples, the methods include detecting expression of either a mature form of the miR or a precursor form (e.g., a pri-miRNA or pre-miRNA) of the miR. Typically, miR detection methods involve sequence specific detection, such as by RT-PCR or microarray analysis. miR-specific primers and probes can be designed using the precursor and mature miR nucleic acid sequences that are known in the art (e.g., available on the World Wide Web at mirbase.org).

In some embodiments of the methods, the change in expression (e.g., a statistically significant increase or decrease in expression) of one or more miR nucleic acids is at least 2-fold, such as at least 3-fold, at least 4-fold, at least 5-fold, at least 10-fold, including about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold, about 30-fold, and about 100-fold in a sample from the subject. In some examples, the change detected is an increase or decrease in expression as compared to a control, such as a reference value or a healthy control subject. In some examples, the detected increase or decrease is an increase or decrease of at least two-fold compared with the control or standard. Controls or standards for comparison to a sample, for the determination of differential expression, include a sample obtained from a healthy subject (or a population of healthy subjects) or a historical control or standard value (e.g., a previously tested control sample or group of samples that represent baseline or normal values, such as baseline or normal values in a healthy subject). In some examples the control is a standard value representing the average value (or average range of values) obtained from a plurality of samples (such as an average value or range of values of expression of one or more miR nucleic acids from normal subjects).

In some embodiments, the methods further include providing an appropriate therapy for the subject diagnosed with a tumor. In some examples, the therapy includes administering an agent that inhibits expression of one or more miRNA nucleic acids, such as an agent that inhibits a miR nucleic acid identified as up-regulated in a sample from a subject relative to a control. In other examples, the therapy includes administering an agent that includes administering one or more miR nucleic acids, such one or more miR nucleic acids that are been identified as down-regulated in a sample from a subject relative to a control (for example, as described in Section IV).

The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.

Example 1 Materials and Methods

HNSCC Patient Samples: Fresh frozen HNSCC tissue and mucosa samples were collected from University of Michigan Medical Center as part of an IRB approved protocol. The clinical characterization of the HNSCC patients is summarized in Table 2. The collected tissues were snap frozen and mounted in OCT freezing media (Fisher), cut in 7 micrometer sections, and stained by H&E standard methods. The stained slides were scanned using a SCANSCOPE image capture device (Aperio), and examined with IMAGESCOPE software (Aperio) to ensure the presence of tumor or mucosa squamous epithelium. The stained slides were used to macrodissect tissue blocks to attain a minimum of 70% desired squamous tumor or epithelium cells in each sample.

TABLE 2 Tumor, treatment, and outcome characteristics of human HNSCC specimens Specimen Gender Age Primary Sites Stage/TNM Differentiation Tobacco/pack Alcohol/Quit 2900 M 57 Lateral tongue T2N0M0 Moderate NA NA 3100 M 75 Anterior tongue T1N0M0 Poor MD MD 3300 F 60 Lateral tongue T3N1M0 Moderate NA NA 4300 F 47 Lateral tongue T3N0M0 Well Y/14 NA 4500 F 25 Anterior tongue T4N2cM0 Moderate NA NA 8200 M 72 Tonsil T4N0M0 Well  Y/150 Y 8400 M 44 Lateral tongue T2N0M0 Well Y/20 Y/Y 8500 F 40 Lateral tongue T2N0M0 Well NA NA 8800 M 47 Floor of mouth T4N2bM0 Moderate Y/45 Y 4400 F 41 Floor of mouth T1N0M0 Well Y/60 Y/Y 7300 M 55 Floor of mouth T4N2cM0 Well Y/30 Y 7500 F 71 Hard palate T4N0M0 Moderate NA NA 7800 M 55 Lateral tongue T4N2bM0 Poor Y/60 Y/Y 8300 F 50 Lateral tongue T2N0M0 Well Y/28 NA HNSCC tumor specimens from oral cavity were obtained from University of Michigan and designated as UMSC. Primary sites, the origin of the primary tumor; TNM, tumor-node-metastasis (staging system). Y: Yes; NA: not available.

microRNA Isolation, Library Preparation and Sequencing from HNSCC Samples: Large and small RNA was purified using mirVana™ miRNA isolation Kit (Life Technologies) following a modified manufacturer's protocol. Fifteen-twenty mg of frozen tissue was homogenized in 1 mL of TRIZOL (Invitrogen) using a TissueLyser II tissue disrupter (Qiagen). Following homogenization, extraction was performed using a standard phenol-chloroform method. To the extracted aqueous phase, 10% additive (v/v) was added and then the standard manufacturer's protocol for fractionating large and small RNA was performed. RNA concentration was determined using a NANODROP spectrometer (Thermo Scientific), and total RNA integrity was verified on a Bioanalyzer 2100 instrument using an RNA 6000 Nano kit (Agilent Technologies). Sufficient presence of microRNA in small RNA enriched samples was verified by Bioanalyzer using the small RNA kit (Agilent Technologies).

Small RNA sequencing libraries were constructed using the SOLiD™ Total RNA-Seq Kit (Life Technologies) by manufacturer's protocol. Briefly, 1 μg of enriched small RNA (<200 bases) was used for ligation into sequencing adaptors. cDNA libraries were reverse transcribed and then size selected by separation on denaturing urea 10% PAGE. Bands were excised that correspond to an insert size of 18-38 nucleotides. The library was then amplified and barcoded by in-gel PCR. Library size was verified using the DNA 1000 kit on the Bioanalyzer 2100 (Agilent Technologies). cDNA library concentration was determined by RT-PCR by the SOLiD™ library TAQMAN quantification kit. Equal parts of eight cDNA libraries were multiplexed together and 0.6 pmol of multiplexed pool was used for emulsion PCR using the SOLiD™ EZ Bead™ system with E20 reagents. Emulsification, amplification, and bead enrichment were carried out according to the manufacturer's protocols. Enriched beads for each pool were 3′ labeled using the SOLiD™ pre-deposition plus kit according to the manufacturer's protocol. 4×10⁸ beads were deposited per lane of a 6-lane flow chip, and sequencing of the flow chip was then performed on the SOLiD™ 5500 system next generation sequencer with SOLiD™ Small RNA SP Kit (Life Technologies).

microRNA Mapping, Expression Profiling Quantification, and Differential Abundance Analysis: The sequencing reads were mapped to human reference genome Hg19 using miRNA module in LifeScope™ 2 (Life Technologies). The downstream steps were mainly performed using miRDeep2 software package (Friedländer et al., Nature Biotechnology 26:407-415, 2008). Briefly, the mapping results in sam format were converted to the arf format used in miRDeep2 and in turn the miRDeep2.pl script was used to identify all the known and novel miRNAs in the sequencing results using default settings. Finally all the identified miRNAs were quantified based on the reads numbers assigned to them and normalized using the total counts per million in that sample.

SAMseq's (samr v2.0, R 3.0.2) two-class unpaired analyses with a read count input matrix and an FDR threshold of 0.05 was used to identify miRNAs that were differentially expressed. Each run generated a pair of files: genes “up” and “down,” then ranked the filtered results by a median-based fold change.

miRNA Hierarchical Cluster Analysis: Hierarchical cluster analysis of microRNA expression was performed using Partek Genomics Suite 6.6 from notebook. RPM (reads per million)-normalized microRNA expression was ranked by variance across both normal and tumor samples and the top 50% most variant microRNAs were selected to remove low expressers. Differentially expressed microRNA between tumor and mucosa specimens were compared and filtered by p-value<0.05 following a two-tailed student's T test. Expression data were scaled to the mean expression, and then hierarchical clustering was performed using Pearson's dissimilarity algorithm with complete linkage.

Integrative Analysis to Identify miRNA-mRNA Pairs in HNSCC TCGA Data: miRNA and mRNA abundance for 279 tumor specimens were extracted from Level 3 data (available on the World Wide Web at tcga-data.nci.nih.gov/docs/publications/hnsc_2014). miRNA read counts for 5p and 3p strands were normalized to RPM aligned to miRBase annotated miRNAs. miRNAs were ranked by RPM variance across the samples, and the most variable 50% with a minimum expression of at least 50 RPM were used for integrated analysis. Gene expression was calculated from RNA-Seq data with RSEM v1.1.132 and zeros replaced with the minimum non-zero RSEM values (0.0033). The most-variant 50% of genes were used for integrated analysis. Both miRNA and mRNA expression data were log₂ transformed.

A multi-step approach was applied to identify miRNA-mRNA target relationship. Linear regression was used to identify pair-wise negative correlation of miRNA and mRNA expression, in conjunction with available prediction tools from miRNA target databases. A high confidence dataset of global miRNA-mRNA interactions was generated.

Copy Number Variation (CNV) Data Analysis: Copy number data for 279 tumor specimens were extracted from Level 3 data. The CNV number associated with each gene was defined as the segmented GISTIC5 value at the corresponding genomic location. The Integrative Genomics Viewer (IGV) was used to visualize copy number data. Linear regression was applied to assess the correlation between miRNA expression and CNV.

TCGA DNA methylation Data Analysis: For DNA methylation data analysis, we used Level 3 DNA methylation data for 279 tumor specimens from TCGA (The Cancer Genome Atlas, Nature 517:576-582, 2015). The data were represented as beta values (β) from Illumina Human Methylation 450k array. CpG probes in promoter regions of miRNAs from miR-30 family were found using coordinates of transcription start sites (TSS) from PROmiRNA (available on the World Wide Web at promirna.molgen.mpg.de; Marsico et al., Genome Biol. 14:R84, 2013). The promoter region was specified as +/−1500 bp from TSS. For every CpG probe, we estimated the difference of miRNA abundance between unmethylated (β<0.1) and methylated (β>0.3) samples using t-test. BH corrected P-values (FDR) from t-test were used to find CpG probes that significantly differentially expressed between unmethylated and methylated groups using 0.05 as a threshold. Then, methylation beta values were averaged across significant probes per miR and correlated with the corresponding miR expression using Spearman's correlation test.

Survival Analysis: The R survival statistical package, version 2.37-2 (available on the World Wide Web at CRAN.R-project.org/package=survival) was used to analyze overall survival times, produce Kaplan-Meier plots, and compute log-rank test p-values. Subjects were dichotomized as low miRNA expression (<median) and high miRNA expression (≥median), using the median expression of each miRNA as a cutoff. To compare overall survival time by CNV, subjects were categorized as having MIR30E/A deletion if their GISTIC copy number value was less than −0.1, otherwise they were considered to have no deletion.

Associations of miR-30 Genetic Alterations and Expression with Stage, Site, Smoking and HPV Status of HNSCC from TCGA Datasets: Fisher's exact tests were used to assess associations between miR-30a expression/methylation and clinical characteristics, or between miR-30e expression/copy number loss and clinical characteristics. Statistical analyses were performed using R version 3.2.2. Significance was defined as p<0.05. Tumor site was classified as oral cavity if the tumor samples came from any of the following anatomic subdivisions: buccal mucosa, floor of mouth, hard palate, lip, oral cavity, oral tongue, and alveolar ridge; tumor site was classified as oropharynx if the tumor samples came from tonsil, base of tongue or oropharynx.

Inverse Correlation of miR-30a Expression with Putative Target Genes: Linear regression analysis was performed as described previously (Cancer Genome Atlas, Nature 517:576-582, 2015) to assess inverse relationship between expressions of miR-30a-5p and its putative target genes using HNSCC TCGA datasets. P-values from linear regression measure the statistical significance of inverse relationship.

HNSCC Cell Lines: A panel of 10 HNSCC cell lines was obtained from the University of Michigan squamous cell carcinoma (UM-SCC) series (Brenner et al., Head Neck 32:417-426, 2010). The origin of these UM-SCC cell lines was authenticated by genotyping with 9 markers as described in Brenner et al. Preserved frozen stocks of lines were used within three months of culture. UM-SCC cell lines were cultured in minimal essential medium supplemented with 10% fetal calf serum, penicillin and streptomycin (100 μg/mL), MEM Non-Essential Amino Acids, and Sodium Pyruvate (1 mM). Human primary oral keratinocytes (HOK) from oral gingival mucosa were purchased from Lonza, and used as a control cell line. The cells were cultured in serum free Oral Keratinocyte Medium with supplements (Science Cell) for less than five passages.

In vitro microRNA mimic viability screen: Cells were maintained in MEM containing 10% heat inactivated fetal bovine serum (FBS) supplemented with non-essential amino acids and sodium pyruvate. Transfections were performed in 384 well plates (Corning 3570). Cell viability was measured using CELLTITER-GLO luminescent cell viability assay (Promega). For transfections, 20 μL of serum free media containing LIPOFECTAMINE RNAiMax reagent (0.1 μL) was added to wells containing miRNA mimic (0.8 pmol). Lipid and miRNA mimic were allowed to complex for 45 min at ambient temperature before addition of 1500 cells in MEM, 20% FBS to yield final transfection mixtures containing 20 nM miRNA mimic in MEM, 10% FBS.

The screening campaign was conducted a miRNA mimic library (Qiagen) based on Sanger miRBase 13.0 and consisting of ˜800 mimics Viability (CellTiter Glo, Promega) was assayed 72 h post-transfection on a PerkinElmer Envision 2104 Multilabel plate reader. Ambion SILENCER Select Negative Control #2 was incorporated on all screening plates for normalization (16 wells per plate; the median negative control value on each plate was used to normalize sample wells). Qiagen's AllStars Cell Death control was incorporated as a positive transfection control (16 wells per plate). All screen plates exhibited assay z′-factors greater than 0.6. Negative control normalized viability data was converted into robust z-scores using the median absolute deviation (MAD) (Chung et al., J. Biomol. Screen 13:149-158, 2008).

RT-PCR Validation of mRNA Targets: 2×10⁵ UM-SCC-46 cells were plated in each well of a 6-well plate. 15 nM of mirVana microRNA mimic or inhibitor (Life Technologies) was reverse transfected using 3.75 μL of LIPOFECTAMINE RNAiMAX (Life Technologies) by standard manufacturer's protocol for 48-72 hr. Then cells were washed with normal media and PBS, and collected into 0.5 mL TRIZOL reagent. Total RNA was purified using mirVana miRNA isolation Kit (Ambion). Two μg of total RNA was reverse transcribed using high capacity cDNA reverse transcription kit (Applied Biosystems) following manufacturer's instructions. mRNA expression levels were assessed by real time-PCR using TAQMAN gene expression assays (Applied Biosystems), and 40 ng of cDNA was used in each reaction. Reactions were run on an ABI 7900HT real-time PCR machine. Expression levels were normalized to 18S RNA as an endogenous loading control.

Western Blotting: UM-SCC-46 cells were transfected as described above and then lysed into 100 μL of SDS lysis buffer (1% SDS, 50 mM Tris pH 8.0, 10 mM EDTA, Protease inhibiter (Roche), and Halt Phosphatase Inhibitor (Thermo Scientific)). Samples were sonicated using a probe sonicator four times for 5 sec each on ice. Lysates were cleared by centrifugation at 14,000×g for 10 min at 4° C. Protein concentration was determined using the BCA Protein Assay (Thermo Scientific). 25 μg of total protein was subjected to SDS-PAGE on a 4-12% gradient Bis-Tris gel (Invitrogen). Protein was transferred to a 0.45-μm PVDF IMMOBILON-FL membrane (Millipore) using the XCELL transfer system (Invitrogen). Primary antibodies used for probing are listed below. Appropriate IRDye fluorescently labeled secondary antibodies were used for detection at a dilution of 1:5000 on an ODYSSEY® Quantitative Florescent imager using standard manufacturer's protocol (LI-COR). Bands were quantitated using Odyssey imaging software version 3.0.30.

Primary Antibodies: EGFR 1:1000 dilution (Cell Signaling Technology, #4405), FRZD2 1:500 dilution (Abcam, #52565), IRS1 1:1000 dilution (Cell Signaling Technology, #3407), ITGA6 1:1000 dilution (Cell Signaling Technology, #3750), IGF1R 1:1000 dilution (Cell Signaling Technology, #3018), MET 1:1000 dilution (Cell Signaling Technology, #8198), Pan-AKT 1:1000 dilution (Cell Signaling Technology, #2920), pi-AKT Ser473 1:1000 dilution (Cell Signaling Technology, #4060) Src 1:1000 dilution (Cell Signaling Technology, #2110), pi-Src Tyr416 1:1000 dilution (Cell Signaling Technology, #2101), Stat3 1:1000 dilution (Cell Signaling Technology, #9139), pi-Stat3 Ser727 1:1000 dilution (Cell Signaling Technology, #9134).

Luciferase Reporter Assays: Vectors encoding the wild-type or mutant 3′ UTR of EGFR, IGF1R, MET, and IRS1 cloned behind Renilla luciferase were purchased from Switchgear Genomics. Cells were seeded at 1×10⁴ per well in white bottom 96-well plates. The next day, 100 ng of vector and 15 nM of microRNA mimics were co-transfected using 0.2 μL of DharmaFECT™ Duo transfection reagent (Thermo Scientific). Cells were incubated for 48 hr. For normalization of cell number, 100 μL of CELLTITER-FLUOR cell viability assay reagent (Promega) was added to each well, and cells were incubated for 30 min at 37° C. Florescence was read at 505 nm for assessing cell viability. Luciferase activity was detected using the Renilla-Glo® Luciferase Assay System (Promega) following manufacturer's instructions. Relative luciferase activity was normalized to florescence viability readings for each well. All measurements represent the mean of 6 replicates in each experimental condition.

XTT Proliferation Assay: Cells were seeded at 2×10³ cells/well in 96-well plates and reverse transfected with 15 nM oligonucleotide for 48 hours with 0.15 μL of RNAiMAX as described above. Following transfection, 200 μL of control or media containing 2 μM cisplatin was placed on cells for 3 hr. Cells were washed with warm media, and then fresh media was added. Cell proliferation was assayed on the indicated days with sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) Cell Proliferation Kit (Roche Diagnostics), following manufacturer's instructions. XTT assay reagent was added for 4 hours prior to assay. At each time point, absorbance was read at 450 nM and 655 nm, and Δ absorbance was calculated. All time points represent the mean of 6 replicates in each experimental condition.

Migration Assay: Cells were seeded at 4×10⁵ cells/well in 6-well plates and reverse transfected with 15 μM oligonucleotide for 48 hours as described above. After transfection, the media was replaced and a scratch devoid of cells was created in each well laterally and longitudinally with a p1000 pipet tip. Four marked locations in each scratch were imaged a various time points at 100× magnification. The area of the scratch was determined using ImageJ software (Schneider et al., Nat. Methods 9:971-675, 2012), and the percent of migration into the empty area over time was calculated.

MATRIGEL Invasion Assay: Cells were seeded in 6-well plates and reverse transfected with 15 nM oligonucleotide for 48 hours with RNAiMAX as described above. Following transfection, cells were trypsinized and suspended in DMEM without additives. BioCoat™ Growth Factor Reduced Invasion Chambers were prepared as per manufacturer's instructions (BD Biosciences). 5×10⁴ cells were placed in the top of each chamber. The bottom sides of chambers were placed in wells containing 100 ng/mL rEGF (Millipore) as a chemoattractant in DMEM. Chambers were incubated for 24 hours at 37° C. Non-invading cells were removed by scrubbing the top of invasion membranes, and invading cells were stained with 0.05% crystal violet solution in methanol for 1 min (Sigma). Invasion membranes were mounted on glass slides and invading cells counted at 100× magnification.

Colony Formation Assay: Cells were seeded in 6-well plates and reverse transfected with 15 nM oligonucleotide for 48 hours with RNAiMAX as described above. Following transfection, cells were trypsinized and re-plated in 6-well plates at varying densities. Cells were incubated for 11 days and then stained with 0.1% crystal violet/methanol solution. Colonies with >50 cells were counted in three replicate wells, and the fraction of surviving cells was calculated.

Development of miR30a Nanoparticles Bearing Anti-transferrin Receptor Single-chain Antibody Fragment: Fluorescent siRNA to test nanoparticle in vivo delivery was synthesized by Trilink Biotechnologies, and the formulation of the oligonucleotides into liposomes was performed as previously described (Pirollo et al., Hum. Gene Ther. 17:117-124, 2006; Pirollo et al., Cancer Res. 67:2938-2943, 2007; Yu et al., Nucleic Acids Res. 32:e48, 2004). Briefly, 1:1 molar ratios of each single-stranded antisense and cognate sense oligonucleotide were annealed. Cationic liposome (dioleoyltrimethylammonium phosphate (DOTAP) and dioleoylphosphatidylethanolamine (DOPE), Avanti Polar Lipids, Alabaster, AL) was prepared at a 1:1 molar ratio by ethanol injection (Xu et al., Nol. Med. 7:723-734, 2001). The anti-transferrin receptor single-chain antibody fragment (TfRscFv) was mixed with the liposome at the previously established ratio of 1:30 (w/w) (Yu et al., Nucleic Acids Res. 32:e48, 2004). The miRNA molecules were subsequently added to the admixture at a ratio of 1 μg siRNA to 7 nmol liposome, followed by sizing and confirmation of nanosize particle distributions of the final immunoliposome formulations by dynamic light scattering with a Malvern Zetasizer 3000 HS (Malvern, Worcestershire, UK). miR-30a mimic oligonucleotide with a guide strand sequence 5″-UGUAAACAUCCUCGACUGGAAGCU-3′ (SEQ ID NO: 1) and a passenger strand sequence of 5′-AGCUUCCAGUCGGAUGUUUACACG-3′ (SEQ ID NO: 72) were synthesized by Trilink Biotechnologies. Following annealing the mimic was formulated as described above. Complexed miR30a mimic is referred to as miR-30a-scL.

In Vivo Tumor targeting and Growth Assays: All animal experiments were carried out under protocols approved by the Animal Care and Use Committee of the NIDCD, and were in compliance with the Guide for the Care and Use of Laboratory Animal Resource, (1996) National Research Council. Six to eight week old athymic nu/nu female mice (obtained from Frederick Cancer Research and Development Center, NCI) were injected subcutaneously (s.c.) with 2×10⁶ UM-SCC-46 cells in 100 μL of 30% Type 3 BME Cultrex (Trevigen)/MEM media on the right leg. Once tumors reached ˜100 mm³ (approximately 1 week after injection), mice were randomized into four groups for treatment (n=4-5 mice each); Control and miR-30a-scL. Nine doses of 3 mg/kg miR-30a-scL was administered via tail vain injection on Monday, Wednesday, and Friday (MWF) over three weeks for a total of nine dosages. Tumor size was measured on MWF with external calipers and volume calculated with the formula V=½L*W². Tumor growth is reported as mean volume with standard error of the mean. Kaplan-Meier survival analysis was performed in GraphPad PRISM software (v6.05). Survival statistics were performed using the Log-rank (Mantel-Cox) test, and Hazard ratio calculated via Log-rank test.

Immunofluorescence: Fresh tumors were embedded in OCT and then frozen immediately on dry ice. Tumor tissues were sectioned into 5 μm sections. Sections were fixed for 7 minutes at −20° C. with ice-cold methanol (EMD Millipore Corporation, Billerica, MA). Samples were then washed three times with PBS. Sections were blocked by incubation in a humidifying chamber at RT for one hour with blocking solution 1 (3% BSA+0.05% Tween 20 in 1×PBS) followed by a one-hour incubation with blocking solution 2 (10% NGS in 1×PBS). Sections were then incubated with primary antibody diluted in dilution solution (1% BSA+0.1% Tween 20 in 1×PBS) overnight at 4° C. in a humidifying chamber. After washing the cells five times with 1×PBS, the slides were mounted with Vectashield mounting medium with DAPI (Vector Laboratories Inc, Burlingame, CA) in the dark. Samples were analyzed on a LSM 780 confocal microscope (Carl Zeiss Microimaging, Thornwood, NY). Confocal data was analyzed using Zen 2012 SP1 (black edition) software and the degree of color intensity was ascertained using Zen 2012 (blue edition) software.

Example 2 Decreased Expression of miR-30 Family Members in HNSCC Tissue

To examine miRNA (miRs) differentially expressed in HNSCC tissues, miR sequencing data of 279 HNSCC with 16 squamous mucosa control specimens published by TCGA (Cancer Genome Atlas 2015) were analyzed. Through differential expression analysis between tumor and mucosa specimens, 129 miRs, including 77 increased and 53 decreased miRs (FDR<0.2; Table 3, FIG. 1 ; FIGS. 2A and 2B) were identified. These observations were validated by miR sequencing and expression analysis of an independent panel of 13 HNSCC specimens from oral cavity and 9 matched mucosa samples from the University of Michigan (Table 4). Pair-wise comparison of significantly altered and validated miRs in both data sets uncovered decreased expression of several members of the miR-30 family, and several miRs identified in prior studies (FIGS. 2C and 2D; Tables 3 and 4). Notably, miR-30-5p family members exhibited at least 2-fold decreased expression spanning >70% of specimens in both cohorts.

TABLE 3 Differentially expressed miRNAs in HNSCC (TCGA set) miRNA MIMAT ID Geneind Score FoldChange qval Increased expression hsa-miR-21-5p MIMAT0000076 12 1799.9 2.848 0 hsa-miR-196b-5p MIMAT0001080 101 1719.9 6.054 0 hsa-miR-455-3p MIMAT0004784 126 1714.45 5.598 0 hsa-miR-106b-3p MIMAT0004672 150 1699.15 2.131 0 hsa-let-7d-3p MIMAT0004484 142 1658.35 1.833 0 hsa-miR-151a-5p MIMAT0004697 123 1634.75 2.301 0 hsa-miR-423-5p MIMAT0004748 124 1620.05 2.205 0 hsa-miR-424-5p MIMAT0001341 103 1554.25 2.837 0 hsa-miR-181b-5p MIMAT0000257 43 1513.55 1.724 0 hsa-miR-1307-3p MIMAT0005951 132 1488.5 1.985 0 hsa-miR-320a MIMAT0000510 83 1418.85 1.965 0 hsa-miR-185-5p MIMAT0000455 79 1402.75 1.853 0 hsa-let-7d-5p MIMAT0000065 4 1402.05 1.483 0 hsa-miR-2355-5p MIMAT0016895 133 1388.9 2.368 0 hsa-miR-193b-3p MIMAT0002819 110 1374.6 3.458 0 hsa-miR-183-5p MIMAT0000261 45 1361.35 2.469 0 hsa-miR-25-3p MIMAT0000081 16 1347.85 1.547 0 hsa-miR-99b-3p MIMAT0004678 151 1333.4 1.798 0 hsa-miR-181a-5p MIMAT0000256 42 1325.4 1.582 0 hsa-miR-182-5p MIMAT0000259 44 1308.85 2.178 0 hsa-miR-93-5p MIMAT0000093 24 1282.15 2.317 0 hsa-miR-589-5p MIMAT0004799 128 1276.8 1.686 0 hsa-miR-28-3p MIMAT0004502 117 1236.75 1.574 0 hsa-miR-103a-3p MIMAT0000101 30 1230.4 1.437 0 hsa-miR-92b-3p MIMAT0003218 112 1223.3 2.018 0 hsa-miR-146b-5p MIMAT0002809 109 1221.2 1.906 0 hsa-miR-944 MIMAT0004987 131 1211.9 1.928 0 hsa-miR-197-3p MIMAT0000227 33 1171.35 1.551 0 hsa-miR-542-3p MIMAT0003389 115 1155.65 1.97 0 hsa-miR-92a-3p MIMAT0000092 23 1132.25 1.612 0 hsa-miR-423-3p MIMAT0001340 102 1129.25 1.848 0 hsa-miR-708-5p MIMAT0004926 130 1119.8 1.866 0 hsa-miR-15b-5p MIMAT0000417 57 1097.6 1.473 0 hsa-miR-148b-3p MIMAT0000759 99 1097.4 1.442 0 hsa-miR-484 MIMAT0002174 107 1084.6 1.556 0 hsa-miR-342-3p MIMAT0000753 97 1063.8 1.875 0 hsa-let-7i-5p MIMAT0000415 56 1049.75 1.504 0 hsa-miR-224-5p MIMAT0000281 53 1038 2.3 0 hsa-miR-16-5p MIMAT0000069 8 1025.6 1.404 0 hsa-miR-210-3p MIMAT0000267 49 1022.25 2.406 0 hsa-miR-222-3p MIMAT0000279 51 1021.1 1.716 0 hsa-miR-151a-3p MIMAT0000757 98 1020.25 1.43 0 hsa-miR-181a-2-3p MIMAT0004558 145 1015.45 1.452 0 hsa-miR-106b-5p MIMAT0000680 86 993 1.334 0 hsa-miR-17-5p MIMAT0000070 9 991.5 1.816 0 hsa-let-7e-5p MIMAT0000066 5 983.4 1.6 0 hsa-miR-193a-5p MIMAT0004614 121 929.5 1.591 0 hsa-miR-15a-5p MIMAT0000068 7 929 1.501 0 hsa-miR-708-3p MIMAT0004927 154 915.35 1.55 0 hsa-miR-132-3p MIMAT0000426 63 898.15 1.336 0 hsa-miR-181a-3p MIMAT0000270 136 878.8 1.372 0 hsa-miR-191-5p MIMAT0000440 70 859.15 1.539 0 hsa-miR-9-5p MIMAT0000441 71 810.95 2.349 0 hsa-miR-99b-5p MIMAT0000689 89 778.8 1.323 0 hsa-miR-574-3p MIMAT0003239 113 738.3 1.38 0 hsa-miR-205-5p MIMAT0000266 48 721.95 1.562 0 hsa-let-7i-3p MIMAT0004585 146 708.95 1.506 0.113 hsa-miR-365a-3p MIMAT0000710 92 695.85 1.406 0.212 hsa-miR-223-3p MIMAT0000280 52 690 1.721 0.212 hsa-miR-20a-5p MIMAT0000075 11 687.7 1.623 0.212 hsa-miR-425-5p MIMAT0003393 116 678.25 1.683 0.212 hsa-miR-200c-3p MIMAT0000617 84 667.55 1.401 0.212 hsa-miR-625-3p MIMAT0004808 153 655.6 1.371 0.212 hsa-miR-155-5p MIMAT0000646 85 631.85 1.358 0.311 hsa-miR-192-5p MIMAT0000222 32 629.6 1.233 0.311 hsa-miR-21-3p MIMAT0004494 143 615.1 1.748 0.406 hsa-miR-186-5p MIMAT0000456 80 613.95 1.177 0.406 hsa-miR-23a-3p MIMAT0000078 14 578.15 1.224 0.602 hsa-miR-200c-5p MIMAT0004657 149 536.1 1.448 0.787 hsa-miR-98-5p MIMAT0000096 25 525.65 1.1 0.787 hsa-miR-629-5p MIMAT0004810 129 505.75 1.178 0.974 hsa-miR-24-3p MIMAT0000080 15 482.85 1.075 1.311 hsa-miR-146a-5p MIMAT0000449 76 477.95 1.237 1.311 hsa-miR-221-3p MIMAT0000278 50 477 1.227 1.311 hsa-miR-142-3p MIMAT0000434 66 430.8 1.419 1.838 hsa-miR-28-5p MIMAT0000085 20 402.7 1.09 2.323 hsa-miR-22-3p MIMAT0000077 13 391.85 1.163 2.479 Decreased expression hsa-miR-101-3p MIMAT0000099 28 −1893.1 0.269 0 hsa-miR-100-5p MIMAT0000098 27 −1867.35 0.259 0 hsa-miR-126-5p MIMAT0000444 137 −1849.95 0.417 0 hsa-miR-375 MIMAT0000728 93 −1819.6 0.029 0 hsa-miR-99a-5p MIMAT0000097 26 −1811.3 0.207 0 hsa-let-7c-5p MIMAT0000064 3 −1629.3 0.286 0 hsa-miR-30a-5p MIMAT0000087 22 −1600.15 0.391 0 hsa-miR-30e-5p MIMAT0000692 90 −1598 0.522 0 hsa-miR-27b-3p MIMAT0000419 59 −1545.15 0.414 0 hsa-miR-199b-5p MIMAT0000263 46 −1544.4 0.398 0 hsa-miR-378a-5p MIMAT0000731 139 −1537.6 0.396 0 hsa-miR-125b-5p MIMAT0000423 61 −1530.95 0.467 0 hsa-miR-338-3p MIMAT0000763 100 −1482.1 0.397 0 hsa-miR-29a-3p MIMAT0000086 21 −1469.7 0.474 0 hsa-miR-29c-3p MIMAT0000681 87 −1439.25 0.286 0 hsa-miR-30a-3p MIMAT0000088 135 −1417.6 0.332 0 hsa-miR-26a-5p MIMAT0000082 17 −1361.5 0.595 0 hsa-miR-140-3p MIMAT0004597 119 −1347.05 0.579 0 hsa-miR-378a-3p MIMAT0000732 94 −1330.5 0.489 0 hsa-miR-10b-5p MIMAT0000254 40 −1282 0.485 0 hsa-miR-23b-3p MIMAT0000418 58 −1268.4 0.656 0 hsa-miR-203a-3p MIMAT0000264 47 −1176.7 0.409 0 hsa-miR-381-3p MIMAT0000736 96 −1054.75 0.376 0 hsa-miR-486-5p MIMAT0002177 108 −983.9 0.474 0 hsa-miR-379-5p MIMAT0000733 95 −980.65 0.527 0 hsa-miR-30e-3p MIMAT0000693 138 −881.8 0.687 0 hsa-miR-26b-5p MIMAT0000083 18 −879.55 0.691 0 hsa-miR-199a-3p MIMAT0000232 35 −874.45 0.712 0 hsa-miR-199b-3p MIMAT0004563 118 −869.1 0.71 0 hsa-miR-582-3p MIMAT0004797 127 −720.2 0.693 0.964 hsa-miR-451a MIMAT0001631 105 −692.2 0.458 1.299 hsa-miR-126-3p MIMAT0000445 73 −639.75 0.709 2.003 hsa-miR-143-3p MIMAT0000435 67 −633.15 0.651 2.003 hsa-miR-199a-5p MIMAT0000231 34 −611.7 0.695 2.633 hsa-miR-29b-3p MIMAT0000100 29 −580.2 0.837 2.633 hsa-miR-10a-5p MIMAT0000253 39 −569.5 0.596 2.758 hsa-miR-206 MIMAT0000462 82 −535.9 0.05 2.88 hsa-miR-145-5p MIMAT0000437 68 −535.8 0.793 2.88 hsa-miR-34a-5p MIMAT0000255 41 −508.05 0.787 3.023 hsa-miR-127-5p MIMAT0004604 120 −497.3 0.875 3.023 hsa-miR-127-3p MIMAT0000446 74 −483.45 0.779 3.137 hsa-miR-30d-5p MIMAT0000245 38 −475.45 0.846 3.274 hsa-miR-148a-3p MIMAT0000243 36 −466.6 0.899 3.274 hsa-miR-144-5p MIMAT0004600 148 −412.75 0.565 3.864 hsa-miR-30b-5p MIMAT0000420 60 −404.5 0.895 3.992 hsa-miR-200b-3p MIMAT0000318 54 −390.75 0.933 4.118 hsa-miR-17-3p MIMAT0000071 134 −349.75 0.852 4.713 hsa-miR-374a-3p MIMAT0004688 152 −314.95 0.808 5.143 hsa-miR-532-5p MIMAT0002888 111 −276.15 0.894 5.982 hsa-miR-149-5p MIMAT0000450 77 −271.75 0.823 5.982 hsa-miR-150-5p MIMAT0000451 78 −195 0.779 7.762 hsa-let-7b-5p MIMAT0000063 2 −184.35 0.97 8.004 hsa-let-7a-5p MIMAT0000062 1 −174.75 0.898 8.242

TABLE 4 Validation of differentially expressed miRNAs in HNSCC (UMSC set) miRNA MIMAT ID Geneind Score FoldChange qval Increased expression hsa-miR-517a-3p MIMAT0002852 1414 54.65 3.3E+09 0 hsa-miR-517c-3p MIMAT0002866 1416 54.55 1.5E+09 0 hsa-miR-517b-3p MIMAT0002857 1415 52.95 3.3E+09 0 hsa-miR-132-5p MIMAT0004594 167 49.8 3.551 0 hsa-miR-542-5p MIMAT0003340 1467 46.5 4.807 0 hsa-miR-223-5p MIMAT0004570 365 45.5 10.963 0 hsa-miR-29b-1-5p MIMAT0004514 415 45.35 4.115 0 hsa-miR-2355-5p MIMAT0016895 373 42.1 2.314 4.332 hsa-miR-196a-5p MIMAT0000226 292 41.3 11.348 4.332 hsa-miR-196b-5p MIMAT0001080 294 41.15 14.732 4.332 hsa-miR-181a-3p MIMAT0000270 241 40.4 4.319 5.56 hsa-miR-181a-2-3p MIMAT0004558 242 39.3 4.229 5.56 hsa-miR-941 MIMAT0004984 1722 39.15 4.512 5.56 hsa-miR-503-5p MIMAT0002874 1382 39.05 18.902 5.56 hsa-miR-132-3p MIMAT0000426 166 38.4 1.889 6.749 hsa-miR-520f-3p MIMAT0002830 1445 36.75 2.5E+08 6.749 hsa-miR-9-5p MIMAT0000441 1701 36.5 11.27 6.749 hsa-miR-519d-3p MIMAT0002853 1434 35.95 3.7E+08 7.95 hsa-miR-515-3p MIMAT0002827 1407 35.8 2.6E+08 7.95 hsa-miR-519e-3p MIMAT0002829 1435 35.15 1.5E+08 7.95 hsa-miR-520g-3p MIMAT0002858 1446 35.1 3.1E+08 7.95 hsa-miR-520h MIMAT0002867 1447 35 4.2E+08 7.95 hsa-miR-301b-3p MIMAT0004958 421 34.95 2.786 7.95 hsa-miR-424-5p MIMAT0001341 825 34.75 3.119 7.95 hsa-miR-21-5p MIMAT0000076 332 34.55 8.413 7.95 hsa-miR-455-5p MIMAT0003150 1068 34.5 2.6 7.95 hsa-miR-542-3p MIMAT0003389 1466 34.15 2.303 8.87 hsa-miR-185-5p MIMAT0000455 254 33.75 2.669 9.747 hsa-miR-187-3p MIMAT0000262 258 33.05 4.158 11.136 hsa-miR-28-3p MIMAT0004502 400 32.15 2.285 11.764 hsa-miR-450b-5p MIMAT0004909 1024 32.05   2E+08 11.764 hsa-let-7i-5p MIMAT0000415 16 32 3.185 11.764 hsa-miR-455-3p MIMAT0004784 1067 31.45 3.077 13.442 hsa-miR-1256 MIMAT0005907 92 31.1 2.352 15.247 hsa-miR-518d-5p MIMAT0005456 1423 29.65 1.3E+08 20.059 hsa-miR-34c-5p MIMAT0000686 614 29.6 2.194 20.059 hsa-miR-146a-3p MIMAT0004608 203 29.3 3.4E+08 20.059 hsa-miR-214-5p MIMAT0004564 347 29.15 2.011 20.059 hsa-miR-29a-5p MIMAT0004503 413 29.15 1.772 20.059 Decreased Expression hsa-miR-100-5p MIMAT0000098 19 −53.5 0.548 0 hsa-miR-99a-5p MIMAT0000097 1730 −52.65 0.408 0 hsa-miR-375 MIMAT0000728 741 −51.5 0.036 0 hsa-miR-204-5p MIMAT0000265 319 −50.5 0.103 0 hsa-miR-92b-3p MIMAT0003218 1710 −48.4 0.352 0 hsa-miR-423-5p MIMAT0004748 824 −47.25 0.553 0 hsa-miR-1247-5p MIMAT0005899 82 −46.75 0.092 0 hsa-miR-139-5p MIMAT0000250 187 −46.15 0.344 0 hsa-miR-99a-3p MIMAT0004511 1731 −45.75 0.267 0 hsa-miR-125b-2-3p MIMAT0004603 99 −45.65 0.302 0 hsa-miR-30d-5p MIMAT0000245 445 −44.15 0.318 0 hsa-miR-193a-3p MIMAT0000459 284 −42.75 0.321 0 hsa-miR-365a-3p MIMAT0000710 657 −42.4 0.393 0 hsa-miR-378b MIMAT0014999 750 −40.9 0.307 0 hsa-miR-328-3p MIMAT0000752 585 −40.35 0.42 0 hsa-miR-338-3p MIMAT0000763 595 −40.1 0.276 0 hsa-miR-497-5p MIMAT0002820 1368 −39.95 0.319 0 hsa-miR-92a-3p MIMAT0000092 1707 −39.8 0.639 0 hsa-miR-378e MIMAT0018927 753 −39.65 0.347 0 hsa-miR-30a-5p MIMAT0000087 438 −39.4 0.452 0 hsa-miR-26a-5p MIMAT0000082 391 −38.85 0.435 0 hsa-miR-195-5p MIMAT0000461 290 −38.7 0.429 0 hsa-miR-30c-5p MIMAT0000244 442 −37.9 0.386 0 hsa-miR-210-3p MIMAT0000267 334 −37.3 0.477 2.822 hsa-miR-30e-5p MIMAT0000692 447 −37.15 0.434 2.822 hsa-miR-423-3p MIMAT0001340 823 −37.05 0.513 2.822 hsa-miR-30b-5p MIMAT0000420 440 −36.8 0.488 2.822 hsa-miR-136-3p MIMAT0004606 181 −35.4 0.319 2.822 hsa-miR-200b-5p MIMAT0004571 313 −35.4 0.548 2.822 hsa-miR-24-1-5p MIMAT0000079 381 −35.4 0.641 2.822 hsa-miR-378d MIMAT0018926 752 −35.1 0.365 2.822 hsa-miR-378g MIMAT0018937 755 −34.95 0.364 2.822 hsa-miR-887-3p MIMAT0004951 1692 −34.85 0.249 2.822 hsa-miR-205-5p MIMAT0000266 320 −34.5 0.405 2.822 hsa-miR-885-5p MIMAT0004947 1691 −34.4 0 2.822 hsa-miR-211-5p MIMAT0000268 335 −34 0.074 2.822 hsa-miR-378f MIMAT0018932 754 −33.95 0.361 2.822 hsa-miR-222-3p MIMAT0000279 362 −33.8 0.596 2.822 hsa-miR-23c MIMAT0018000 379 −33.65 0.598 2.822 hsa-miR-378c MIMAT0016847 751 −33.45 0.516 2.822 hsa-miR-376a-3p MIMAT0000729 742 −32.85 0.483 4.58 hsa-miR-335-5p MIMAT0000765 591 −32.75 0.218 4.58 hsa-miR-378i MIMAT0019074 757 −32.5 0.558 4.58 hsa-miR-378a-3p MIMAT0000732 748 −32.45 0.477 4.58 hsa-miR-378h MIMAT0018984 756 −32.45 0.296 4.58 hsa-miR-125b-5p MIMAT0000423 97 −32.4 0.624 4.58 hsa-miR-381-3p MIMAT0000736 762 −32.35 0.129 4.58 hsa-miR-24-3p MIMAT0000080 380 −32.3 0.856 4.58 hsa-miR-486-3p MIMAT0004762 1351 −32.1 0.172 4.58 hsa-miR-664a-3p MIMAT0005949 1647 −32.1 0.34 4.58 hsa-miR-532-3p MIMAT0004780 1461 −32 0.37 4.58 hsa-miR-30a-3p MIMAT0000088 439 −31.65 0.429 4.58 hsa-miR-95-3p MIMAT0000094 1726 −31.5 0.444 5.174 hsa-miR-337-5p MIMAT0004695 594 −30.9 0.251 5.478 hsa-miR-361-5p MIMAT0000703 627 −29.85 0.601 7.87 hsa-miR-874-3p MIMAT0004911 1683 −29.85 0.397 7.87 hsa-miR-200a-3p MIMAT0000682 310 −29.55 0.326 8.977 hsa-miR-145-5p MIMAT0000437 198 −29.25 0.65 9.861 hsa-miR-4284 MIMAT0016915 862 −28.7 0.281 10.464 hsa-miR-377-5p MIMAT0004689 747 −28.65 0.133 10.464 hsa-miR-30e-3p MIMAT0000693 448 −28.55 0.585 10.464 hsa-miR-33b-5p MIMAT0003301 601 −28.2 0.313 10.746 hsa-miR-744-5p MIMAT0004945 1666 −28.2 0.396 10.746 hsa-miR-186-5p MIMAT0000456 256 −27.35 0.516 13.582 hsa-miR-499a-5p MIMAT0002870 1372 −27 0 14.255 hsa-miR-141-3p MIMAT0000432 190 −26.75 0.471 14.255 hsa-miR-26b-5p MIMAT0000083 394 −26.7 0.667 14.255 hsa-miR-181c-5p MIMAT0000258 244 −26.45 0.399 14.255 hsa-miR-133b MIMAT0000770 173 −26.35 0.106 14.255 hsa-miR-203a-3p MIMAT0000264 318 −26.3 0.51 14.255 hsa-miR-136-5p MIMAT0000448 180 −26.25 0.628 14.968 hsa-miR-376c-3p MIMAT0000720 745 −25.95 0.294 14.968 hsa-miR-3622a-5p MIMAT0018003 647 −25.9 0 14.968 hsa-miR-154-5p MIMAT0000452 226 −25.85 0.397 14.968 hsa-miR-133a-3p MIMAT0000427 172 −25.75 0.099 14.968 hsa-miR-574-3p MIMAT0003239 1543 −25.7 0.434 14.968 hsa-mir-1280 MIMAT0005946 132 −25.65 0.425 14.968 hsa-miR-149-5p MIMAT0000450 214 −25.65 0.473 14.968 hsa-miR-214-3p MIMAT0000271 346 −25.6 0.492 14.968 hsa-miR-1291 MIMAT0005881 146 −25.3 0 16.057 hsa-miR-126-5p MIMAT0000444 101 −25.2 0.627 16.057 hsa-miR-484 MIMAT0002174 1348 −25.15 0.525 16.057 hsa-miR-23a-3p MIMAT0000078 375 −24.9 0.79 16.057 hsa-miR-99b-5p MIMAT0000689 1732 −24.9 0.676 16.057 hsa-miR-199b-5p MIMAT0000263 304 −24.7 0.562 16.435 hsa-miR-1271-5p MIMAT0005796 118 −24.45 0.624 16.686 hsa-miR-1268a MIMAT0005922 111 −24.3 0 16.933 hsa-miR-186-3p MIMAT0004612 257 −24.1 0.396 17.415 hsa-miR-3615 MIMAT0017994 635 −24.1 0.37 17.415 hsa-miR-422a MIMAT0001339 822 −23.7 0 18.026 hsa-miR-1249-3p MIMAT0005901 84 −23.4 0.287 18.627

Example 3 miR-30 Family Members Inhibit HNSCC Proliferation

An independent functional genomics screen was performed after transfecting a library of 781 miRs into the human HNSCC line UM-SCC-1 to identify candidate miRs that inhibited proliferation (Table 5). To enrich screening hits for miRs with relevance to disease biology, miRs that displayed high anti-proliferative activity (MAD score <−1) were filtered against miRs that also displayed reduced expression by sequence profiling in both TCGA and UMSC validation datasets (FIGS. 3A and 3B). Nine miRs with decreased expression in tumor specimens were identified that displayed significant inhibitory activity when re-expressed during the functional genomic screen (FIG. 3C). Strikingly, several members of the miR-30-5p family were again present among this highly selected class of miRs, supporting the biologic and functional importance of miR-30-5p family members in HNSCC. Among these, miR-30a-5p and miR-30e-5p were the most highly expressed in mucosa samples and decreased across the tumor specimens (FIG. 3D).

TABLE 5 Candidate miRNAs that inhibit HNSCC proliferation Gene Signal MAD Score MIMAT ID hsa-miR-29b-1-5p 4.187766 −2.2489101 MIMAT0004514 hsa-miR-593-5p 8.12201 −2.0705311 MIMAT0003261 hsa-miR-603 9.64568 −2.0014477 MIMAT0003271 hsa-miR-137 10.4889 −1.9632159 MIMAT0000429 hsa-miR-217 10.51062 −1.9622312 MIMAT0000274 hsa-miR-570-3p 10.55155 −1.9603754 MIMAT0003235 hsa-miR-27b-5p 13.10053 −1.8448044 MIMAT0004588 hsa-miR-216b-5p 13.18732 −1.8408692 MIMAT0004959 hsa-miR-589-5p 14.47781 −1.7823586 MIMAT0004799 hsa-miR-9-5p 14.53328 −1.7798433 MIMAT0000441 hsa-miR-145-5p 15.30917 −1.7446645 MIMAT0000437 hsa-miR-96-5p 15.68504 −1.7276227 MIMAT0000095 hsa-miR-657 15.87208 −1.7191421 MIMAT0003335 hsa-miR-608 17.80167 −1.6316544 MIMAT0003276 hsa-miR-619-3p 18.3711 −1.6058364 MIMAT0003288 hsa-miR-548o-3p 18.76871 −1.5878087 MIMAT0005919 hsa-miR-26a-5p 18.84667 −1.584274 MIMAT0000082 hsa-miR-633 19.39796 −1.5592783 MIMAT0003303 hsa-miR-542-5p 19.68481 −1.5462724 MIMAT0003340 hsa-miR-330-3p 20.29708 −1.5185119 MIMAT0000751 hsa-miR-1272 20.4797 −1.5102322 MIMAT0005925 hsa-miR-136-5p 20.69347 −1.5005399 MIMAT0000448 hsa-miR-1236-3p 20.87731 −1.4922045 MIMAT0005591 hsa-miR-375 21.15436 −1.4796432 MIMAT0000728 hsa-miR-875-5p 21.1604 −1.4793693 MIMAT0004922 hsa-miR-802 21.51106 −1.4634702 MIMAT0004185 hsa-miR-1270 21.73955 −1.4531104 MIMAT0005924 hsa-miR-491-5p 21.80712 −1.4500466 MIMAT0002807 hsa-miR-548d-3p 21.98693 −1.441894 MIMAT0003323 hsa-miR-1201 22.4862 −1.4192573 dead hsa-miR-1826 22.56671 −1.4156069 dead hsa-miR-888-5p 22.91194 −1.3999539 MIMAT0004916 hsa-miR-513a-3p 23.13434 −1.3898705 MIMAT0004777 hsa-miR-612 23.63225 −1.367295 MIMAT0003280 hsa-miR-30c-5p 23.73198 −1.3627735 MIMAT0000244 hsa-miR-1299 23.87786 −1.356159 MIMAT0005887 hsa-miR-1975 24.18666 −1.3421584 dead hsa-miR-24-1-5p 24.37669 −1.3335424 MIMAT0000079 hsa-miR-340-5p 24.59735 −1.3235374 MIMAT0004692 hsa-miR-138-2-3p 24.66306 −1.320558 MIMAT0004596 hsa-miR-541-5p 24.8673 −1.3112979 MIMAT0004919 hsa-miR-142-3p 25.09606 −1.300926 MIMAT0000434 hsa-miR-544a 25.14354 −1.2987732 MIMAT0003164 hsa-miR-567 25.30231 −1.2915744 MIMAT0003231 hsa-miR-146a-5p 25.30952 −1.2912476 MIMAT0000449 hsa-miR-630 25.58343 −1.2788285 MIMAT0003299 hsa-miR-18a-5p 25.87251 −1.2657217 MIMAT0000072 hsa-miR-616-3p 25.9572 −1.2618816 MIMAT0004805 hsa-miR-215-5p 26.08764 −1.2559675 MIMAT0000272 hsa-miR-578 26.42948 −1.2404685 MIMAT0003243 hsa-miR-30b-5p 26.86759 −1.2206044 MIMAT0000420 hsa-miR-186-5p 27.10501 −1.2098401 MIMAT0000456 hsa-miR-590-5p 27.12312 −1.2090186 MIMAT0003258 hsa-miR-518c-5p 27.12724 −1.2088321 MIMAT0002847 hsa-miR-7-5p 27.31268 −1.200424 MIMAT0000252 hsa-miR-342-3p 27.32802 −1.1997288 MIMAT0000753 hsa-miR-30a-5p 27.47793 −1.1929316 MIMAT0000087 hsa-miR-30e-5p 27.52222 −1.1909236 MIMAT0000692 hsa-miR-153-3p 27.61561 −1.1866895 MIMAT0000439 hsa-miR-139-5p 27.66021 −1.1846672 MIMAT0000250 hsa-miR-421 27.67275 −1.1840984 MIMAT0003339 hsa-miR-522-3p 27.88499 −1.1744755 MIMAT0002868 hsa-miR-580-3p 27.89437 −1.1740503 MIMAT0003245 hsa-miR-642a-5p 28.16026 −1.1619948 MIMAT0003312 hsa-miR-200c-3p 28.36733 −1.152606 MIMAT0000617 hsa-miR-503-5p 28.56057 −1.1438447 MIMAT0002874 hsa-miR-17-5p 28.65503 −1.139562 MIMAT0000070 hsa-miR-125b-2-3p 28.79045 −1.1334221 MIMAT0004603 hsa-miR-20a-5p 28.9898 −1.1243834 MIMAT0000075 hsa-miR-205-5p 29.07725 −1.1204183 MIMAT0000266 hsa-miR-618 29.10751 −1.1190463 MIMAT0003287 hsa-miR-30e-3p 29.33285 −1.1088292 MIMAT0000692 hsa-miR-124-5p 29.93332 −1.0816041 MIMAT0004591 hsa-miR-29a-5p 30.21309 −1.0689194 MIMAT0004503 hsa-miR-129-2-3p 30.31542 −1.0642796 MIMAT0004605 hsa-miR-599 30.36961 −1.0618225 MIMAT0003267 hsa-miR-191-5p 30.40741 −1.0601087 MIMAT0000440 hsa-miR-548b-5p 30.48026 −1.0568057 MIMAT0004798 hsa-miR-1244 30.49915 −1.0559492 MIMAT0005896 hsa-miR-452-5p 30.56421 −1.0529995 MIMAT0001635 hsa-miR-664a-3p 30.57374 −1.0525673 MIMAT0005949 hsa-miR-1184 30.70965 −1.0464051 MIMAT0005829 hsa-miR-586 30.75168 −1.0444994 MIMAT0003252 hsa-miR-573 30.87112 −1.0390839 MIMAT0003238 hsa-miR-885-5p 30.99188 −1.0336087 MIMAT0004947 hsa-miR-548h-5p 31.03215 −1.031783 MIMAT0005928 hsa-miR-542-3p 31.06854 −1.0301329 MIMAT0003389 hsa-miR-338-3p 31.07923 −1.0296484 MIMAT0000763 hsa-miR-200b-3p 31.15171 −1.0263622 MIMAT0000318 hsa-miR-651-5p 31.20514 −1.0239397 MIMAT0003321 hsa-miR-155-5p 31.22419 −1.0230761 MIMAT0000646 hsa-miR-526b-5p 31.3515 −1.0173037 MIMAT0002835 hsa-miR-1178-3p 31.37379 −1.0162931 MIMAT0005823 hsa-miR-449b-5p 31.38433 −1.015815 MIMAT0003327 hsa-miR-216a-5p 31.44441 −1.0130911 MIMAT0000273 hsa-miR-224-5p 31.57519 −1.0071617 MIMAT0000281 hsa-miR-19b-3p 31.59959 −1.0060554 MIMAT0000074 hsa-miR-506-3p 31.61057 −1.0055571 MIMAT0002878 hsa-miR-30d-5p 31.62978 −1.0046861 MIMAT0000245 hsa-miR-26b-5p 31.69762 −1.0016106 MIMAT0000083

Example 4 Correlation of Inversely Expressed Targets of miRNAs and Pro-Growth Signaling and Metastasis mRNAs

To identify the network of target mRNAs regulated by several miRNAs in HNSCC and underlying their potential function, the reduced expression of miR-30a-5p, miR-30b-5p, miR-30d-5p, miR-30e-5p, miR-26a-5p, miR-26b-5p, miR-145-5p, miR-205-5p, and miR-375 were each analyzed for inverse correlation with mRNAs of potentially biologic importance in cancer. Linear regression analysis was performed between each miRNA and genome-wide mRNA expression levels obtained from RNA-seq performed on 279 HNSCC tumor specimens in the TCGA dataset. The results are shown in Tables 6-14.

As an example, 91 mRNAs were detected as inversely expressed to miR-30a using an FDR≤0.05, and also contained predicted or verified binding sites for miR-30a-5p in the 3′ UTR based on the Ingenuity Pathway Analysis (IPA) microRNA target filter (Table 6). The significant anti-correlation of miR-30a-5p with several representative target genes is presented in FIG. 4 . miR-30a-5p expression displayed an inverse relationship to several oncogenes previously shown to be overexpressed in HNSCC, including EGFR, MET, ITGA6 and SERPINE1 (FIG. 4 ) (Van Waes et al., Cancer Res. 55:5434-5444, 1995; Van Waes et al., Int. J. Radiat. Oncol. Biol. Phys. 77:447-454, 2010; Freudlsperger et al., Expert Opin. Ther. Targets 15:63-74, 2011).

TABLE 6 mRNAs inversely expressed and containing predicted or validated binding sites to miR-30a-5p Source Confidence Symbol t.stat p-value q-value TarBase,TargetSc Experimentally NT5E −2.67544 0.00785943 0.042443335 an Human Observed, High (predicted) TarBase,TargetSc Experimentally SLC7A11 −7.34317 1.8519E−12 2.47526E−10 an Human Observed, High (predicted) TarBase Experimentally WNT5A −3.21244 0.00145446 0.011477956 Observed TarBase Experimentally MET −4.49672 9.7643E−06 0.000186635 Observed miRecords Experimentally STX1A −5.73134 2.3616E−08 1.04475E−06 Observed TargetScan High (predicted) ADAM12 −5.8907 1.0009E−08 4.93575E−07 Human TargetScan High (predicted) ADAMTS14 −4.448 1.2095E−05 0.000223621 Human TargetScan High (predicted) ADAMTS6 −3.11958 0.00198133 0.014647111 Human TargetScan High (predicted) AFAP1L2 −3.57478 0.00040639 0.004129055 Human TargetScan High (predicted) BCL11B −7.45518 9.0434E−13 1.30665E−10 Human TargetScan High (predicted) BNC1 −10.1613 3.9863E−21  3.3215E−18 Human TargetScan High (predicted) CALB2 −2.60695 0.00957701 0.049262735 Human TargetScan High (predicted) CAMK2N2 −4.33529 1.9703E−05 0.000337565 Human TargetScan High (predicted) CBX2 −7.41229 1.1909E−12 1.66992E−10 Human TargetScan Moderate CCNA1 −3.39196 0.00078393 0.007013279 Human (predicted) TargetScan High (predicted) CCNE2 −3.58521 0.00039112 0.004002625 Human TargetScan Moderate CD80 −3.23442 0.00135044 0.010822133 Human (predicted) TargetScan High (predicted) CDCA7 −2.94594 0.00346369 0.022650361 Human TargetScan Moderate CDHR1 −3.55523 0.00043656 0.004375406 Human (predicted) TargetScan High (predicted) CELSR3 −4.19807 3.5211E−05 0.000549357 Human TargetScan Moderate CERS3 −6.93548 2.3632E−11 2.38628E−09 Human (predicted) TargetScan High (predicted) CHST1 −3.42212 0.00070477 0.006439431 Human TargetScan High (predicted) CHST2 −6.88903 3.1387E−11 3.07078E−09 Human TargetScan High (predicted) CNGB3 −4.62375 5.5397E−06 0.000115408 Human TargetScan High (predicted) COL13A1 −6.52577 2.7564E−10  2.0983E−08 Human TargetScan High (predicted) CTHRC1 −3.81302 0.00016563 0.001984823 Human TargetScan High (predicted) DDIT4 −3.52927 0.00047985 0.004724036 Human TargetScan Moderate DSP −5.75525 2.0785E−08 9.34316E−07 Human (predicted) TargetScan High (predicted) E2F7 −5.78932 1.7316E−08 7.96717E−07 Human TargetScan High (predicted) EFNA3 −4.17635 3.8546E−05 0.000592557 Human TargetScan Moderate EGFR −2.69295 0.00746753 0.040839291 Human (predicted) TargetScan High (predicted) EPB41L4B −3.15221 0.00177887 0.013456245 Human TargetScan High (predicted) FAM43A −4.71164 3.7153E−06 8.21663E−05 Human TargetScan High (predicted) FAP −4.57488 6.8998E−06 0.000139116 Human TargetScan High (predicted) FOXD1 −5.39201 1.3836E−07 4.85439E−06 Human TargetScan High (predicted) FZD2 −5.21242  3.41E−07 1.05844E−05 Human TargetScan High (predicted) GJA1 −6.45364 4.2012E−10 3.04202E−08 Human TargetScan High (predicted) GLDC −2.71789 0.00693956 0.038631316 Human TargetScan Moderate GNRHR −4.11924 4.8817E−05 0.000721673 Human (predicted) TargetScan High (predicted) GRHL1 −2.67624 0.00784124 0.042369061 Human TargetScan High (predicted) HEPHL1 −5.0097 9.1733E−07 2.48043E−05 Human TargetScan High (predicted) HOXA11 −5.77494 1.8706E−08 8.52358E−07 Human TargetScan High (predicted) HTRA3 −2.92943 0.00364778 0.023577439 Human TargetScan High (predicted) IGF1R −3.52927 0.00021693 0.000384284 Human TargetScan High (predicted) IL1A −6.20891 1.7114E−09 1.04732E−07 Human TargetScan High (predicted) IL28RA −4.58937 6.4663E−06 0.000131627 Human TargetScan High (predicted) IRS1 −2.61196 0.00944086 0.048733913 Human TargetScan High (predicted) IRX4 −4.38851 1.5668E−05 0.000278244 Human TargetScan High (predicted) ITGA5 −5.94408 7.4786E−09 3.82354E−07 Human TargetScan High (predicted) ITGA6 −6.76279 6.7415E−11 6.04954E−09 Human TargetScan High (predicted) KIAA1804 −3.06917 0.00233624 0.016671132 Human TargetScan High (predicted) KIF3C −4.79377 2.5442E−06 5.94757E−05 Human TargetScan High (predicted) LHX1 −7.00892 1.5048E−11 1.59942E−09 Human TargetScan High (predicted) LOX −3.09258 0.00216471 0.015701083 Human TargetScan High (predicted) LRRC3 −4.33577 1.9662E−05 0.000336972 Human TargetScan High (predicted) MAF −3.14025 0.00185073 0.013882679 Human TargetScan High (predicted) MFHAS1 −4.75352  3.065E−06 6.97331E−05 Human TargetScan High (predicted) MYBL2 −7.83707 7.4462E−14 1.39556E−11 Human TargetScan High (predicted) MYH10 −3.74269 0.00021693 0.002477083 Human TargetScan Moderate MYO1H −2.68 0.00775571 0.042020701 Human (predicted) TargetScan High (predicted) NEFL −5.76182 2.0067E−08  9.0609E−07 Human TargetScan High (predicted) NID1 −4.56143 7.3271E−06 0.000146362 Human TargetScan High (predicted) NOD2 −5.23065  3.115E−07 9.79208E−06 Human TargetScan High (predicted) NREP −3.09434 0.00215234 0.015631917 Human TargetScan High (predicted) NTM −3.79283 0.00017904 0.002115612 Human TargetScan High (predicted) ONECUT2 −2.66567 0.0080862 0.043367382 Human TargetScan High (predicted) OVOL1 −3.56263 0.0004249 0.00428063 Human TargetScan High (predicted) PAG1 −3.29063 0.00111491 0.009292512 Human TargetScan High (predicted) PCDH17 −2.62238 0.00916308 0.047653736 Human TargetScan High (predicted) PDGFRB −3.1546 0.00176483 0.013372471 Human TargetScan Moderate PHLDB2 −7.25139 3.3136E−12 4.15821E−10 Human (predicted) TargetScan Moderate PNPLA1 −6.83038 4.4825E−11 4.20919E−09 Human (predicted) TargetScan High (predicted) PPFIA1 −3.44793 0.000643 0.005981654 Human TargetScan High (predicted) PPP1R14C −5.52887 6.8493E−08 2.63407E−06 Human TargetScan High (predicted) PPP4R4 −2.9497 0.00342301 0.022444469 Human TargetScan High (predicted) RAB38 −5.19914 3.6418E−07 1.11991E−05 Human TargetScan High (predicted) RHEBL1 −2.87936 0.00426207 0.026591947 Human TargetScan High (predicted) RTN4R −5.76779 1.9436E−08 8.81367E−07 Human TargetScan High (predicted) SCN8A −3.00949 0.00283162 0.019369396 Human TargetScan High (predicted) SERPINE1 −6.14674 2.4297E−09  1.4251E−07 Human TargetScan High (predicted) SLC44A5 −4.0284 7.0695E−05 0.000981803 Human TargetScan Moderate SLCO6A1 −4.63823  5.189E−06 0.000109185 Human (predicted) TargetScan High (predicted) SNX10 −6.11018 2.9822E−09 1.70412E−07 Human TargetScan High (predicted) SOCS1 −2.84294 0.00476672 0.028990247 Human TargetScan Moderate STAT1 −2.94123 0.0035153 0.022913435 Human (predicted) TargetScan High (predicted) THBS2 −3.48948 0.00055409 0.00530563 Human TargetScan High (predicted) TMC7 −4.4635 1.1301E−05 0.000211182 Human TargetScan Moderate TNFSF9 −4.07698 5.8042E−05 0.000833474 Human (predicted) TargetScan High (predicted) TRIM9 −2.6338 0.00886708 0.046491218 Human TargetScan High (predicted) TRPA1 −5.02466 8.5363E−07 2.33216E−05 Human TargetScan High (predicted) WNT7B −8.91065 4.4225E−17 1.68683E−14 Human

TABLE 7 mRNAs inversely expressed and containing predicted or validated binding sites to miR-30b-5p (MIMAT0000420) Gene beta t.stat p.value FDR ABCA12 −0.003 −3.7 0.00024 0.0029 ABCA6 −0.0024 −3.2 0.0014 0.012 ADAM12 −0.0041 −4.6 7.70E−06 0.00019 ADAM19 −0.0016 −2.6 0.0095 0.048 ADAMTS14 −0.0026 −4 6.90E−05 0.0011 ADAMTS3 −0.0034 −4.1 4.80E−05 0.00083 ADAMTS5 −0.003 −4.3 2.50E−05 0.00049 ADAMTS9 −0.0018 −2.8 0.0058 0.033 ADRA2A −0.0031 −2.7 0.0079 0.042 AFAP1L2 −0.0018 −3.6 0.00039 0.0043 AGAP2 −0.0014 −2.8 0.0049 0.03 AJAP1 −0.0042 −3.3 0.0012 0.01 ANGPT2 −0.0022 −4.1 5.70E−05 0.00094 ANTXR1 −0.0018 −3.7 0.00028 0.0033 APOL6 −0.0018 −3.3 0.0011 0.0095 ARHGAP29 −0.0016 −2.9 0.004 0.026 ARHGAP42 −0.0017 −3.2 0.0014 0.011 ARNTL2 −0.0018 −4.4 1.30E−05 0.00029 ARRDC4 −0.002 −3.9 0.00012 0.0017 ARSE −0.0043 −4 8.30E−05 0.0013 ATP8B2 −0.0016 −3.2 0.0018 0.014 BCHE −0.0039 −2.9 0.0047 0.029 BDKRB2 −0.0022 −4.8 3.40E−06 9.80E−05 BICD1 −0.0018 −4 8.10E−05 0.0012 BMP2 −0.0021 −3.2 0.0014 0.012 BNC1 −0.0021 −4.1 4.80E−05 0.00083 BNC2 −0.0022 −2.9 0.0041 0.026 BST1 −0.0014 −2.6 0.0092 0.047 CACNA1C −0.003 −4.8 2.40E−06 7.50E−05 CALB2 −0.0049 −4.6 7.90E−06 0.00019 CALCR −0.0042 −2.6 0.0098 0.049 CALD1 −0.0026 −5.6 5.10E−08 3.10E−06 CAMK2N1 −0.0019 −3.1 0.0023 0.017 CCNA1 −0.0048 −3.1 0.0021 0.016 CCRN4L −0.0023 −4.9 1.90E−06 6.00E−05 CD248 −0.0018 −2.7 0.0078 0.042 CD84 −0.0023 −2.7 0.0083 0.044 CDH11 −0.0033 −3.9 0.00014 0.0019 CDH13 −0.0021 −3.5 0.00046 0.0049 CDK6 −0.0021 −4.5 1.10E−05 0.00026 CHN1 −0.0023 −4.2 4.50E−05 0.00078 CHST2 −0.0026 −3.4 0.00078 0.0073 CLCA2 −0.0034 −4.9 2.00E−06 6.50E−05 CLEC5A −0.0019 −3.5 5.00E−04 0.0052 CLSTN2 −0.0041 −3.9 0.00011 0.0016 CNRIP1 −0.0019 −3.8 0.00022 0.0027 CNTN1 −0.0035 −2.9 0.0038 0.024 COL12A1 −0.004 −5.3 2.70E−07 1.30E−05 COL13A1 −0.002 −3.6 0.00042 0.0045 COL14A1 −0.0021 −3 0.0033 0.022 COL5A2 −0.0043 −5.2 3.40E−07 1.50E−05 COL8A1 −0.0039 −3.9 0.00014 0.0019 CPN2 −0.0088 −4.8 3.00E−06 8.80E−05 CSGALNACT1 −0.0021 −4.4 1.70E−05 0.00035 CTGF −0.0022 −3.4 0.00093 0.0084 CTHRC1 −0.0029 −3.4 0.00087 0.0079 CTSK −0.0037 −5.1 5.40E−07 2.20E−05 CYP8B1 −0.0044 −2.9 0.0046 0.028 DACT1 −0.003 −3.4 0.00092 0.0083 DAPP1 −0.0014 −2.7 0.0067 0.037 DCBLD1 −0.0025 −5 9.60E−07 3.50E−05 DDX60 −0.0028 −4.3 2.90E−05 0.00056 DENND2A −0.0016 −2.9 0.0047 0.029 DENND2C −0.0015 −2.9 0.0036 0.023 DGKI −0.0032 −3.2 0.0016 0.013 DIO2 −0.0023 −3 0.0027 0.019 DLEU7 −0.0027 −3 0.0026 0.018 DLX1 −0.004 −3.2 0.0016 0.013 DNASE2B −0.0065 −3 0.0034 0.023 DOCK10 −0.0016 −2.7 0.0077 0.041 DSC1 −0.0088 −5.7 2.50E−08 1.70E−06 DSC3 −0.0011 −2.7 0.0067 0.037 DSEL −0.003 −4.7 5.00E−06 0.00013 DSP −0.0015 −2.7 0.0073 0.04 ECM2 −0.0025 −4.1 4.90E−05 0.00084 EDIL3 −0.0042 −5.1 7.80E−07 3.00E−05 EDNRA −0.0032 −5.6 4.70E−08 2.90E−06 EDNRB −0.0017 −2.9 0.0036 0.024 EFCAB4B −0.0019 −2.9 0.0036 0.023 ELFN2 −0.0038 −2.8 0.0047 0.029 EML1 −0.0026 −4.6 8.10E−06 2.00E−04 EML5 −0.0018 −2.7 0.0079 0.042 ENPEP −0.0019 −3 0.0031 0.021 ENPP1 −0.0021 −2.8 0.0058 0.034 EPHA3 −0.0028 −3.2 0.0016 0.013 FAM124A −0.0016 −2.8 0.0058 0.034 FAM155A −0.0026 −3 0.0031 0.021 FAM20A −0.0019 −2.8 0.0054 0.032 FAM26E −0.0036 −5.5 7.80E−08 4.40E−06 FAM43A −0.002 −4.1 5.50E−05 0.00092 FAP −0.0042 −4.9 1.60E−06 5.30E−05 FBLN7 −0.0019 −3.3 0.0011 0.0096 FBXO39 −0.0023 −3.1 0.0025 0.018 FGD5 −0.0015 −2.9 0.0043 0.027 FGF5 −0.0064 −3.4 0.00072 0.0069 FIGN −0.0033 −3.2 0.0014 0.011 FLVCR2 −0.0027 −5 9.70E−07 3.50E−05 FMN1 −0.0026 −3.3 0.0012 0.01 FRMD5 −0.0038 −3 0.0031 0.021 GALNT13 −0.0038 −2.7 0.0074 0.04 GALNT6 −0.0042 −5.6 5.60E−08 3.40E−06 GBP1 −0.0024 −3.2 0.0014 0.011 GCOM1 −0.0029 −3 0.0025 0.018 GFPT2 −0.0022 −3.2 0.0017 0.013 GJA1 −0.0032 −5.3 2.20E−07 1.10E−05 GOLGA6L1 −0.0061 −3 0.0031 0.021 GOLGA7B −0.0037 −3.9 0.00011 0.0016 GPM6B −0.0017 −3.3 0.00093 0.0084 GPR124 −0.0021 −3.7 0.00023 0.0029 GPR157 −0.0017 −3.2 0.0017 0.013 GPRIN3 −0.0021 −3.1 0.0019 0.015 GUCY1A2 −0.0029 −4 7.10E−05 0.0011 GUCY1A3 −0.0024 −3.7 0.00031 0.0036 GXYLT2 −0.002 −2.6 0.0091 0.047 HAPLN1 −0.0032 −3.1 0.0024 0.017 HAS2 −0.0035 −4.3 2.70E−05 0.00053 HECW1 −0.0034 −3.5 0.00046 0.0049 HEPHL1 −0.0063 −4.5 1.00E−05 0.00024 HGF −0.0043 −4 7.30E−05 0.0012 HHIPL1 −0.003 −4.6 6.70E−06 0.00017 HMCN1 −0.0043 −5.2 4.90E−07 2.00E−05 HOXA1 −0.0023 −3.4 9.00E−04 0.0082 HS3ST3A1 −0.0026 −3.5 0.00056 0.0057 HS3ST3B1 −0.0021 −3 0.0034 0.022 HTRA3 −0.0031 −3.8 0.00017 0.0022 IFIT1 −0.0036 −3.9 0.00014 0.002 IL1A −0.0032 −3.2 0.0017 0.013 INHBA −0.0041 −3.9 0.00013 0.0019 IRS1 −0.0021 −4 7.20E−05 0.0011 ITGA1 −0.0025 −4.2 3.60E−05 0.00065 ITGA5 −0.0024 −3.8 0.00018 0.0023 ITGA6 −0.0021 −3.7 0.00028 0.0033 ITGA8 −0.0038 −3.6 0.00041 0.0045 ITGA9 −0.0018 −2.7 0.0066 0.037 JAM2 −0.0022 −3.5 0.00063 0.0063 KCND2 −0.003 −3 0.0034 0.023 KCNJ15 −0.0028 −4.3 2.10E−05 0.00042 KIAA1024 −0.0015 −2.8 0.0055 0.032 KIAA1644 −0.0034 −4 9.80E−05 0.0015 KLF7 −0.0027 −5.6 5.70E−08 3.40E−06 KLHL4 −0.0036 −2.6 0.0087 0.045 KRT82 −0.0051 −2.7 0.0068 0.038 KRTAP1-5 −0.0054 −2.8 0.0057 0.033 LAMA1 −0.0042 −3.4 0.00078 0.0073 LAMA4 −0.003 −5.1 7.00E−07 2.70E−05 LAMC3 −0.0038 −4.9 1.80E−06 6.00E−05 LHX1 −0.0095 −4.1 5.50E−05 0.00092 LHX8 −0.0041 −2.9 0.0045 0.028 LHX9 −0.0059 −2.8 0.0057 0.033 LILRB2 −0.0022 −3 0.0032 0.021 LIPC −0.0028 −3.1 0.0019 0.015 LOX −0.0023 −3.5 0.00055 0.0056 LPAR3 −0.002 −3.3 0.00096 0.0086 LPPR4 −0.0018 −2.9 0.0043 0.027 LPPR5 −0.0078 −4 8.30E−05 0.0013 LRCH2 −0.0026 −3.4 0.00078 0.0073 LRRC15 −0.006 −5.2 4.50E−07 1.90E−05 LRRC17 −0.0033 −3.1 0.0022 0.016 LSAMP −0.0028 −2.9 0.004 0.026 LTBP2 −0.0021 −3.8 0.00019 0.0024 MAF −0.0014 −2.8 0.0048 0.029 MAN1A1 −0.0019 −3.5 5.00E−04 0.0052 MAP2 −0.004 −4.8 2.70E−06 8.00E−05 ME1 −0.0017 −2.7 0.0073 0.04 MFAP3L −0.0024 −3.5 0.00047 0.005 MICAL2 −0.0022 −3.9 1.00E−04 0.0015 MME −0.0045 −5.2 4.90E−07 2.00E−05 MMP16 −0.0055 −5.2 3.40E−07 1.50E−05 MOCS1 −0.0015 −3 0.0029 0.02 MPZL3 −0.0025 −4.8 2.30E−06 7.30E−05 MS4A7 −0.0024 −3.6 0.00044 0.0047 MXRA5 −0.0033 −4.6 6.20E−06 0.00016 MYH10 −0.0025 −4.7 4.20E−06 0.00012 NAV3 −0.0042 −5.3 2.10E−07 1.00E−05 NEGR1 −0.0036 −3.8 2.00E−04 0.0026 NFASC −0.0017 −3.1 0.0025 0.018 NHSL2 −0.0024 −2.7 0.0082 0.043 NID1 −0.0032 −4.9 1.70E−06 5.50E−05 NID2 −0.0033 −4.5 9.40E−06 0.00022 NIPAL1 −0.0025 −4.1 6.30E−05 0.001 NIPAL4 −0.0044 −4.3 2.10E−05 0.00043 NLRP3 −0.0017 −2.7 0.0083 0.044 NOD2 −0.0027 −5.2 4.40E−07 1.80E−05 NRG1 −0.0025 −3.2 0.0014 0.011 NT5E −0.0033 −4.1 5.80E−05 0.00096 NTM −0.0034 −4.9 2.10E−06 6.70E−05 NTNG1 −0.0051 −2.9 0.0039 0.025 OLFML2A −0.0015 −2.9 0.004 0.026 PAG1 −0.0021 −4 8.40E−05 0.0013 PAQR5 −0.0036 −4.4 1.60E−05 0.00034 PCDH10 −0.0071 −3.9 0.00013 0.0018 PCDH17 −0.0025 −3.7 0.00023 0.0028 PDE3A −0.0035 −4.5 1.10E−05 0.00025 PDE7B −0.0022 −4 7.50E−05 0.0012 PDGFC −0.0025 −4.5 9.10E−06 0.00022 PDGFRB −0.0028 −4.2 3.60E−05 0.00065 PHLDB2 −0.0018 −3.2 0.0016 0.013 PI15 −0.0023 −2.9 0.0043 0.027 PLA2G4D −0.0034 −2.7 0.0072 0.04 PLXDC1 −0.0018 −3.2 0.0015 0.012 PLXDC2 −0.0025 −4.5 1.20E−05 0.00027 PLXNC1 −0.0028 −3.7 0.00024 0.003 PNPLA1 −0.0065 −5.5 8.70E−08 4.90E−06 PPFIA2 −0.0049 −3.4 0.00076 0.0072 PPP1R14C −0.0014 −2.9 0.0035 0.023 PRDM1 −0.0021 −4.9 2.00E−06 6.40E−05 PRDM5 −0.0023 −4 9.20E−05 0.0014 PREX2 −0.0022 −2.6 0.0098 0.049 PRICKLE1 −0.0027 −4.4 1.30E−05 3.00E−04 PRRG1 −0.0018 −3.8 0.00019 0.0024 PRRX1 −0.002 −2.9 0.0037 0.024 PTGDR −0.0031 −4.1 6.30E−05 0.001 PTGER2 −0.0021 −2.9 0.0044 0.027 PTGER3 −0.0038 −4.4 1.40E−05 0.00031 PTGS1 −0.0021 −2.9 0.0043 0.027 PTPRB −0.0016 −3.2 0.0014 0.012 PTPRD −0.0058 −5.3 3.20E−07 1.40E−05 RAB27B −0.0019 −3.5 5.00E−04 0.0052 RAB38 −0.0027 −4 9.40E−05 0.0014 RAB3B −0.0057 −4.1 4.80E−05 0.00083 RAI14 −0.0013 −2.7 0.0076 0.041 RASGRF2 −0.0027 −4.1 6.00E−05 0.00099 RECK −0.0022 −3.9 0.00014 0.0019 RFTN2 −0.0016 −2.9 0.0046 0.028 RSAD2 −0.0035 −3.8 0.00019 0.0024 RUNX1T1 −0.0036 −3.6 0.00044 0.0047 S100A7A −0.0065 −3.6 0.00032 0.0037 SAMHD1 −0.0022 −3.8 0.00019 0.0024 SDC2 −0.0023 −3.5 0.00062 0.0062 SDK2 −0.0026 −2.9 0.0038 0.024 SEC14L2 −0.0021 −3.6 0.00039 0.0043 SERPINE1 −0.0032 −3.7 0.00032 0.0037 SERPING1 −0.0024 −4.1 6.20E−05 0.001 SGIP1 −0.0033 −4.7 5.30E−06 0.00014 SH3TC2 −0.002 −2.8 0.0052 0.031 SHROOM4 −0.0017 −3 0.0034 0.022 SLC10A6 −0.0034 −3.9 0.00012 0.0017 SLC16A10 −0.0018 −2.8 0.0054 0.032 SLC22A15 −0.0014 −2.8 0.0048 0.029 SLC24A2 −0.008 −4.7 4.60E−06 0.00013 SLC28A3 −0.0043 −5 8.70E−07 3.20E−05 SLC2A9 −0.0022 −4.7 4.30E−06 0.00012 SLC38A4 −0.0031 −3.9 0.00012 0.0017 SLC39A8 −0.0016 −3.6 0.00043 0.0046 SLC41A2 −0.003 −5.3 2.30E−07 1.10E−05 SLC44A5 −0.0026 −2.6 0.0097 0.049 SLC7A11 −0.0027 −2.9 0.0044 0.027 SNAI1 −0.0014 −2.8 0.0058 0.034 SNX10 −0.0021 −3.9 0.00011 0.0015 SPTLC3 −0.0061 −6.1 3.40E−09 3.30E−07 STC1 −0.002 −3 0.0025 0.018 SULF2 −0.0026 −4.4 1.40E−05 0.00031 TCHHL1 −0.0077 −3.4 0.00082 0.0076 TGFA −0.0023 −5.2 4.30E−07 1.80E−05 TGM5 −0.0047 −4.3 2.50E−05 0.00049 THBS2 −0.0041 −5.2 4.10E−07 1.80E−05 TIMP2 −0.0035 −6 8.00E−09 6.70E−07 TIMP3 −0.0029 −4 7.80E−05 0.0012 TLL1 −0.0027 −2.8 0.0058 0.034 TLN2 −0.0015 −2.8 0.0051 0.03 TLR8 −0.0031 −3.6 0.00035 0.004 TM4SF18 −0.0019 −3.9 0.00014 0.0019 TM6SF2 −0.004 −3.2 0.0017 0.014 TMEM154 −0.0023 −4.2 4.50E−05 0.00079 TMEM26 −0.0025 −3.7 0.00028 0.0033 TMEM79 −0.0021 −3.4 7.00E−04 0.0067 TMEM86A −0.0031 −5.5 9.80E−08 5.40E−06 TNFSF13B −0.0019 −2.7 0.0073 0.04 TREML2 −0.0038 −4.3 2.80E−05 0.00053 TRPA1 −0.0047 −4.4 1.40E−05 0.00032 TRPC6 −0.0019 −3.5 0.00059 0.0059 TRPS1 −0.0024 −4.8 3.40E−06 9.80E−05 TSHZ2 −0.0018 −2.8 0.0048 0.029 TSPAN11 −0.003 −4.1 5.90E−05 0.00097 TSPAN2 −0.0034 −4.1 5.80E−05 0.00095 UNC5C −0.0041 −3.1 0.0022 0.016 UNC80 −0.0048 −2.8 0.005 0.03 USP2 −0.0025 −2.8 0.0047 0.029 VCAN −0.0038 −4.4 1.90E−05 4.00E−04 VGLL3 −0.0036 −4.9 1.40E−06 4.80E−05 VIM −0.0018 −3.7 0.00031 0.0036 WIPF1 −0.0014 −2.6 0.0092 0.047 WISP1 −0.0032 −3.8 2.00E−04 0.0026 WNT5A −0.0034 −5.6 4.40E−08 2.80E−06 XYLT1 −0.0018 −2.7 0.0071 0.039 ZCCHC24 −0.0017 −3.7 0.00023 0.0028 ZDHHC21 −0.0015 −2.7 0.0076 0.041 ZNF208 −0.0035 −2.7 0.0084 0.044 ZNF365 −0.0052 −6.1 3.00E−09 3.00E−07 ZNF521 −0.0028 −4.2 4.30E−05 0.00076 ZNF681 −0.003 −2.9 0.0039 0.025

TABLE 8 mRNAs inversely expressed to and containing predicted or validated binding sites miR-30d-5p (MIMAT0000245) Gene beta t.stat p.value FDR ABCC2 −0.00014 −3.3 0.0011 0.0095 ACTBL2 −0.00024 −2.9 0.0043 0.027 ADAM12 −0.00015 −3.2 0.0014 0.012 ADAMTS14 −0.00014 −4.2 4.10E−05 0.00073 AFAP1L2 −0.00012 −4.6 7.00E−06 0.00018 AJAP1 −0.00019 −2.8 0.005 0.03 ARNTL2 −8.20E−05 −4 9.00E−05 0.0014 ARRDC4 −7.50E−05 −2.7 0.0067 0.037 BDKRB2 −0.00011 −4.5 9.50E−06 0.00023 BNC1 −0.00014 −5.2 4.60E−07 1.90E−05 C6orf141 −0.00023 −5 1.20E−06 4.20E−05 CALD1 −1.00E−04 −4.2 3.10E−05 0.00059 CAMK2A −0.00028 −4.6 5.30E−06 0.00014 CAMK2N1 −0.00011 −3.6 0.00044 0.0047 CCNA1 −0.00033 −4.2 3.30E−05 0.00062 CCRN4L −0.00011 −4.5 8.60E−06 0.00021 CDH13 −0.00011 −3.7 0.00023 0.0029 CDK6 −0.00011 −4.6 6.60E−06 0.00017 CHST2 −0.00013 −3.2 0.0014 0.012 CLCA2 −0.00015 −4.1 5.50E−05 0.00092 CLCF1 −8.70E−05 −2.9 0.0039 0.025 COL12A1 −0.00017 −4.2 3.30E−05 0.00062 COL13A1 −8.80E−05 −3 0.0032 0.022 COL5A2 −0.00017 −4 9.80E−05 0.0015 CTHRC1 −0.00013 −2.8 0.0051 0.031 DACT1 −0.00013 −2.8 0.0063 0.035 DCBLD1 −0.00016 −6.5 3.80E−10 5.20E−08 DDX60 −0.00012 −3.3 0.001 0.0089 DLX1 −0.00021 −3.3 0.001 0.0092 DNAH17 −2.00E−04 −3.4 0.00081 0.0075 DNMT3B −1.00E−04 −3.7 0.00025 0.003 DSC1 −0.00029 −3.5 0.00049 0.0052 EDNRA −9.10E−05 −3 0.0031 0.021 EML1 −8.60E−05 −2.9 0.0042 0.026 EPHB2 −1.00E−04 −2.6 0.0088 0.046 F3 −0.00012 −2.8 0.006 0.034 FAM26E −0.00011 −3 0.0026 0.018 FAP −0.00019 −4.2 4.00E−05 0.00072 FOXD1 −1.00E−04 −2.9 0.004 0.025 FOXL2 −0.00021 −2.9 0.0035 0.023 FZD2 −7.90E−05 −3 0.0026 0.018 GALNT6 −0.00023 −5.8 2.20E−08 1.60E−06 GBP1 −0.00013 −3.4 0.00073 0.007 GJA1 −0.00016 −5.1 6.20E−07 2.50E−05 GOLGA7B −0.00024 −4.9 1.60E−06 5.40E−05 GPR39 −0.00015 −3 0.003 0.021 HAS2 −0.00013 −3.1 0.002 0.015 HECW1 −0.00013 −2.7 0.0082 0.043 HEPHL1 −0.00026 −3.6 0.00042 0.0046 HOXA1 −0.00014 −3.9 0.00011 0.0015 HSPB3 −3.00E−04 −3.2 0.0017 0.013 HTRA3 −0.00016 −3.8 0.00018 0.0024 IFFO2 −7.80E−05 −2.7 0.0082 0.043 IFIT1 −0.00018 −3.7 3.00E−04 0.0035 IL1A −0.00019 −3.7 0.00024 0.003 INHBA −0.00023 −4.2 4.00E−05 0.00071 IRS1 −9.10E−05 −3.3 0.00094 0.0084 ITGA5 −0.00016 −5 8.60E−07 3.20E−05 ITGA6 −1.00E−04 −3.5 0.00056 0.0057 KCNJ15 −0.00012 −3.5 0.00057 0.0057 KIAA1644 −0.00015 −3.4 0.00066 0.0064 KLF7 −0.00011 −4.3 2.20E−05 0.00045 KRT82 −0.00034 −3.5 0.00048 0.0051 LAMA1 −0.00019 −3 0.0032 0.022 LETM2 −1.00E−04 −3.4 0.00089 0.0081 LHX1 −0.00061 −5.2 4.70E−07 2.00E−05 LPCAT1 −9.50E−05 −4 6.80E−05 0.0011 LRRC17 −0.00015 −2.7 0.008 0.042 MAF −8.20E−05 −3.2 0.0016 0.013 MELK −6.40E−05 −2.9 0.0036 0.024 MICAL2 −1.00E−04 −3.6 0.00037 0.0041 MME −0.00015 −3.3 0.0011 0.0097 MYH10 −1.00E−04 −3.7 0.00025 0.003 NAV3 −2.00E−04 −4.7 4.00E−06 0.00011 NEXN −0.00015 −3.7 0.00029 0.0034 NIPAL4 −2.00E−04 −3.7 0.00023 0.0029 NNMT −0.00012 −3.4 0.00088 0.008 NOD2 −1.00E−04 −3.7 0.00027 0.0032 NRG1 −0.00015 −3.8 2.00E−04 0.0026 NT5E −0.00017 −4 8.60E−05 0.0013 PAQR5 −0.00015 −3.5 5.00E−04 0.0052 PDGFC −0.00013 −4.4 1.40E−05 0.00031 PHLDB2 −1.00E−04 −3.6 0.00033 0.0037 PNPLA1 −2.00E−04 −3.2 0.0017 0.013 PPP1R14C −0.00014 −6.3 1.50E−09 1.60E−07 PSMB9 −8.70E−05 −2.8 0.0056 0.032 PTGS1 −0.00011 −3 0.0028 0.02 PTPRD −0.00019 −3.3 0.001 0.0091 RAB38 −0.00016 −4.6 7.60E−06 0.00019 RSAD2 −0.00014 −2.8 0.0051 0.03 S100A7A −0.00026 −2.8 0.0057 0.033 SEC14L2 −0.00013 −4.4 1.60E−05 0.00035 SERPINA3 −0.00024 −3.8 0.00018 0.0023 SERPINE1 −0.00021 −4.7 5.00E−06 0.00014 SERPING1 −9.30E−05 −3 0.0034 0.023 SLC24A2 −0.00034 −3.7 0.00022 0.0027 SLC2A9 −8.60E−05 −3.4 0.00077 0.0072 SLC7A5 −8.00E−05 −2.8 0.0056 0.033 SNX10 −1.00E−04 −3.6 0.00039 0.0043 SPTLC3 −0.00017 −3.2 0.0018 0.014 SULF2 −0.00013 −4.3 2.50E−05 0.00049 SYNC −0.00011 −3.2 0.0014 0.011 TGFA −1.00E−04 −4.3 2.60E−05 0.00051 THBS2 −0.00013 −3 0.0028 0.019 TIMP3 −0.00012 −3.1 0.0021 0.016 TLL1 −0.00013 −2.7 0.0081 0.043 TLN2 −7.40E−05 −2.8 0.0061 0.035 TMEM86A −8.60E−05 −2.9 0.0045 0.028 TNFSF9 −0.00012 −4 8.30E−05 0.0013 TRPA1 −0.00015 −2.7 0.0082 0.043 USP2 −0.00013 −2.8 0.0048 0.029 ZNF365 −0.00015 −3.2 0.0017 0.013

TABLE 9 mRNAs inversely expressed and containing predicted or validated binding sites to miR-30e-5p (MIMAT0000692) Gene beta t.stat p.value FDR 42433 −2.00E−04 −3.8 0.00017 0.0022 ABCA12 −0.00011 −3.3 0.0011 0.0093 ABCC11 −0.00013 −4.5 9.80E−06 0.00023 ABCC2 −0.00011 −3.4 0.00086 0.0079 ACTBL2 −0.00018 −2.8 0.0056 0.033 ACTC1 −0.00032 −3 0.0029 0.02 ADAM12 −0.00023 −6.4 5.60E−10 7.20E−08 ADAMTS14 −0.00014 −5.4 1.80E−07 9.00E−06 ADAMTS5 −8.70E−05 −3 0.0033 0.022 ADRA1D −0.00011 −2.8 0.0055 0.032 ANGPT2 −0.00012 −5.8 1.80E−08 1.30E−06 ANTXR2 −6.60E−05 −2.7 0.0078 0.042 ARRDC4 −7.10E−05 −3.2 0.0013 0.011 BAG2 −9.10E−05 −3.8 0.00015 0.002 BICD1 −9.00E−05 −4.8 2.90E−06 8.50E−05 BMP2 −9.50E−05 −3.6 0.00045 0.0048 BNC1 −9.70E−05 −4.6 8.20E−06 2.00E−04 BVES −0.00012 −3.9 0.00014 0.002 C1QL1 −0.00015 −4 7.60E−05 0.0012 C3orf72 −0.00036 −5 1.20E−06 4.20E−05 C6orf141 −0.00013 −3.3 0.0011 0.0093 CALD1 −0.00012 −6.4 9.60E−10 1.10E−07 CAMK2A −0.00017 −3.5 0.00064 0.0063 CCNA1 −0.00029 −4.7 4.30E−06 0.00012 CCRN4L −9.40E−05 −4.9 1.90E−06 6.20E−05 CD248 −0.00012 −4.7 4.60E−06 0.00013 CDH11 −0.00014 −3.9 0.00011 0.0016 CDH13 −1.00E−04 −4.3 2.50E−05 0.00049 CDK6 −9.20E−05 −4.6 5.40E−06 0.00014 CHN1 −6.50E−05 −2.8 0.0056 0.033 CHST2 −0.00017 −5.5 1.00E−07 5.60E−06 CLCF1 −6.40E−05 −2.7 0.0081 0.043 CLSTN2 −0.00012 −2.8 0.0058 0.033 COL12A1 −0.00022 −7.4 2.00E−12 5.90E−10 COL13A1 −0.00013 −5.9 1.20E−08 9.10E−07 COL5A2 −0.00022 −6.6 1.90E−10 2.80E−08 COL8A1 −0.00016 −3.9 0.00011 0.0015 CSMD3 −0.00031 −3.2 0.0016 0.013 CTHRC1 −0.00018 −5.1 6.60E−07 2.60E−05 CTSK −9.10E−05 −3 0.003 0.021 DACT1 −0.00017 −4.7 3.80E−06 0.00011 DCBLD1 −0.00013 −6.8 9.60E−11 1.60E−08 DCLK3 −8.70E−05 −3.2 0.0017 0.013 DDIT4 −8.20E−05 −3.6 0.00043 0.0046 DDX60 −8.70E−05 −3.1 0.002 0.015 DLX1 −0.00035 −7.3 4.80E−12 1.20E−09 DNAH17 −0.00014 −3 0.0032 0.022 DNMT3B −0.00011 −4.8 2.30E−06 7.10E−05 DSC1 −0.00022 −3.3 0.0011 0.0098 DSG2 −5.90E−05 −3 0.0031 0.021 EBF2 −0.00014 −2.7 0.0081 0.043 EDIL3 −0.00011 −3.1 0.002 0.015 EDNRA −9.80E−05 −4 7.20E−05 0.0011 EGFR −6.10E−05 −2.6 0.0088 0.045 EIF5A2 −7.80E−05 −3.7 0.00024 0.0029 ELAVL2 −0.00015 −2.6 0.0092 0.047 EML1 −9.70E−05 −4.1 4.90E−05 0.00084 ENPEP −0.00015 −6 7.40E−09 6.30E−07 EPB41L4B −7.00E−05 −3.4 0.00093 0.0084 EPHB2 −0.00011 −3.6 0.00038 0.0042 FADS1 −8.30E−05 −3.3 0.0011 0.0094 FAM26E −0.00014 −5 8.50E−07 3.20E−05 FAP −0.00023 −6.9 3.80E−11 7.20E−09 FGF5 −0.00044 −5.9 1.40E−08 1.10E−06 FOXD1 −1.00E−04 −3.6 0.00036 0.004 FOXL2 −0.00028 −5.1 6.30E−07 2.50E−05 FSD1L −5.50E−05 −2.9 0.0036 0.023 FST −0.00017 −5.8 1.60E−08 1.20E−06 FZD2 −0.00012 −6.3 1.00E−09 1.20E−07 GALNT6 −0.00018 −5.9 1.30E−08 1.00E−06 GFPT2 −8.80E−05 −3.1 0.0025 0.018 GJA1 −0.00015 −6.2 2.70E−09 2.70E−07 GOLGA7B −0.00021 −5.4 1.20E−07 6.40E−06 GUCY1A2 −0.00014 −4.8 2.90E−06 8.80E−05 GXYLT2 −9.00E−05 −2.8 0.0059 0.034 HAPLN1 −0.00024 −5.6 4.80E−08 3.00E−06 HAS2 −0.00011 −3.1 0.0022 0.016 HDAC9 −7.50E−05 −2.7 0.0079 0.042 HECW1 −2.00E−04 −5 9.50E−07 3.50E−05 HEPHL1 −0.00016 −2.6 0.0097 0.049 HEYL −0.00012 −5.1 6.80E−07 2.70E−05 HHIPL1 −9.10E−05 −3.3 0.001 0.009 HOXA1 −0.00011 −3.8 0.00021 0.0027 HOXA11 −0.00017 −2.7 0.0066 0.037 HOXD11 −0.00035 −6.5 5.30E−10 6.80E−08 HOXD8 −9.50E−05 −4.8 2.20E−06 6.80E−05 HSPB3 −0.00039 −5.5 1.20E−07 6.20E−06 HTRA3 −2.00E−04 −6.2 2.80E−09 2.80E−07 IFIT1 −0.00013 −3.3 0.00099 0.0088 IFIT1B −0.00025 −3.1 0.0018 0.014 IL1A −0.00012 −2.9 0.0044 0.027 INHBA −0.00034 −8.5 2.10E−15 1.50E−12 IRS1 −7.50E−05 −3.5 0.00061 0.0061 IRX4 −0.00017 −3.4 0.00088 0.008 ITGA1 −1.00E−04 −4.1 6.50E−05 0.001 ITGA5 −2.00E−04 −8.5 1.70E−15 1.30E−12 ITGA6 −0.00011 −5 8.50E−07 3.20E−05 KCND2 −0.00016 −3.7 0.00026 0.0032 KCNJ15 −9.80E−05 −3.6 0.00046 0.0048 KIAA1644 −0.00013 −3.7 0.00026 0.0031 KIF3C −0.00012 −6.4 8.20E−10 1.00E−07 KLF14 −0.00016 −2.7 0.0083 0.044 KLF7 −0.00011 −5.6 5.70E−08 3.40E−06 KRT82 −0.00022 −2.8 0.0054 0.032 LAMA1 −0.00027 −5.4 1.30E−07 6.60E−06 LAMA4 −0.00011 −4.5 9.20E−06 0.00022 LAMC3 −9.70E−05 −2.9 0.0036 0.024 LETM2 −6.40E−05 −2.6 0.0095 0.048 LHX1 −0.00045 −4.7 4.40E−06 0.00012 LHX5 −0.00032 −4 7.10E−05 0.0011 LOX −8.40E−05 −3 0.0028 0.019 LPAR3 −7.70E−05 −3.1 0.0021 0.016 LPCAT1 −9.00E−05 −4.9 1.90E−06 6.10E−05 LPPR5 −0.00025 −3.1 0.0025 0.018 LRRC15 −0.00017 −3.4 0.00067 0.0065 LRRC17 −0.00014 −3.2 0.0016 0.013 LRRC3 −6.40E−05 −2.8 0.005 0.03 LTBP2 −8.90E−05 −3.9 0.00011 0.0016 MAP2 −0.00011 −3 0.0027 0.019 MFAP3L −7.80E−05 −2.7 0.0067 0.037 MICAL2 −0.00013 −6 7.90E−09 6.70E−07 MME −0.00019 −5.2 3.50E−07 1.50E−05 MMP16 −0.00025 −5.7 2.80E−08 1.90E−06 MURC −0.00017 −3.6 0.00034 0.0039 MXRA5 −9.70E−05 −3.3 0.0013 0.011 MYH10 −0.00013 −6 6.50E−09 5.60E−07 NAV3 −0.00017 −5 8.40E−07 3.10E−05 NCAM1 −0.00014 −2.9 0.0035 0.023 NEXN −0.00014 −4.4 1.70E−05 0.00037 NID1 −0.00017 −6.6 2.80E−10 4.00E−08 NID2 −0.00016 −5.4 1.40E−07 7.30E−06 NIPAL4 −0.00014 −3.3 0.00096 0.0086 NNMT −9.60E−05 −3.5 0.00057 0.0058 NRG1 −0.00012 −3.8 0.00021 0.0027 NT5E −0.00018 −5.4 1.40E−07 7.10E−06 NTM −0.00016 −5.7 4.00E−08 2.50E−06 NUAK1 −9.60E−05 −4.1 6.50E−05 0.0011 OLFML2A −6.00E−05 −2.8 0.0052 0.031 PAQR5 −0.00011 −3.2 0.0016 0.013 PARVB −7.80E−05 −4.1 5.20E−05 0.00088 PCDH17 −8.90E−05 −3.1 0.0018 0.014 PDE3A −8.90E−05 −2.7 0.008 0.042 PDGFC −1.00E−04 −4.3 2.60E−05 5.00E−04 PDGFRB −0.00012 −4.4 1.60E−05 0.00035 PDZK1 −0.00011 −2.7 0.0084 0.044 PFN2 −9.10E−05 −3 0.0029 0.02 PHLDB2 −0.00015 −7.1 1.30E−11 3.00E−09 PI15 −0.00013 −4.2 3.30E−05 0.00062 PLEKHG4B −0.00011 −2.7 0.0082 0.043 PNPLA1 −2.00E−04 −4.1 5.40E−05 9.00E−04 PPP1R14C −1.00E−04 −5.4 1.30E−07 6.80E−06 PRICKLE1 −7.20E−05 −2.8 0.0054 0.032 PRRG1 −5.30E−05 −2.7 0.0085 0.045 PTPRD −0.00013 −2.8 0.0051 0.031 RAB38 −8.80E−05 −3.1 0.0022 0.016 RAB3B −0.00016 −2.7 0.0065 0.036 RAI14 −6.40E−05 −3.1 0.0018 0.014 RASD2 −0.00011 −3.1 0.0022 0.016 RASL11B −9.70E−05 −3 0.003 0.02 RHOBTB1 −8.30E−05 −3.9 1.00E−04 0.0015 RSAD2 −0.00013 −3.2 0.0013 0.011 RTN4R −6.80E−05 −3.5 0.00053 0.0054 S100A7A −2.00E−04 −2.7 0.0066 0.037 SAMD4A −6.90E−05 −3.2 0.0015 0.012 SDC2 −9.50E−05 −3.5 0.00065 0.0064 SDK2 −0.00012 −3.3 0.0012 0.01 SEC14L2 −9.90E−05 −4.1 5.00E−05 0.00085 SERPINE1 −0.00027 −8.4 3.40E−15 2.30E−12 SGCD −0.00013 −3.2 0.0017 0.013 SGIP1 −0.00014 −4.9 1.60E−06 5.30E−05 SLC16A10 −8.70E−05 −3.4 0.00087 0.008 SLC24A2 −0.00049 −7.3 2.90E−12 8.10E−10 SLC2A9 −7.30E−05 −3.6 0.00037 0.0041 SLC35F3 −0.00017 −3.3 0.0011 0.0097 SLC38A4 −9.30E−05 −2.8 0.0062 0.035 SLC7A5 −9.40E−05 −4.2 4.20E−05 0.00074 SNAI1 −6.10E−05 −2.8 0.0048 0.029 SNX10 −9.60E−05 −4.4 1.90E−05 4.00E−04 SOX11 −0.00036 −6.4 7.50E−10 9.30E−08 SPSB4 −0.00014 −2.9 0.0039 0.025 STAC −0.00014 −3.6 0.00036 0.004 STC1 −0.00011 −4.2 3.30E−05 0.00061 SULF2 −1.00E−04 −4.2 3.50E−05 0.00064 SYNC −0.00011 −4.1 6.10E−05 0.001 TCHHL1 −0.00028 −3 0.0031 0.021 TGFA −7.10E−05 −3.8 0.00018 0.0023 THBS2 −2.00E−04 −6.4 9.00E−10 1.10E−07 TIMP2 −8.20E−05 −3.3 0.0013 0.011 TIMP3 −0.00013 −4.4 1.30E−05 3.00E−04 TLL1 −0.00012 −3 0.0035 0.023 TLN2 −8.30E−05 −3.9 0.00011 0.0016 TM6SF2 −0.00026 −5 9.00E−07 3.30E−05 TMC7 −8.40E−05 −3.8 2.00E−04 0.0025 TMEM26 −8.00E−05 −2.8 0.0056 0.033 TMEM86A −7.90E−05 −3.3 0.0011 0.0095 TNFSF9 −7.90E−05 −3.2 0.0017 0.013 TRIB3 −1.00E−04 −5.4 1.20E−07 6.50E−06 TRIM9 −0.00013 −3.7 0.00031 0.0036 USP2 −0.00012 −3.5 6.00E−04 0.006 VCAN −0.00016 −4.5 1.10E−05 0.00026 WISP1 −0.00011 −3.2 0.0017 0.013 WNT7B −6.10E−05 −3.3 0.0011 0.0096

TABLE 10 mRNAs inversely expressed and containing predicted or validated binding sites to miR-26a-5p (MIMAT0000082) Gene beta t.stat p.value FDR ABCC11 −0.00033 −4.4 1.50E−05 0.00033 ABCC2 −0.00028 −3.3 0.00098 0.0088 ACVR1C −0.00023 −4 8.10E−05 0.0012 ADAM12 −0.00034 −3.5 0.00051 0.0053 ADM −3.00E−04 −5.3 3.10E−07 1.40E−05 ANO1 −0.00035 −3.7 0.00023 0.0028 ARRDC4 −0.00022 −3.9 0.00013 0.0018 ARSJ −0.00018 −3 0.0026 0.018 BEND6 −2.00E−04 −3.1 0.0021 0.015 BICD1 −0.00017 −3.5 0.00057 0.0058 C19orf77 −0.00043 −2.9 0.0035 0.023 C3orf72 −0.00079 −4.2 3.00E−05 0.00057 CCRN4L −0.00021 −4.3 2.60E−05 0.00051 CDK6 −0.00021 −4.1 6.40E−05 0.001 CHST2 −0.00034 −4.2 3.90E−05 0.00069 COL11A1 −0.00057 −3.3 0.00094 0.0085 COL12A1 −0.00035 −4.3 2.60E−05 0.00051 COL4A2 −0.00024 −3.7 0.00028 0.0033 COL5A1 −0.00032 −3.6 4.00E−04 0.0043 CT62 −0.00065 −3 0.0031 0.021 CYP27B1 −0.00022 −2.7 0.0066 0.037 DCBLD1 −0.00022 −4.1 6.00E−05 0.00099 DDIT4 −3.00E−04 −5.1 5.30E−07 2.20E−05 DNAH17 −0.00037 −3 0.003 0.021 DNAJB5 −2.00E−04 −3.8 0.00015 0.002 DNMT3B −0.00027 −4.7 4.10E−06 0.00012 DSC3 −0.00015 −3.4 0.00093 0.0084 DSG2 −0.00017 −3.3 0.0012 0.01 EIF5A2 −0.00015 −2.7 0.0078 0.042 ENPEP −0.00021 −3.2 0.0015 0.012 EREG −4.00E−04 −2.6 0.0093 0.048 F2RL1 −0.00023 −3.3 0.0012 0.0099 FADS1 −0.00017 −2.6 0.0098 0.049 FAM83B −0.00014 −2.7 0.008 0.042 FAM89A −0.00025 −4.9 1.50E−06 4.90E−05 FAT1 −0.00019 −3.1 0.0019 0.015 FERMT1 −2.00E−04 −4 8.10E−05 0.0012 FHL2 −0.00015 −2.8 0.0049 0.03 FN1 −3.00E−04 −2.8 0.0061 0.035 FOXD1 −0.00023 −3.1 0.0022 0.016 GOLGA7B −3.00E−04 −2.9 0.0038 0.024 GPSM1 −0.00019 −3.6 4.00E−04 0.0044 HAPLN1 −0.00032 −2.9 0.0043 0.027 HAS3 −0.00019 −2.6 0.0088 0.045 HES2 −0.00029 −4.8 2.90E−06 8.60E−05 HHLA1 −0.00058 −2.9 0.0037 0.024 HIST1H3H −0.00019 −2.9 0.0043 0.027 HMGA2 −0.00055 −4.6 5.60E−06 0.00015 HNF4A −0.00065 −3 0.0026 0.018 HOXC9 −0.00043 −3.2 0.0014 0.011 HOXD13 −0.00057 −2.6 0.0095 0.048 HOXD8 −0.00018 −3.6 0.00034 0.0039 HOXD9 −0.00017 −3.4 0.00079 0.0074 HSD17B6 −0.00021 −4.3 2.20E−05 0.00045 HSPA12A −0.00021 −2.9 0.0039 0.025 HTR2C −0.0011 −3.9 0.00014 0.002 HTR7 −0.00038 −3.8 0.00015 0.002 INHBA −0.00056 −5.1 8.20E−07 3.10E−05 ITGA3 −0.00021 −3.2 0.0015 0.012 ITGA5 −0.00033 −5.2 4.50E−07 1.90E−05 ITGA6 −0.00027 −4.5 8.70E−06 0.00021 KANK4 −0.00053 −3.9 0.00012 0.0017 KCNJ15 −0.00025 −3.6 0.00046 0.0048 KIF26B −0.00023 −3.1 0.002 0.015 KIF3C −0.00024 −4.6 7.10E−06 0.00018 KIRREL −0.00018 −2.8 0.0052 0.031 KLF7 −0.00027 −5.1 5.50E−07 2.20E−05 LAMA1 −0.00058 −4.5 1.20E−05 0.00028 LHFPL5 −0.00052 −2.7 0.0073 0.04 LHX1 −7.00E−04 −2.8 0.0061 0.035 LHX9 −0.00085 −3.8 0.00016 0.0022 LMX1B −0.00046 −3 0.0034 0.022 LOXL2 −0.00035 −4.6 6.70E−06 0.00017 LPAR3 −2.00E−04 −3.2 0.0017 0.013 LRP12 −0.00015 −2.9 0.0041 0.026 MAGEA9B −0.00089 −2.8 0.0058 0.034 MEIS3 −0.00021 −2.9 0.0036 0.024 MET −0.00019 −4 9.80E−05 0.0015 MFSD2A −0.00016 −3.4 0.00088 0.0081 MME −0.00029 −3 0.0033 0.022 MSX2 −0.00032 −4.1 4.80E−05 0.00082 MYH10 −0.00024 −4.2 3.80E−05 0.00068 NAGS −0.00017 −3.3 0.0011 0.0095 NDRG1 −3.00E−04 −5.2 5.10E−07 2.10E−05 NID1 −0.00022 −3 0.0029 0.02 NKPD1 −0.00026 −3.1 0.0019 0.014 NOX5 −0.00036 −3.2 0.0013 0.011 OTUB2 −0.00017 −3.2 0.0018 0.014 PCSK9 −0.00031 −3.6 0.00042 0.0046 PHLDA1 −0.00014 −2.7 0.0079 0.042 PHLDB2 −0.00035 −6.3 1.40E−09 1.60E−07 PNPLA3 −0.00037 −3.8 0.00019 0.0025 POPDC3 −0.00044 −3 0.0031 0.021 PTPRH −0.00036 −3.8 0.00017 0.0023 PYGL −0.00034 −5.6 7.10E−08 4.10E−06 RBM44 −0.00032 −3.5 0.00049 0.0051 RGS20 −3.00E−04 −3.4 7.00E−04 0.0068 RNASE7 −0.00034 −2.6 0.0094 0.048 SERPINA10 −0.00058 −2.8 0.0054 0.032 SH2D5 −0.00048 −4.3 2.50E−05 0.00049 SHANK2 −0.00033 −2.8 0.0049 0.03 SLC22A1 −0.00032 −2.7 0.0071 0.039 SLC2A9 −0.00022 −4.3 2.60E−05 0.00051 SLC6A7 −0.00048 −2.9 0.0044 0.027 SOX11 −0.00072 −4.8 2.50E−06 7.60E−05 STON2 −0.00023 −5.1 7.50E−07 2.90E−05 TFAP2E −0.00029 −3.9 0.00014 0.002 TMC7 −0.00024 −4.3 2.40E−05 0.00048 TNS4 −0.00026 −4 9.40E−05 0.0014 TRIP13 −0.00012 −2.7 0.0077 0.041 TRPC4 −0.00024 −2.7 0.0078 0.042 TRPV3 −0.00041 −4.1 4.80E−05 0.00082 ZIC5 −0.00057 −3.2 0.0017 0.013

TABLE 11 mRNAs inversely expressed and containing predicted or validated binding sites to miR-26b-5p (MIMAT0000083) Gene beta t.stat p.value FDR ADAM12 −0.0015 −3.7 0.00023 0.0028 ADAMTS5 −0.00088 −2.8 0.0048 0.029 ALX4 −0.0025 −3 0.0031 0.021 APCDD1 −0.00068 −2.7 0.0069 0.038 ARSJ −0.00072 −3 0.0028 0.019 ASPN −0.0012 −2.7 0.0076 0.041 AVPR1A −0.00094 −2.7 0.0068 0.038 BCAT1 −0.00093 −2.7 0.0067 0.037 BEND6 −0.00069 −2.6 0.0091 0.047 BICD1 −0.00057 −2.8 0.0051 0.031 C14orf37 −0.00072 −2.7 0.0074 0.04 C3orf72 −0.0021 −2.7 0.0076 0.041 CACNA1C −0.00081 −2.9 0.0036 0.024 CALCRL −0.00058 −2.7 0.0084 0.044 CCRN4L −0.00057 −2.8 0.0062 0.035 CDH11 −0.001 −2.7 0.0066 0.037 CLSTN2 −0.0016 −3.6 0.00034 0.0039 CNTNAP2 −0.0025 −3.8 0.00018 0.0023 COL10A1 −0.0019 −3.1 0.0022 0.016 COL11A1 −0.0024 −3.5 0.00055 0.0056 COL12A1 −0.0012 −3.7 0.00026 0.0031 COL1A2 −0.0013 −3.3 0.0011 0.0092 COL5A1 −0.0012 −3.1 0.002 0.015 CRISPLD2 −0.00084 −3.2 0.0014 0.011 DCBLD1 −0.00064 −2.9 0.0044 0.027 DCLK1 −0.0012 −2.6 0.0089 0.046 DNAH17 −0.0013 −2.6 0.009 0.046 EFCAB4B −0.00086 −3.2 0.0017 0.013 EML5 −0.00084 −3 0.0032 0.022 ENPEP −0.00084 −3.1 0.002 0.015 ENTPD3 −0.00081 −2.9 0.0037 0.024 F2RL1 −0.00082 −2.9 0.0047 0.029 FAM169A −0.00068 −3 0.0032 0.021 FAM198B −0.00083 −3 0.0028 0.019 FAM26E −0.001 −3.4 0.00076 0.0072 FMN1 −0.00092 −2.7 0.0079 0.042 FN1 −0.0013 −3.1 0.0023 0.017 FNDC1 −0.0014 −3.1 0.0025 0.018 FOXD1 −0.00099 −3.3 0.0011 0.0093 GPC4 −0.001 −2.7 0.0079 0.042 GPC6 −0.0012 −2.8 0.0049 0.03 GPX8 −0.00068 −3.3 0.0012 0.01 GREB1 −0.00076 −2.9 0.0043 0.027 GUCY1A2 −0.00085 −2.7 0.0067 0.037 HOXA13 −0.0036 −4.3 2.80E−05 0.00054 HOXD8 −0.00069 −3.3 0.00099 0.0088 HS3ST3A1 −0.00085 −2.7 0.0084 0.044 HSD17B6 −0.00064 −3.2 0.0016 0.012 HTR7 −0.0011 −2.8 0.0053 0.031 INPP4B −0.00094 −3.3 0.00097 0.0087 ITGA5 −0.00079 −2.9 0.0037 0.024 ITGA6 −0.00064 −2.6 0.0087 0.045 KCND2 −0.0014 −3.2 0.0013 0.011 KCNJ15 −0.00093 −3.2 0.0013 0.011 KIF26B −0.0012 −3.9 0.00011 0.0016 KIRREL −0.00072 −2.8 0.0061 0.035 KLK2 −0.0026 −2.7 0.0068 0.038 LAMA1 −0.0017 −3.1 0.0019 0.014 LHX9 −0.0024 −2.6 0.0094 0.048 LINGO1 −0.00075 −2.7 0.0074 0.04 LMX1B −0.0019 −3 0.0033 0.022 LOX −0.00093 −3.2 0.0014 0.012 LOXL2 −0.00094 −3 0.0033 0.022 LPAR3 −0.00074 −2.9 0.0046 0.028 LRP12 −0.00056 −2.6 0.0086 0.045 LUM −0.00089 −2.6 0.0087 0.045 MFAP3L −9.00E−04 −3.1 0.0024 0.018 MFAP5 −0.0017 −3.5 0.00047 0.005 MME −0.0016 −4 7.30E−05 0.0011 MMP16 −0.0018 −3.9 0.00012 0.0017 MSX2 −0.0011 −3.5 0.00059 0.0059 MYH10 −0.00086 −3.7 0.00026 0.0032 NDRG1 −0.00069 −2.8 0.0056 0.033 NID1 −0.0013 −4.6 5.30E−06 0.00014 OTUB2 −0.00063 −2.9 0.0041 0.026 PCDHB16 −0.001 −3.5 0.00049 0.0051 PDE3A −0.001 −2.9 0.0036 0.023 PGM2L1 −0.00068 −2.8 0.0062 0.035 PHLDB2 −0.00075 −3.1 0.0018 0.014 PLOD2 −0.00075 −3.5 0.00052 0.0054 PRDM5 −0.00069 −2.7 0.0076 0.041 PRKG1 −0.00099 −3 0.0026 0.019 PRSS35 −0.0019 −2.8 0.0056 0.033 PTPRD −0.0017 −3.5 0.00046 0.0049 RBMS3 −0.00088 −3 0.0029 0.02 RNF128 −0.0012 −2.7 0.0078 0.042 RNF152 −0.00066 −2.8 0.0062 0.035 SALL1 −0.0017 −2.6 0.0097 0.049 SEMA6D −0.0011 −2.9 0.0037 0.024 SESN3 −0.001 −4 8.90E−05 0.0014 SFRP4 −0.0017 −2.7 0.0075 0.04 SHANK2 −0.0016 −3.4 0.00068 0.0066 SLC2A9 −0.00062 −2.9 0.0035 0.023 SNX10 −0.00066 −2.8 0.0052 0.031 SOX11 −0.0017 −2.7 0.0081 0.043 SPOCK1 −0.0013 −3.1 0.0021 0.015 ST6GALNAC5 −0.0013 −3.4 0.00078 0.0073 STON2 −0.00052 −2.8 0.0059 0.034 SULF1 −0.001 −2.9 0.0047 0.029 SYT13 −0.0033 −3.8 2.00E−04 0.0026 SYT14 −0.0025 −3.2 0.0016 0.013 TET1 −0.00077 −2.7 0.0084 0.044 TRPC4 −0.0011 −2.9 0.0046 0.028 TRPS1 −0.00063 −2.8 0.0055 0.032 VCAN −0.0011 −3 0.0031 0.021 VEPH1 −0.0021 −3.9 0.00013 0.0018 VGLL3 −9.00E−04 −2.8 0.0062 0.035 WNT2 −0.0015 −2.8 0.0056 0.033 WNT5A −0.00078 −2.9 0.0042 0.026 WT1 −0.0029 −3 0.003 0.02 ZFHX4 −0.0014 −4 9.50E−05 0.0014 ZNF469 −0.0011 −3 0.0032 0.021 ZNF704 −0.00093 −2.9 0.0035 0.023

TABLE 12 mRNAs inversely expressed and containing predicted or validated binding sites to miR-145-5p (MIMAT0000437) Gene beta t.stat p.value FDR APOL1 −0.00077 −3.3 0.001 0.0091 CCNA2 −0.00037 −3.2 0.0013 0.011 CMPK2 −0.00078 −3.2 0.0018 0.014 DDX60 −0.00066 −3 0.0031 0.021 DEPDC1B −0.00039 −3 0.0027 0.019 ELOVL7 −7.00E−04 −4 9.20E−05 0.0014 EPHA4 −0.00049 −2.7 0.007 0.039 ESCO2 −0.00036 −2.6 0.0088 0.046 FAM169A −0.00046 −2.6 0.0089 0.046 GCNT4 −0.00054 −2.9 0.004 0.026 GPR150 −0.0017 −2.8 0.0048 0.029 HOXA1 −0.00064 −2.8 0.0057 0.033 HS6ST2 −0.0012 −3 0.0033 0.022 IFI44L −0.00094 −3 0.0029 0.02 KIAA0895 −0.00043 −2.7 0.0065 0.037 PBK −0.00036 −2.7 0.0083 0.044 PHEX −7.00E−04 −2.9 0.0042 0.027 PRF1 −0.00066 −2.7 0.007 0.038 RAB27B −5.00E−04 −2.8 0.0057 0.033 SGPP2 −0.00058 −2.8 0.0059 0.034 SH2D4A −0.00043 −2.6 0.0091 0.047 SPC24 −4.00E−04 −2.6 0.0087 0.045 TLX2 −0.0019 −2.8 0.005 0.03 ZIC2 −0.0013 −4 8.70E−05 0.0013 ZIC5 −0.0018 −3.3 0.001 0.0089 PLEKHH1 −0.00085 −5.2 4.40E−07 1.90E−05 GDPD4 −0.0027 −4.6 8.10E−06 2.00E−04 CAGE1 −0.0013 −4 7.40E−05 0.0012 C14orf73 −0.0016 −4 8.50E−05 0.0013 C9orf84 −0.00078 −3.8 0.00017 0.0023 C15orf42 −0.00054 −3.7 0.00023 0.0029 SEC16B −0.00074 −3.6 0.00034 0.0039 SATL1 −0.00061 −3.6 0.00036 0.004 WARS −0.00081 −3.6 4.00E−04 0.0044 POLQ −0.00049 −3.6 0.00041 0.0044 CSAG3 −0.0027 −3.6 4.00E−04 0.0044 OR2A1 −0.001 −3.6 0.00044 0.0047 ZBP1 −0.0012 −3.5 0.00051 0.0053 KIAA0101 −0.00045 −3.5 0.00051 0.0053 NCRNA00114 −0.0017 −3.5 0.00057 0.0058 NEIL3 −0.00054 −3.5 0.00059 0.0059 CDCA2 −0.00045 −3.5 0.00064 0.0063 HIST1H2AJ −0.0016 −3.4 0.00069 0.0066 C16orf75 −5.00E−04 −3.4 0.00072 0.0069 SLC44A5 −0.0011 −3.4 0.00092 0.0083 CASP5 −0.0013 −3.3 0.00097 0.0087 HERC5 −0.00073 −3.3 0.001 0.0089 ACE2 −0.00087 −3.3 0.001 0.0091 TTK −0.00036 −3.3 0.0011 0.0093 RRM2 −0.00039 −3.3 0.0011 0.0098

TABLE 13 mRNAs inversely expressed and containing predicted or validated binding sites to miR-205-5p (MIMAT0000266) Gene beta t.stat p.value FDR BAI3 −9.90E−05 −4 8.20E−05 0.0013 42430 −5.30E−05 −6.1 4.10E−09 3.80E−07 A2M −6.90E−05 −9.2 1.10E−17 1.50E−14 AASS −2.40E−05 −3 0.0027 0.019 ABCA6 −9.40E−05 −8.8 1.90E−16 1.90E−13 ABCC12 −0.00012 −3.8 0.00016 0.0021 ABCD2 −9.50E−05 −5.3 2.30E−07 1.10E−05 ACACB −5.40E−05 −5.8 2.30E−08 1.60E−06 ACSL5 −4.60E−05 −4.5 1.00E−05 0.00024 ACTC1 −0.00012 −2.9 0.0041 0.026 ADAM28 −5.20E−05 −3.7 0.00022 0.0028 ADAMTS16 −0.00012 −4.8 3.30E−06 9.70E−05 ADAMTS18 −0.00014 −6.4 8.40E−10 1.00E−07 ADAMTS4 −4.80E−05 −4.8 3.10E−06 9.20E−05 ADAMTS5 −8.20E−05 −7.9 7.20E−14 3.30E−11 ADAMTS9 −7.20E−05 −7.8 1.30E−13 5.70E−11 ADAMTSL1 −0.00011 −8.8 2.30E−16 2.20E−13 ADAMTSL2 −2.60E−05 −3.2 0.0013 0.011 ADCY2 −0.00011 −5.4 1.50E−07 7.50E−06 ADCYAP1 −9.20E−05 −4.7 3.50E−06 1.00E−04 ADCYAP1R1 −0.00011 −3.6 0.00046 0.0048 ADD2 −0.00011 −4.5 1.10E−05 0.00025 ADH1B −0.00018 −4.8 2.30E−06 7.20E−05 ADORA3 −6.40E−05 −6.1 3.90E−09 3.70E−07 ADRA1B −6.40E−05 −3.1 0.0019 0.014 AFF3 −8.80E−05 −5.5 1.00E−07 5.60E−06 AGTR1 −0.00019 −7.9 8.50E−14 3.80E−11 AKAP2 −7.00E−05 −6.8 9.10E−11 1.50E−08 AKAP7 −4.40E−05 −5.8 1.90E−08 1.40E−06 AKT3 −4.10E−05 −4.9 1.70E−06 5.70E−05 ALCAM −2.70E−05 −2.7 0.0065 0.036 ALDH3B1 −4.50E−05 −6 5.20E−09 4.70E−07 ALPK3 −6.60E−05 −6.2 2.10E−09 2.20E−07 ALX4 −8.70E−05 −2.8 0.006 0.034 AMOT −7.60E−05 −4.8 2.70E−06 8.20E−05 ANGPTL7 −0.00017 −5 1.30E−06 4.40E−05 ANK2 −0.00011 −8.7 3.60E−16 3.30E−13 ANTXR1 −4.00E−05 −5.2 3.40E−07 1.50E−05 APBA1 −2.50E−05 −3.2 0.0015 0.012 APLNR −7.80E−05 −7.2 8.00E−12 1.90E−09 APOC4 −8.90E−05 −3 0.003 0.02 APOL6 −4.60E−05 −5.6 5.10E−08 3.10E−06 AQP1 −5.70E−05 −7.7 3.00E−13 1.10E−10 AQP9 −6.20E−05 −4 8.50E−05 0.0013 AR −0.00012 −5.9 1.40E−08 1.10E−06 ARHGAP15 −5.50E−05 −5.7 2.90E−08 2.00E−06 ARHGAP24 −3.80E−05 −4.2 3.90E−05 7.00E−04 ARHGAP26 −2.70E−05 −3.2 0.0018 0.014 ARHGAP31 −4.90E−05 −6.5 3.20E−10 4.50E−08 ARHGAP42 −3.30E−05 −3.9 0.00012 0.0017 ASPA −0.00012 −5 1.00E−06 3.60E−05 ASTN1 −8.80E−05 −2.8 0.0053 0.031 ATP10A −8.80E−05 −9.6 6.90E−19 1.30E−15 ATP6V0A4 −0.00011 −4.3 2.00E−05 0.00042 ATP8A1 −6.00E−05 −5.7 3.30E−08 2.20E−06 ATRNL1 −7.90E−05 −3.2 0.0014 0.011 AVPR1A −5.00E−05 −4 7.50E−05 0.0012 AXIN2 −5.90E−05 −6.7 1.20E−10 1.90E−08 B3GALT5 −0.00012 −3.2 0.0014 0.011 B4GALT6 −3.70E−05 −4.1 6.00E−05 0.00099 BACH2 −3.60E−05 −3.6 0.00039 0.0043 BCAS1 −4.30E−05 −2.6 0.0097 0.049 BCL2 −4.50E−05 −4.5 8.60E−06 0.00021 BEND4 −0.00013 −4 9.20E−05 0.0014 BEST3 −9.70E−05 −2.9 0.0038 0.025 BHLHE41 −3.50E−05 −3.3 0.00098 0.0088 BICC1 −8.80E−05 −6.9 3.80E−11 7.40E−09 BICD1 −2.10E−05 −2.8 0.0053 0.031 BMF −2.10E−05 −2.7 0.0073 0.04 BMP3 −0.00011 −2.9 0.0041 0.026 BMP6 −5.50E−05 −6.3 1.50E−09 1.60E−07 BMP8A −3.10E−05 −2.7 0.0064 0.036 BMPER −5.50E−05 −3.4 0.00073 0.007 BNC2 −9.10E−05 −8.2 8.90E−15 5.30E−12 BPI −0.00012 −3.8 2.00E−04 0.0025 BST1 −7.00E−05 −9.2 1.60E−17 2.10E−14 BTLA −7.20E−05 −4.5 9.00E−06 0.00022 BTN3A2 −3.00E−05 −3.5 0.00047 0.0049 C10orf10 −3.50E−05 −3.8 0.00017 0.0022 C10orf128 −8.30E−05 −6.1 4.90E−09 4.50E−07 C10orf131 −7.40E−05 −2.6 0.0089 0.046 C10orf71 −0.00015 −3.3 0.0013 0.011 C11orf21 −7.70E−05 −4.1 5.40E−05 9.00E−04 C12orf68 −4.30E−05 −4 8.00E−05 0.0012 C15orf52 −2.90E−05 −2.9 0.0044 0.027 C17orf72 −4.10E−05 −4.7 4.60E−06 0.00013 C17orf82 −6.20E−05 −3.3 0.0011 0.0093 C1QTNF3 −4.20E−05 −2.9 0.0035 0.023 C22orf34 −0.00012 −3.9 0.00013 0.0018 C3orf36 −4.70E−05 −3.9 0.00015 0.002 C4orf40 −9.20E−05 −3.3 0.001 0.0089 C6 −0.00022 −6.2 2.70E−09 2.70E−07 C7 −0.00016 −5.4 1.50E−07 7.60E−06 CA13 −3.50E−05 −3.5 0.00061 0.0061 CA3 −0.00012 −4.3 2.70E−05 0.00052 CA8 −0.00013 −5.4 1.40E−07 7.10E−06 CABP4 −7.10E−05 −3.8 0.00019 0.0024 CACNA2D2 −4.40E−05 −4.4 1.90E−05 0.00039 CADM1 −6.80E−05 −6.1 3.30E−09 3.20E−07 CADPS2 −6.50E−05 −7.3 4.40E−12 1.20E−09 CALCRL −4.70E−05 −6.2 2.50E−09 2.50E−07 CALN1 −1.00E−04 −3.1 0.0024 0.017 CAMK2A −7.90E−05 −4.3 2.70E−05 0.00052 CAMK4 −6.00E−05 −4.4 1.50E−05 0.00032 CCDC141 −9.40E−05 −6.1 4.10E−09 3.90E−07 CCDC144A −6.20E−05 −2.7 0.0085 0.045 CCDC152 −5.50E−05 −4.5 1.20E−05 0.00028 CCDC68 −7.20E−05 −3.9 1.00E−04 0.0015 CCDC80 −7.00E−05 −7.4 1.60E−12 4.90E−10 CCDC85A −9.80E−05 −6.9 5.10E−11 9.40E−09 CCL13 −7.20E−05 −5 8.40E−07 3.20E−05 CCL21 −6.20E−05 −3.3 0.00098 0.0087 CCL22 −2.90E−05 −2.7 0.0076 0.041 CCR5 −6.40E−05 −5.4 1.20E−07 6.50E−06 CCR7 −4.30E−05 −3.3 0.0011 0.0098 CCR8 −4.60E−05 −2.7 0.0085 0.044 CD163L1 −6.30E−05 −5.9 1.30E−08 1.00E−06 CD180 −6.50E−05 −5.6 4.60E−08 2.90E−06 CD1D −5.30E−05 −5.6 5.40E−08 3.30E−06 CD226 −6.90E−05 −4.7 4.90E−06 0.00013 CD28 −6.60E−05 −5.1 5.20E−07 2.10E−05 CD300E −8.30E−05 −3.1 0.0025 0.018 CD4 −5.90E−05 −6.3 1.50E−09 1.70E−07 CD84 −8.70E−05 −6.8 8.00E−11 1.40E−08 CD93 −5.90E−05 −7.9 6.20E−14 2.90E−11 CDH11 −7.90E−05 −6 5.60E−09 5.00E−07 CDK14 −3.70E−05 −3.4 0.00077 0.0072 CECR1 −6.80E−05 −6.1 4.10E−09 3.80E−07 CERKL −6.50E−05 −6.3 1.50E−09 1.70E−07 CES1 −9.70E−05 −3.9 0.00012 0.0017 CFL2 −3.20E−05 −4.6 5.80E−06 0.00015 CHN1 −4.70E−05 −5.4 1.30E−07 6.70E−06 CHRDL1 −0.00017 −6.2 2.00E−09 2.10E−07 CHRFAM7A −4.30E−05 −3.3 0.00099 0.0088 CHRNA7 −8.00E−05 −3.6 0.00039 0.0043 CHRNB2 −6.10E−05 −2.8 0.005 0.03 CHST11 −2.60E−05 −2.8 0.0051 0.03 CHST6 −6.40E−05 −4.8 2.60E−06 7.90E−05 CIITA −5.40E−05 −4.5 9.50E−06 0.00023 CLDN11 −8.70E−05 −7.7 3.10E−13 1.20E−10 CLEC10A −6.90E−05 −5.1 7.80E−07 3.00E−05 CLIC5 −9.30E−05 −7 1.70E−11 3.60E−09 CMKLR1 −7.80E−05 −7.7 3.60E−13 1.30E−10 CMTM7 −4.10E−05 −4.8 2.30E−06 7.10E−05 CMYA5 −8.20E−05 −4.3 2.50E−05 0.00049 CNR1 −0.00011 −4.8 2.40E−06 7.40E−05 CNTNAP2 −8.70E−05 −3.6 0.00036 0.0041 COL14A1 −8.50E−05 −8.3 5.20E−15 3.40E−12 COL1A1 −7.20E−05 −4.7 4.40E−06 0.00012 CPE −2.80E−05 −2.8 0.0055 0.032 CPEB1 −9.80E−05 −4.8 2.50E−06 7.70E−05 CREB5 −3.20E−05 −3.1 0.0022 0.016 CRISPLD2 −5.20E−05 −5.7 4.00E−08 2.60E−06 CRMP1 −3.80E−05 −3.5 0.00064 0.0063 CSF1 −3.80E−05 −5 1.30E−06 4.40E−05 CSMD2 −6.30E−05 −3.9 0.00011 0.0016 CTLA4 −3.60E−05 −2.6 0.0087 0.045 CTSO −4.90E−05 −6.8 5.70E−11 1.00E−08 CXCL11 −8.90E−05 −4 9.90E−05 0.0015 CXCR5 −5.80E−05 −3.2 0.0018 0.014 CXorf21 −6.60E−05 −5.5 8.40E−08 4.80E−06 CXXC4 −9.50E−05 −3.2 0.0015 0.012 CYBB −8.00E−05 −7 2.40E−11 4.90E−09 CYP19A1 −7.10E−05 −5.4 1.30E−07 6.70E−06 CYP21A2 −5.50E−05 −2.9 0.0046 0.028 CYP2A7 −8.30E−05 −2.9 0.0047 0.029 CYP4V2 −4.60E−05 −5.7 3.20E−08 2.10E−06 CYSLTR2 −9.20E−05 −6.1 5.00E−09 4.50E−07 CYTH4 −4.90E−05 −5.2 4.30E−07 1.80E−05 DAAM2 −7.20E−05 −7.4 1.50E−12 4.60E−10 DAB1 −0.00012 −4.2 3.60E−05 0.00065 DACH1 −8.90E−05 −6.7 1.20E−10 1.90E−08 DAGLA −3.90E−05 −4.2 3.50E−05 0.00064 DBX2 −0.00014 −3.8 0.00019 0.0024 DCHS1 −5.60E−05 −5.9 1.10E−08 8.90E−07 DCHS2 −6.70E−05 −3.6 0.00036 0.004 DCLK3 −3.00E−05 −2.8 0.0048 0.029 DCN −7.80E−05 −7.9 8.70E−14 3.90E−11 DDAH1 −5.10E−05 −5.6 5.10E−08 3.10E−06 DDN −4.50E−05 −2.7 0.0067 0.037 DDR2 −8.20E−05 −7.1 1.30E−11 2.80E−09 DGKG −5.20E−05 −3.8 0.00017 0.0023 DGKI −8.30E−05 −5.5 1.10E−07 6.00E−06 DIO2 −7.10E−05 −6.2 1.80E−09 1.90E−07 DLC1 −4.60E−05 −5.5 8.30E−08 4.70E−06 DLG2 −7.70E−05 −3.4 0.00092 0.0083 DMD −3.80E−05 −3.4 0.00081 0.0075 DNAH9 −5.70E−05 −3.1 0.002 0.015 DNM3 −4.10E−05 −4.6 6.30E−06 0.00016 DOCK3 −4.10E−05 −3.8 0.00016 0.0022 DOK6 −7.10E−05 −5.6 4.70E−08 2.90E−06 DPP4 −3.40E−05 −2.8 0.0057 0.033 DPYSL3 −7.00E−05 −7 2.60E−11 5.30E−09 DUSP27 −0.00014 −3.3 0.0011 0.0093 DUSP4 −3.70E−05 −4 9.30E−05 0.0014 EBF1 −6.20E−05 −7.4 1.50E−12 4.70E−10 ECM2 −7.00E−05 −7.8 1.80E−13 7.20E−11 EDA2R −0.00011 −11 8.70E−24 4.10E−20 EDIL3 −7.50E−05 −5.8 1.60E−08 1.20E−06 EDN3 −0.00019 −5.2 3.80E−07 1.70E−05 ELAVL4 −7.70E−05 −3.2 0.0014 0.011 ELFN2 −5.80E−05 −2.7 0.0079 0.042 ELOVL6 −3.30E−05 −3.7 3.00E−04 0.0035 ELTD1 −5.90E−05 −8.9 1.10E−16 1.10E−13 EMR2 −3.10E−05 −3.6 0.00035 0.004 EMX2 −6.20E−05 −3.3 0.0012 0.01 ENPP4 −9.40E−05 −8.2 9.20E−15 5.50E−12 ENPP5 −9.20E−05 −4 8.40E−05 0.0013 EPHA3 −8.70E−05 −6.5 3.90E−10 5.30E−08 EPHA7 −0.00014 −4.5 1.20E−05 0.00027 EPHX4 −7.50E−05 −4.4 1.50E−05 0.00032 EPS8 −6.90E−05 −6.8 6.00E−11 1.10E−08 ERBB4 −0.00016 −4.8 3.10E−06 9.20E−05 ERC2 −5.00E−05 −3.4 0.00071 0.0068 ERMN −7.10E−05 −5 1.00E−06 3.70E−05 ESRRG −0.00012 −4.2 4.40E−05 0.00077 ETV1 −6.50E−05 −6.2 2.80E−09 2.80E−07 ETV5 −4.30E−05 −4.9 1.50E−06 5.20E−05 ETV7 −2.80E−05 −2.7 0.0083 0.044 F2RL2 −6.40E−05 −4.6 6.10E−06 0.00016 FABP4 −9.80E−05 −3.9 0.00014 0.0019 FAM124A −6.00E−05 −6.9 3.50E−11 6.80E−09 FAM124B −7.60E−05 −7.5 1.00E−12 3.20E−10 FAM131B −5.10E−05 −5.6 4.80E−08 3.00E−06 FAM134B −5.60E−05 −5.3 2.80E−07 1.30E−05 FAM155A −9.20E−05 −7 1.90E−11 4.10E−09 FAM169A −2.60E−05 −3.1 0.0021 0.016 FAM174B −4.80E−05 −6.5 3.80E−10 5.20E−08 FAM179A −3.80E−05 −3.3 0.0012 0.01 FAM180A −5.10E−05 −3.7 0.00029 0.0034 FAM19A5 −6.40E−05 −5 8.40E−07 3.10E−05 FAM26E −6.80E−05 −6.6 1.80E−10 2.80E−08 FAM49A −5.60E−05 −7 1.70E−11 3.70E−09 FAM78A −4.90E−05 −6 5.40E−09 4.90E−07 FAR2 −4.40E−05 −5.6 4.80E−08 3.00E−06 FBN1 −8.50E−05 −7.1 1.50E−11 3.30E−09 FERMT2 −7.20E−05 −8.6 9.80E−16 7.80E−13 FETUB −9.80E−05 −2.7 0.0067 0.037 FGF1 −4.50E−05 −4.4 1.30E−05 3.00E−04 FGF10 −0.00016 −5.2 4.90E−07 2.00E−05 FGF14 −0.00012 −8.4 3.90E−15 2.60E−12 FGF2 −6.70E−05 −5.7 2.90E−08 2.00E−06 FGF7 −9.30E−05 −8.7 4.20E−16 3.80E−13 FGFR1 −6.00E−05 −6.7 1.20E−10 2.00E−08 FHL5 −8.70E−05 −5.4 1.30E−07 6.80E−06 FMN1 −4.80E−05 −3.9 0.00014 0.002 FMO2 −9.40E−05 −4.6 6.80E−06 0.00017 FNDC5 −5.30E−05 −3.4 0.00092 0.0083 FOXF1 −5.60E−05 −5.9 1.20E−08 9.40E−07 FOXI2 −9.30E−05 −2.8 0.0052 0.031 FPR1 −6.20E−05 −6.2 1.90E−09 2.00E−07 FREM2 −1.00E−04 −3 0.0032 0.022 FRY −7.00E−05 −6.9 3.20E−11 6.30E−09 FSD2 −0.00012 −3.5 0.00048 0.005 FSTL1 −6.20E−05 −7.1 1.00E−11 2.40E−09 FXYD2 −7.60E−05 −4.7 4.80E−06 0.00013 FXYD6 −8.00E−05 −6.7 1.00E−10 1.70E−08 FZD3 −4.90E−05 −5.5 1.10E−07 5.90E−06 FZD8 −2.50E−05 −2.7 0.0077 0.041 GAB3 −4.90E−05 −5.6 5.00E−08 3.10E−06 GABRA4 −1.00E−04 −2.9 0.0035 0.023 GADD45G −3.30E−05 −3.7 0.00025 0.003 GALNT13 −6.30E−05 −2.8 0.0048 0.029 GALNT5 −5.20E−05 −3.4 9.00E−04 0.0082 GCNT4 −3.90E−05 −4.4 1.70E−05 0.00036 GDF10 −0.00017 −7.3 4.80E−12 1.20E−09 GDPD1 −2.20E−05 −2.6 0.0095 0.048 GDPD5 −2.40E−05 −3 0.0033 0.022 GFRA1 −7.80E−05 −5 1.00E−06 3.70E−05 GFRA2 −6.30E−05 −5.6 6.40E−08 3.80E−06 GJA5 −6.00E−05 −6.2 2.20E−09 2.30E−07 GLDN −5.10E−05 −4.8 2.30E−06 7.20E−05 GLIS3 −6.20E−05 −6 7.40E−09 6.30E−07 GLRB −8.60E−05 −5 9.90E−07 3.60E−05 GNE −2.30E−05 −2.8 0.0054 0.032 GNG2 −3.90E−05 −4.7 3.70E−06 0.00011 GNG7 −3.50E−05 −3.6 0.00032 0.0037 GOLM1 −4.80E−05 −6.2 2.00E−09 2.10E−07 GPC6 −0.00011 −7.6 5.40E−13 1.90E−10 GPM6A −8.30E−05 −3 0.0034 0.022 GPR183 −5.70E−05 −6.2 2.60E−09 2.60E−07 GPR31 −9.40E−05 −3 0.0033 0.022 GPR4 −3.40E−05 −4.7 4.70E−06 0.00013 GPR88 −0.00015 −5.1 6.20E−07 2.50E−05 GPX8 −3.60E−05 −4.8 2.90E−06 8.60E−05 GRAMD1B −4.30E−05 −3.8 0.00019 0.0025 GRAP2 −5.10E−05 −4.4 1.40E−05 0.00031 GRB14 −6.60E−05 −3.2 0.0017 0.013 GREB1 −3.50E−05 −3.6 0.00037 0.0041 GREM2 −0.00012 −5.6 4.50E−08 2.80E−06 GRIA1 −0.00012 −3.7 3.00E−04 0.0035 GRID1 −4.60E−05 −4.5 8.80E−06 0.00021 GSG1L −9.10E−05 −3 0.0031 0.021 GSR −2.60E−05 −2.9 0.004 0.026 GUCA1A −6.50E−05 −3.5 0.00055 0.0056 GUCY1A2 −4.80E−05 −4.3 2.60E−05 0.00051 HCN1 −9.90E−05 −3.2 0.0013 0.011 HDX −8.00E−05 −6.3 1.30E−09 1.50E−07 HEYL −4.10E−05 −4.4 1.80E−05 0.00038 HFE2 −0.00017 −3.6 4.00E−04 0.0043 HHIPL1 −5.30E−05 −5.2 4.30E−07 1.80E−05 HIST2H2BE −2.20E−05 −2.6 0.0095 0.048 HLA-DPB1 −6.10E−05 −6.3 1.60E−09 1.80E−07 HLA-DQB1 −6.00E−05 −5.1 8.20E−07 3.10E−05 HS6ST3 −9.80E−05 −3 0.0032 0.021 HSD11B1 −9.10E−05 −6.5 3.70E−10 5.00E−08 HSPA12B −6.10E−05 −8.4 2.70E−15 1.90E−12 HTR1F −9.90E−05 −4.1 5.30E−05 9.00E−04 HUNK −3.30E−05 −2.8 0.0051 0.031 ICA1L −3.60E−05 −4.6 6.20E−06 0.00016 ICAM2 −3.90E−05 −5.4 1.90E−07 9.40E−06 IFI44L −4.70E−05 −3.1 0.0021 0.016 IGFBPL1 −9.00E−05 −2.7 0.0071 0.039 IGLON5 −3.50E−05 −3.2 0.0017 0.013 IKZF1 −5.70E−05 −5 1.10E−06 3.90E−05 IKZF3 −6.70E−05 −3.5 0.00049 0.0051 IL15 −2.60E−05 −3.1 0.0025 0.018 IL16 −4.40E−05 −5.1 5.40E−07 2.20E−05 IL17D −6.70E−05 −3.8 0.00018 0.0023 IL18BP −2.70E−05 −3.2 0.0016 0.013 IL21R −4.70E−05 −4 8.00E−05 0.0012 IL5RA −1.00E−04 −3.2 0.0016 0.013 IL6ST −3.40E−05 −4.3 2.90E−05 0.00055 IMPG2 −4.50E−05 −2.7 0.0069 0.038 IPCEF1 −4.40E−05 −4.2 3.40E−05 0.00063 IRAK3 −3.60E−05 −3.6 0.00036 0.0041 IRF1 −2.40E−05 −3 0.0033 0.022 ITGA11 −8.60E−05 −5.8 2.00E−08 1.50E−06 ITGA8 −7.80E−05 −4.7 5.20E−06 0.00014 ITGB1BP2 −5.90E−05 −4.1 6.20E−05 0.001 ITGB3 −6.20E−05 −5.8 1.50E−08 1.20E−06 JPH4 −7.10E−05 −6.8 6.50E−11 1.20E−08 KAL1 −4.30E−05 −3.7 0.00026 0.0031 KAT2B −3.00E−05 −4 9.10E−05 0.0014 KBTBD11 −3.80E−05 −3.9 0.00015 0.002 KCNAB1 −2.40E−05 −3.3 0.0011 0.0094 KCNB1 −0.00018 −6.1 4.90E−09 4.40E−07 KCNC1 −8.70E−05 −3.3 0.0011 0.0095 KCND1 −2.70E−05 −3 0.0031 0.021 KCND2 −0.00011 −7.5 9.00E−13 2.90E−10 KCNE4 −5.60E−05 −5.3 2.20E−07 1.00E−05 KCNH1 −6.50E−05 −3.1 0.0019 0.014 KCNJ16 −0.00013 −3.5 0.00047 0.0049 KCNJ5 −3.40E−05 −2.7 0.0079 0.042 KCNJ6 −9.20E−05 −3.2 0.0016 0.013 KCNJ8 −5.50E−05 −5.9 1.00E−08 8.40E−07 KCNK3 −9.70E−05 −5.6 5.20E−08 3.20E−06 KCNMB1 −3.70E−05 −5.1 5.70E−07 2.30E−05 KCNMB4 −4.20E−05 −3.5 0.00046 0.0049 KCNN3 −4.50E−05 −4.3 2.40E−05 0.00048 KCNQ1 −3.10E−05 −3.8 0.00016 0.0021 KCNQ3 −7.10E−05 −3.9 1.00E−04 0.0015 KCNT1 −0.00013 −4.1 6.10E−05 0.001 KCNT2 −0.00013 −7.8 1.60E−13 6.70E−11 KDELR3 −2.80E−05 −3.2 0.0016 0.012 KDR −4.70E−05 −5.9 1.20E−08 9.50E−07 KIAA1024 −3.30E−05 −3.8 0.00021 0.0026 KIAA1199 −4.70E−05 −4.7 5.20E−06 0.00014 KIAA1324L −5.00E−05 −5.5 1.10E−07 6.10E−06 KIAA1462 −6.50E−05 −7.5 8.80E−13 2.90E−10 KIF26B −3.80E−05 −3.5 0.00058 0.0058 KIF5C −5.30E−05 −5.5 1.10E−07 5.90E−06 KIF6 −7.10E−05 −3.6 0.00044 0.0047 KIT −7.30E−05 −6.6 2.20E−10 3.20E−08 KLF12 −2.80E−05 −3.2 0.0015 0.012 KLF2 −3.20E−05 −4.2 4.10E−05 0.00072 KLF9 −4.20E−05 −6.1 4.30E−09 4.00E−07 KLHDC8A −9.40E−05 −6 5.90E−09 5.20E−07 KLHL14 −1.00E−04 −3.9 0.00014 0.0019 KLHL6 −4.30E−05 −4.4 1.60E−05 0.00035 KLRB1 −5.70E−05 −4 8.80E−05 0.0013 KLRG1 −7.30E−05 −6.3 1.40E−09 1.60E−07 KLRK1 −7.40E−05 −5.3 2.50E−07 1.20E−05 KMO −3.60E−05 −3.4 0.00089 0.0081 KRBA2 −3.00E−05 −2.9 0.0035 0.023 KSR2 −8.30E−05 −3.7 0.00022 0.0027 LAMA4 −5.80E−05 −6.3 1.40E−09 1.60E−07 LARGE −2.50E−05 −2.9 0.0037 0.024 LAYN −3.10E−05 −3.3 0.001 0.0091 LCA5 −2.00E−05 −2.8 0.0064 0.036 LCN6 −0.00014 −4.5 1.20E−05 0.00027 LCP2 −5.10E−05 −5.7 3.00E−08 2.00E−06 LEF1 −5.10E−05 −5.8 2.30E−08 1.60E−06 LGI2 −5.80E−05 −4.2 3.70E−05 0.00068 LIFR −3.20E−05 −2.8 0.005 0.03 LILRA1 −9.30E−05 −4.1 4.90E−05 0.00084 LILRB1 −6.30E−05 −5.7 2.90E−08 2.00E−06 LILRB2 −6.70E−05 −6 7.10E−09 6.10E−07 LIMCH1 −3.60E−05 −3.3 0.0012 0.01 LIMD2 −2.10E−05 −2.7 0.0074 0.04 LIMS2 −4.70E−05 −6.5 4.00E−10 5.40E−08 LIN7A −7.30E−05 −4.1 6.10E−05 0.001 LMO3 −0.00014 −5 1.30E−06 4.40E−05 LMO7 −3.90E−05 −4.3 2.60E−05 0.00051 LMOD3 −0.00011 −3.2 0.0018 0.014 LMX1A −0.00016 −5 9.30E−07 3.40E−05 LONRF2 −0.00012 −4.6 7.20E−06 0.00018 LONRF3 −8.90E−05 −5.9 1.10E−08 8.80E−07 LOX −3.80E−05 −3.5 0.00046 0.0049 LPAR1 −5.50E−05 −6.9 3.10E−11 6.10E−09 LPPR4 −4.90E−05 −5.1 8.20E−07 3.10E−05 LRRC2 −0.00013 −5.6 5.90E−08 3.50E−06 LRRC4C −0.00016 −6.4 6.10E−10 7.80E−08 LRRK2 −7.30E−05 −6.3 1.00E−09 1.20E−07 LRRN2 −8.20E−05 −5.9 9.20E−09 7.50E−07 LRRTM2 −6.40E−05 −4.3 2.50E−05 0.00049 LSAMP −1.00E−04 −7.3 2.90E−12 8.10E−10 LTA −5.00E−05 −3.5 0.00056 0.0057 LUZP2 −0.00013 −4.7 3.60E−06 1.00E−04 LYZ −9.00E−05 −6.3 1.40E−09 1.60E−07 MAGI2 −2.80E−05 −3.3 0.0013 0.011 MAML3 −3.80E−05 −4.6 6.40E−06 0.00016 MAN1A1 −4.10E−05 −4.8 3.10E−06 9.20E−05 MAP2K6 −3.40E−05 −3.4 0.00074 0.007 MAP6 −5.20E−05 −3.9 0.00012 0.0017 MAP9 −5.80E−05 −4.6 5.90E−06 0.00015 MAPK4 −9.10E−05 −3.4 0.00088 0.008 MAT1A −5.80E−05 −2.8 0.0052 0.031 MCOLN2 −2.80E−05 −3 0.0033 0.022 MDGA1 −3.00E−05 −2.6 0.0089 0.046 MEF2C −7.40E−05 −6.5 4.00E−10 5.40E−08 MERTK −6.40E−05 −6.3 1.20E−09 1.40E−07 MFNG −3.80E−05 −4.7 3.90E−06 0.00011 MGAT4A −6.40E−05 −8.1 1.70E−14 9.40E−12 MMP16 −9.10E−05 −5.5 9.50E−08 5.30E−06 MNDA −5.70E−05 −5.5 7.20E−08 4.20E−06 MPP2 −4.20E−05 −3.7 0.00026 0.0031 MRGPRF −5.50E−05 −6.2 2.30E−09 2.40E−07 MRO −0.00013 −8.7 3.40E−16 3.00E−13 MURC −7.30E−05 −4 7.50E−05 0.0012 MYEF2 −7.80E−05 −6 5.10E−09 4.60E−07 MYO1F −5.30E−05 −6.1 4.70E−09 4.30E−07 MYOCD −6.80E−05 −2.9 0.0045 0.028 MYOZ3 −7.10E−05 −3.7 0.00025 0.003 MYPN −0.00013 −3.7 0.00029 0.0034 MYRIP −9.00E−05 −4.8 2.80E−06 8.50E−05 NAP1L6 −1.00E−04 −3.1 0.0021 0.016 NAT8L −8.50E−05 −5 9.70E−07 3.50E−05 NCAM1 −9.00E−05 −5.2 4.10E−07 1.80E−05 NCAM2 −0.00013 −6.1 4.10E−09 3.80E−07 NEGR1 −0.00011 −7.9 8.50E−14 3.80E−11 NEK10 −5.70E−05 −3 0.0034 0.023 NEXN −7.30E−05 −6.2 1.70E−09 1.90E−07 NHSL2 −8.60E−05 −6.5 5.40E−10 6.90E−08 NID2 −6.10E−05 −5.3 2.10E−07 1.00E−05 NIPSNAP3B −3.10E−05 −3.6 0.00034 0.0038 NKX3-2 −7.00E−05 −3.5 0.00065 0.0064 NLGN4X −5.20E−05 −3.1 0.002 0.015 NLRC3 −4.10E−05 −4.4 1.90E−05 0.00039 NOS1 −9.60E−05 −3.6 0.00043 0.0046 NOTCH4 −3.70E−05 −5.1 7.10E−07 2.80E−05 NPAS3 −8.10E−05 −5 1.00E−06 3.70E−05 NPHP1 −2.70E−05 −3.3 0.001 0.0092 NPTXR −4.50E−05 −3.2 0.0014 0.011 NR3C2 −5.60E−05 −3.8 0.00015 0.0021 NR5A2 −5.00E−05 −6.6 3.10E−10 4.40E−08 NRG2 −0.00011 −5.1 5.90E−07 2.40E−05 NRIP2 −2.60E−05 −3.2 0.0015 0.012 NRXN3 −8.30E−05 −4.3 2.70E−05 0.00052 NT5C1A −1.00E−04 −3.1 0.0025 0.018 NT5E −3.60E−05 −2.7 0.0067 0.037 NTNG1 −0.00012 −4.4 1.50E−05 0.00033 NXPH3 −7.80E−05 −7.9 9.50E−14 4.20E−11 OGN −0.00021 −8.4 4.00E−15 2.60E−12 ORAI2 −2.60E−05 −3.5 0.00057 0.0057 OTOF −6.40E−05 −4.1 5.30E−05 9.00E−04 OTX2 −0.00011 −3 0.0028 0.019 P2RX7 −3.50E−05 −3 0.003 0.02 P2RY14 −5.20E−05 −5.1 5.40E−07 2.20E−05 PACSIN1 −8.00E−05 −5 9.60E−07 3.50E−05 PAK3 −0.00017 −6.2 2.40E−09 2.50E−07 PALM2 −6.00E−05 −6.2 2.00E−09 2.10E−07 PALM2-AKAP2 −5.20E−05 −6.5 4.80E−10 6.30E−08 PAQR8 −5.40E−05 −6.4 9.20E−10 1.10E−07 PARD3B −5.10E−05 −4.6 7.50E−06 0.00019 PAX7 −0.00014 −3.4 0.00076 0.0072 PBX1 −3.50E−05 −2.7 0.0064 0.036 PCDH10 −9.10E−05 −3.1 0.0021 0.015 PCDH19 −9.50E−05 −4.1 6.00E−05 0.00099 PCDH20 −0.00011 −3.5 0.00052 0.0053 PCDHB16 −3.60E−05 −3.4 9.00E−04 0.0082 PCDHB5 −6.50E−05 −4.7 3.70E−06 0.00011 PCSK1 −4.30E−05 −3.2 0.0016 0.013 PCSK2 −0.00011 −3.1 0.0024 0.018 PCYT1B −7.30E−05 −3.2 0.0014 0.012 PDE1lA −0.00014 −4.5 9.30E−06 0.00022 PDE1C −9.50E−05 −5.5 1.00E−07 5.60E−06 PDE3A −7.20E−05 −5.9 1.10E−08 8.70E−07 PDE3B −4.50E−05 −3.9 0.00012 0.0017 PDE5A −3.10E−05 −3.7 0.00024 0.0029 PDE8B −3.00E−05 −3.6 4.00E−04 0.0044 PDK4 −1.00E−04 −7.2 5.00E−12 1.30E−09 PDLIM3 −8.60E−05 −5.3 2.00E−07 9.60E−06 PEG10 −6.60E−05 −3.2 0.0015 0.012 PEG3 −1.00E−04 −6.2 2.40E−09 2.40E−07 PELI2 −4.80E−05 −4.4 1.90E−05 4.00E−04 PGM2L1 −3.00E−05 −3.4 0.00091 0.0083 PGPEP1 −3.10E−05 −3.9 1.00E−04 0.0015 PHACTR1 −4.80E−05 −5.2 4.40E−07 1.90E−05 P115 −3.40E−05 −2.7 0.0072 0.039 P116 −0.00017 −7 2.30E−11 4.70E−09 PIPOX −5.50E−05 −4.7 4.70E−06 0.00013 PKD2L1 −9.10E−05 −4.1 6.60E−05 0.0011 PKHD1 −0.00011 −3.6 0.00038 0.0042 PKIA −4.50E−05 −3.3 0.0011 0.0095 PLA2G16 −6.70E−05 −6.8 8.90E−11 1.50E−08 PLA2G2D −0.00012 −4.4 1.30E−05 0.00029 PLA2G7 −6.40E−05 −5.5 7.90E−08 4.50E−06 PLCB1 −4.70E−05 −5.1 6.80E−07 2.70E−05 PLCL1 −3.90E−05 −4.9 2.00E−06 6.30E−05 PLCXD3 −0.00011 −3.6 0.00043 0.0046 PLEK −5.10E−05 −4.6 6.10E−06 0.00016 PLEKHG1 −4.80E−05 −6 5.60E−09 5.00E−07 PLEKHH2 −3.00E−05 −3 0.0033 0.022 PLN −0.00012 −6.9 3.50E−11 6.70E−09 PLP1 −7.90E−05 −2.8 0.0052 0.031 PLSCR4 −2.90E−05 −3.8 0.00016 0.0021 PLXDC2 −4.80E−05 −5.5 9.60E−08 5.30E−06 PLXNA4 −6.00E−05 −5 1.00E−06 3.80E−05 PLXNC1 −8.00E−05 −7.1 1.60E−11 3.60E−09 PNMA2 −8.80E−05 −6.9 3.50E−11 6.80E−09 PODXL −3.70E−05 −5.1 7.30E−07 2.80E−05 POU6F1 −3.90E−05 −5.3 2.30E−07 1.10E−05 PPAPDC1A −1.00E−04 −5 1.30E−06 4.50E−05 PPM1H −5.90E−05 −4.6 6.50E−06 0.00017 PPM1L −5.20E−05 −4.7 4.20E−06 0.00012 PPP1R3A −0.00016 −3.5 0.00058 0.0059 PRDM16 −8.60E−05 −6.8 5.80E−11 1.00E−08 PREX2 −0.00011 −8.8 2.20E−16 2.10E−13 PRKAG3 −0.00011 −2.9 0.004 0.025 PRLR −6.50E−05 −3.6 0.00036 0.004 PRND −0.00014 −6.2 2.30E−09 2.40E−07 PROX1 −6.70E−05 −4.8 3.30E−06 9.70E−05 PRR15 −4.70E−05 −2.6 0.0088 0.046 PRR16 −5.70E−05 −5.4 1.20E−07 6.40E−06 PRRG3 −0.00013 −3.8 0.00016 0.0021 PRRX1 −6.40E−05 −6.1 4.00E−09 3.80E−07 PRUNE2 −9.60E−05 −5.8 2.10E−08 1.50E−06 PSD −3.60E−05 −4.5 1.20E−05 0.00027 PSD3 −2.10E−05 −2.6 0.0097 0.049 PTCHD1 −0.00014 −4.5 8.90E−06 0.00021 PTGER3 −7.60E−05 −5.7 3.90E−08 2.50E−06 PTGFR −8.70E−05 −6.4 7.90E−10 9.60E−08 PTGIR −3.70E−05 −4.4 1.90E−05 4.00E−04 PTPLAD2 −2.40E−05 −2.8 0.0064 0.036 PTPN7 −3.50E−05 −3.2 0.0015 0.012 PTPRB −6.30E−05 −8.7 3.60E−16 3.30E−13 PTPRC −6.60E−05 −5.7 4.10E−08 2.60E−06 PTPRD −0.00014 −8.3 7.00E−15 4.30E−12 PTPRG −2.60E−05 −3.4 0.00078 0.0074 PTPRJ −4.20E−05 −5.3 2.70E−07 1.20E−05 PTPRM −4.70E−05 −6.2 2.50E−09 2.60E−07 PTPRT −0.00013 −4.1 6.50E−05 0.0011 PTX3 −1.00E−04 −5.2 3.90E−07 1.70E−05 PURG −0.00011 −4.4 1.60E−05 0.00034 PVRL3 −4.40E−05 −3.5 0.00051 0.0053 PYGO1 −1.00E−04 −6 5.60E−09 5.00E−07 RAB15 −3.70E−05 −4.9 2.00E−06 6.30E−05 RAB19 −0.00013 −5.6 6.40E−08 3.80E−06 RAB3B −8.00E−05 −3.6 4.00E−04 0.0044 RAB3C −0.00012 −4 6.80E−05 0.0011 RAB6B −3.90E−05 −3 0.0034 0.023 RAB9B −0.00012 −5.5 9.80E−08 5.40E−06 RARRES3 −5.10E−05 −4.6 5.90E−06 0.00015 RASGRF2 −7.60E−05 −7.8 2.00E−13 8.20E−11 RASGRP1 −3.50E−05 −3 0.0027 0.019 RASL10B −5.00E−05 −4.2 4.50E−05 0.00078 RASSF2 −5.90E−05 −6.7 1.20E−10 2.00E−08 RASSF4 −5.70E−05 −6.9 4.50E−11 8.50E−09 RASSF8 −3.50E−05 −4.3 2.10E−05 0.00043 RBMS3 −8.30E−05 −8.6 6.30E−16 5.30E−13 RBPMS2 −5.90E−05 −6.4 6.50E−10 8.20E−08 RCAN2 −6.80E−05 −7.4 2.20E−12 6.40E−10 REEP2 −4.30E−05 −4.2 4.20E−05 0.00075 RELN −0.00012 −5.8 1.60E−08 1.20E−06 RGAG4 −5.80E−05 −5.8 1.90E−08 1.40E−06 RGS18 −6.70E−05 −6.6 3.10E−10 4.30E−08 RGS5 −4.80E−05 −4.5 1.00E−05 0.00024 RGS8 −8.10E−05 −3.4 0.00089 0.0081 RHOH −4.30E−05 −4.1 5.90E−05 0.00098 RHOU −3.00E−05 −3.6 0.00033 0.0038 RIMKLA −7.40E−05 −3.3 0.0012 0.01 RIMS4 −0.00018 −6.9 4.70E−11 8.80E−09 RLN2 −7.50E−05 −2.7 0.0073 0.04 RNF150 −0.00011 −7.1 1.10E−11 2.60E−09 RNF152 −2.60E−05 −2.9 0.0035 0.023 RNF157 −6.10E−05 −6.8 5.50E−11 1.00E−08 RNF180 −8.00E−05 −7.2 7.70E−12 1.90E−09 ROR2 −6.00E−05 −4.7 4.10E−06 0.00012 RORA −3.00E−05 −3.6 0.00042 0.0045 RPS6KA6 −0.00016 −4.7 4.90E−06 0.00013 RRAGD −3.50E−05 −3.4 0.00067 0.0065 RSPO3 −0.00015 −11 5.90E−23 2.40E−19 RUNX1T1 −1.00E−04 −6.9 5.00E−11 9.20E−09 RUNX2 −3.10E−05 −4.4 1.90E−05 4.00E−04 S1PR1 −6.10E−05 −8.6 9.60E−16 7.70E−13 S1PR3 −6.80E−05 −8.3 4.90E−15 3.20E−12 SALL1 −7.70E−05 −3.1 0.0019 0.015 SALL2 −6.30E−05 −5.2 3.40E−07 1.50E−05 SAMD4A −3.10E−05 −3.7 0.00023 0.0028 SAMD5 −6.40E−05 −4.5 1.20E−05 0.00028 SARDH −4.20E−05 −4 7.40E−05 0.0012 SARM1 −6.00E−05 −6.8 9.50E−11 1.60E−08 SCAMP5 −2.70E−05 −3 0.0031 0.021 SCIN −6.60E−05 −4.6 5.60E−06 0.00015 SCML4 −9.20E−05 −4.8 2.40E−06 7.40E−05 SCN3A −0.00011 −6.8 7.90E−11 1.40E−08 SCN7A −8.80E−05 −2.9 0.0047 0.029 SCN9A −9.20E−05 −4.8 2.60E−06 7.80E−05 SCUBE1 −6.80E−05 −4.8 3.20E−06 9.40E−05 SELE −9.40E−05 −5.7 3.90E−08 2.50E−06 SELP −9.20E−05 −5.5 1.00E−07 5.70E−06 SELPLG −4.40E−05 −5.3 3.00E−07 1.40E−05 SEMA3A −5.90E−05 −4.4 1.60E−05 0.00034 SEMA3E −0.00013 −3.6 0.00034 0.0039 SEMA7A −2.60E−05 −3.5 0.00064 0.0063 SERPINA1 −5.90E−05 −5.6 5.20E−08 3.20E−06 SERPINA5 −0.00012 −5.7 4.20E−08 2.70E−06 SERPING1 −6.20E−05 −6.8 7.10E−11 1.20E−08 SFMBT2 −5.50E−05 −5.5 9.10E−08 5.10E−06 SGCD −0.00011 −7.7 3.30E−13 1.20E−10 SGIP1 −5.00E−05 −4.5 1.10E−05 0.00025 SH2D1A −8.70E−05 −5.8 1.80E−08 1.30E−06 SHE −5.50E−05 −5.7 4.20E−08 2.60E−06 SHISA6 −0.00012 −3.4 0.00082 0.0076 SIDT1 −7.70E−05 −6 7.80E−09 6.60E−07 SIGLEC14 −9.00E−05 −4.2 4.40E−05 0.00078 SIGLEC8 −9.70E−05 −5.4 1.80E−07 9.00E−06 SIGLEC9 −6.50E−05 −7.5 1.10E−12 3.60E−10 SIM1 −0.00011 −3 0.0027 0.019 SLA −5.40E−05 −5.7 2.90E−08 2.00E−06 SLAMF1 −4.70E−05 −3.9 0.00012 0.0017 SLC11A1 −4.60E−05 −4.5 9.00E−06 0.00022 SLC12A3 −8.00E−05 −3.3 0.00095 0.0085 SLC16A10 −5.90E−05 −6.2 1.90E−09 2.00E−07 SLC1A2 −4.10E−05 −2.8 0.0056 0.033 SLC22A16 −6.40E−05 −2.7 0.0069 0.038 SLC24A2 −9.80E−05 −3.5 0.00051 0.0053 SLC2A5 −6.50E−05 −6.9 5.00E−11 9.20E−09 SLC39A14 −2.80E−05 −3.9 0.00013 0.0018 SLC46A2 −7.20E−05 −4.2 3.40E−05 0.00063 SLC4A4 −9.60E−05 −5 1.10E−06 3.80E−05 SLC6A1 −6.80E−05 −4.2 3.40E−05 0.00063 SLC6A20 −9.20E−05 −3.9 0.00011 0.0016 SLC6A4 −7.40E−05 −2.6 0.0094 0.048 SLC7A2 −4.20E−05 −2.9 0.004 0.025 SLC7A3 −0.00011 −3.8 0.00018 0.0023 SLC7A7 −6.70E−05 −7 1.80E−11 3.90E−09 SLC8A1 −5.90E−05 −6.8 5.40E−11 9.90E−09 SLC8A3 −0.00011 −5.3 3.20E−07 1.40E−05 SLC9A7 −3.90E−05 −4.4 1.30E−05 0.00029 SLC9A9 −3.20E−05 −3.2 0.0015 0.012 SLCO5A1 −5.40E−05 −4.6 6.80E−06 0.00017 SLFN12L −3.30E−05 −3.4 0.00085 0.0078 SLIT2 −7.50E−05 −5.7 3.00E−08 2.00E−06 SLIT3 −7.20E−05 −6.2 2.50E−09 2.60E−07 SLITRK4 −0.00016 −6.5 4.30E−10 5.70E−08 SMOC1 −5.30E−05 −3.3 0.00096 0.0086 SMTNL1 −8.00E−05 −3.6 0.00037 0.0042 SMTNL2 −0.00014 −7.3 4.40E−12 1.10E−09 SNAP25 −6.70E−05 −4.8 3.20E−06 9.40E−05 SNED1 −8.70E−05 −8.6 5.70E−16 4.90E−13 SNX32 −7.10E−05 −3.1 0.0022 0.016 SORBS1 −7.20E−05 −7.3 2.80E−12 7.90E−10 SOX17 −6.00E−05 −7.5 1.10E−12 3.50E−10 SOX5 −0.00011 −7 2.10E−11 4.40E−09 SP6 −3.00E−05 −3.7 0.00026 0.0032 SPARC −5.90E−05 −5.4 1.20E−07 6.30E−06 SPATA13 −6.60E−05 −6.4 8.60E−10 1.00E−07 SPN −5.20E−05 −4.8 3.30E−06 9.60E−05 SPOCK2 −4.60E−05 −4.4 1.80E−05 0.00038 SRPX2 −5.50E−05 −7 2.30E−11 4.70E−09 SSC5D −7.10E−05 −6.2 2.70E−09 2.70E−07 ST18 −9.10E−05 −3.8 0.00018 0.0023 ST3GAL1 −2.80E−05 −3.5 0.00062 0.0062 ST3GAL6 −2.20E−05 −3 0.003 0.021 ST6GAL1 −5.60E−05 −5 1.20E−06 4.20E−05 ST6GAL2 −0.00014 −6.3 1.30E−09 1.50E−07 ST6GALNAC3 −6.40E−05 −8.6 1.00E−15 8.00E−13 ST6GALNAC5 −8.00E−05 −6.1 3.30E−09 3.20E−07 ST8SIA4 −5.00E−05 −6.3 1.30E−09 1.50E−07 STARD13 −3.70E−05 −4.8 3.10E−06 9.10E−05 STAT1 −3.20E−05 −3.6 0.00042 0.0045 STC1 −4.40E−05 −4.3 2.10E−05 0.00043 STEAP2 −5.00E−05 −5.6 5.00E−08 3.10E−06 SUCNR1 −5.20E−05 −3.3 0.001 0.0091 SULF1 −8.90E−05 −7.3 4.20E−12 1.10E−09 SV2B −7.10E−05 −3.6 0.00033 0.0037 SVIP −6.00E−05 −5.1 7.20E−07 2.80E−05 SYNPO2 −7.50E−05 −4.5 1.00E−05 0.00024 SYP −4.50E−05 −4.7 3.90E−06 0.00011 SYPL2 −7.40E−05 −4.2 3.30E−05 0.00061 SYT13 −1.00E−04 −3.1 0.002 0.015 SYT9 −9.40E−05 −2.9 0.0039 0.025 SYTL4 −4.90E−05 −5.9 1.30E−08 1.00E−06 TBX15 −6.50E−05 −4.8 2.20E−06 6.90E−05 TBX21 −5.70E−05 −4.5 1.00E−05 0.00024 TCN2 −5.90E−05 −6.7 1.60E−10 2.50E−08 TDGF1 −0.00012 −3.9 0.00013 0.0019 TETI −3.70E−05 −3.5 0.00054 0.0055 THBS1 −4.70E−05 −4.1 5.00E−05 0.00085 THSD7A −0.00011 −8.6 1.10E−15 8.50E−13 TIMD4 −0.00019 −6.4 5.80E−10 7.40E−08 TIMP2 −7.30E−05 −8.3 5.60E−15 3.50E−12 TLR4 −8.60E−05 −9.5 1.80E−18 2.90E−15 TLR8 −8.70E−05 −6.8 9.20E−11 1.60E−08 TM4SF18 −4.50E−05 −6 7.70E−09 6.50E−07 TMEM156 −3.70E−05 −3.2 0.0018 0.014 TMEM170B −7.00E−05 −8.3 5.70E−15 3.60E−12 TMEM182 −2.60E−05 −3.5 0.00064 0.0063 TMEM231 −3.90E−05 −4.3 2.90E−05 0.00056 TMEM26 −6.20E−05 −5.9 1.50E−08 1.10E−06 TMEM47 −6.10E−05 −6.8 8.50E−11 1.50E−08 TMEM86A −2.60E−05 −2.8 0.0055 0.032 TMEM98 −4.10E−05 −4.9 1.70E−06 5.50E−05 TMTC1 −8.40E−05 −6.6 2.60E−10 3.70E−08 TNFSF11 −4.60E−05 −3.3 0.0011 0.0098 TNFSF15 −4.90E−05 −3.6 0.00045 0.0048 TNFSF4 −5.50E−05 −4.8 3.00E−06 9.00E−05 TNFSF8 −8.50E−05 −5.5 9.90E−08 5.40E−06 TNIK −5.80E−05 −5.2 3.20E−07 1.40E−05 TNNI1 −7.10E−05 −3.5 0.00061 0.0061 TNR −0.00012 −4.1 5.50E−05 0.00092 TNS3 −3.80E−05 −4.9 1.40E−06 4.90E−05 TOX −4.70E−05 −4.2 4.00E−05 0.00071 TRAT1 −0.00011 −4.9 2.00E−06 6.30E−05 TREM2 −4.20E−05 −3.8 0.00015 0.0021 TREML2 −4.20E−05 −2.9 0.004 0.025 TRHDE −0.00013 −3.9 0.00011 0.0016 TRIM2 −3.40E−05 −3.1 0.002 0.015 TRIM58 −8.40E−05 −3.3 0.001 0.009 TRPC6 −3.00E−05 −3.5 0.00061 0.0061 TRPM8 −9.60E−05 −3.6 0.00041 0.0045 TRPS1 −2.30E−05 −2.8 0.0052 0.031 TSPAN11 −5.10E−05 −4.4 1.80E−05 0.00038 TSPAN18 −6.80E−05 −5.6 4.80E−08 3.00E−06 TSPAN5 −2.40E−05 −3 0.0031 0.021 TSPAN7 −6.90E−05 −4.6 6.50E−06 0.00017 TTC28 −4.00E−05 −4.4 1.80E−05 0.00037 TTLL7 −3.10E−05 −2.7 0.0077 0.041 TTYH2 −2.50E−05 −3.1 0.0021 0.015 TUB −6.30E−05 −5.2 3.50E−07 1.50E−05 TWIST2 −4.40E−05 −4.4 1.90E−05 0.00039 TYRP1 −9.10E−05 −3.1 0.0024 0.017 UBE2QL1 −3.70E−05 −2.9 0.0041 0.026 UBXN10 −7.60E−05 −5.2 3.30E−07 1.50E−05 UGT2B4 −8.00E−05 −3 0.0032 0.021 UNC5C −9.40E−05 −4.5 1.20E−05 0.00027 USP13 −3.90E−05 −5 1.30E−06 4.60E−05 VASH1 −5.10E−05 −7 2.10E−11 4.40E−09 VASH2 −5.10E−05 −4.3 2.20E−05 0.00044 VAT1L −1.00E−04 −5.5 8.60E−08 4.80E−06 VENTX −7.30E−05 −5.4 1.20E−07 6.60E−06 VGLL2 −0.00012 −2.9 0.0039 0.025 VGLL3 −7.00E−05 −6.2 2.00E−09 2.10E−07 VSIG10 −2.30E−05 −3 0.003 0.021 VWC2 −9.00E−05 −2.6 0.0098 0.049 WFIKKN2 −9.70E−05 −3 0.0034 0.022 WISP2 −0.00015 −8.6 1.00E−15 8.10E−13 WNT2 −9.20E−05 −4.8 2.90E−06 8.50E−05 WNT5A −4.30E−05 −4.4 1.60E−05 0.00035 WNT5B −3.50E−05 −3 0.003 0.02 XCR1 −9.00E−05 −3.8 0.00015 0.0021 XIRP1 −8.70E−05 −3.6 0.00043 0.0046 ZBTB10 −5.30E−05 −5.1 8.20E−07 3.10E−05 ZBTB16 −0.00012 −4.6 8.00E−06 2.00E−04 ZBTB20 −3.30E−05 −3.8 0.00016 0.0022 ZC4H2 −4.80E−05 −4.8 3.20E−06 9.40E−05 ZDHHC15 −0.00013 −6.6 2.80E−10 4.00E−08 ZEB1 −6.90E−05 −8.8 1.50E−16 1.50E−13 ZEB2 −6.80E−05 −8.4 3.80E−15 2.50E−12 ZFP82 −4.50E−05 −4.2 3.20E−05 6.00E−04 ZIK1 −3.20E−05 −3.7 0.00025 0.003 ZNF154 −5.00E−05 −5.7 3.00E−08 2.00E−06 ZNF208 −0.00013 −6.6 3.10E−10 4.30E−08 ZNF215 −7.00E−05 −4.5 8.50E−06 0.00021 ZNF280B −7.30E−05 −3.9 0.00012 0.0017 ZNF287 −2.80E−05 −3 0.003 0.021 ZNF347 −4.10E−05 −3.4 0.00066 0.0065 ZNF366 −5.90E−05 −4.4 1.30E−05 3.00E−04 ZNF429 −3.70E−05 −2.9 0.0038 0.025 ZNF442 −2.60E−05 −3 0.0026 0.018 ZNF618 −3.30E−05 −3.9 0.00012 0.0017 ZNF701 −3.60E−05 −4 7.60E−05 0.0012 ZNF781 −5.80E−05 −3.1 0.0024 0.017 ZNF788 −3.60E−05 −3 0.0026 0.018 ZNF793 −4.90E−05 −2.7 0.0068 0.038 ZNF843 −2.40E−05 −3.3 0.0013 0.011 ZNF844 −5.60E−05 −4.1 5.30E−05 0.00089 ZSCAN1 −8.90E−05 −3.1 0.002 0.015

TABLE 14 mRNAs inversely expressed and containing predicted or validated binding sites to miR-375 (MIMAT0000728) Gene t. stat p. value p. adj ACVR1C −4.70738 3.79E−06 8.36E−05 ADAMDEC1 −2.85571 0.004584 0.028127 ADAMTS2 −8.00448 2.43E−14 5.11E−12 ADAMTS4 −5.61352 4.40E−08 1.79E−06 ADAMTS5 −4.36029 1.77E−05 0.000308 AFAP1L1 −5.85642 1.21E−08 5.81E−07 AFAP1L2 −3.94692 9.80E−05 0.001288 AK5 −3.22616 0.001389 0.011065 APBA2 −5.98525 5.96E−09 3.14E−07 ATP1B4 −2.80475 0.005354 0.0317  BAG2 −6.31936 9.12E−10 6.02E−08 BCAT1 −4.44925 1.20E−05 0.000223 BVES −2.70341 0.007242 0.039902 C10orf55 −7.35354 1.73E−12 2.33E−10 C15orf54 −3.29027 0.001116 0.009302 C1orf180 −2.80204 0.005398 0.0319  C1S −6.47289 3.76E−10 2.76E−08 C2orf48 −3.79852 0.000175 0.002078 C6orf141 −3.84998 0.000143 0.001764 C9orf84 −4.58988 6.45E−06 0.000131 CALB1 −3.21159 0.001459 0.011504 CCDC102B −5.32761 1.92E−07 6.44E−06 CD84 −2.61675 0.009312 0.048237 CDH6 −3.95802 9.38E−05 0.001241 CDK14 −4.82222 2.23E−06 5.31E−05 CDK5R1 −2.75412 0.006233 0.035597 CDK6 −3.82156 0.00016  0.001932 CDYL2 −4.19285 3.60E−05 0.000559 CENPA −7.27305 2.89E−12 3.68E−10 CENPF −5.77959 1.82E−08 8.34E−07 CFHR3 −2.90338 0.003957 0.025106 CHST11 −7.11164 7.96E−12 9.07E−10 CLEC2B −4.19326 3.59E−05 0.000559 CLEC5A −2.80953 0.005277 0.031352 CNGB1 −5.47185 9.20E−08 3.40E−06 COL16A1 −6.91676 2.65E−11 2.64E−09 COL27A1 −7.59153 3.74E−13 5.94E−11 COL5A1 −10.2428 2.13E−21 1.85E−18 COL5A2 −10.2511 2.00E−21 1.75E−18 COL5A3 −7.81021 8.90E−14 1.64E−11 CRISPLD2 −4.86085 1.86E−06 4.55E−05 CSAG1 −4.01632 7.42E−05 0.001022 CYSLTR2 −2.62634 0.00906  0.047249 DAB2 −3.593 0.00038  0.003911 DCLK3 −4.99615 9.79E−07 2.62E−05 DDX60L −4.29871 2.30E−05 0.000385 DFNA5 −6.82695 4.58E−11 4.29E−09 DGKI −3.21627 0.001436 0.01136  DKK3 −3.72321 0.000234 0.002631 DMBX1 −3.69276 0.000262 0.00289  DRP2 −3.04627 0.002516 0.017666 DUSP6 −3.0615 0.002395 0.016999 E2F7 −6.80262 5.30E−11 4.88E−09 ECM2 −3.70034 0.000255 0.002824 EIF5A2 −7.56276 4.51E−13 7.02E−11 EME1 −7.30865 2.31E−12 3.01E−10 ENPEP −7.33148 1.99E−12 2.64E−10 ERCC6L −5.24049 2.97E−07 9.39E−06 EXO1 −6.73046 8.19E−11 7.18E−09 FAM111B −3.21279 0.001453 0.011467 FAM198B −4.22428 3.16E−05 0.000501 FBLN7 −5.13553 4.98E−07 1.47E−05 FBN2 −5.49402 8.20E−08 3.08E−06 FCGR2A −5.69769 2.82E−08 1.22E−06 FCGR3A −5.97743 6.23E−09 3.26E−07 FERMT2 −2.76737 0.005991 0.034542 FJX1 −5.16984 4.21E−07 1.27E−05 FLRT2 −5.50011 7.95E−08 3.00E−06 FN1 −9.32549 2.16E−18 1.08E−15 FOXD1 −6.88267 3.26E−11 3.18E−09 FOXR2 −2.61614 0.009328 0.0483  FPR2 −3.97456 8.78E−05 0.001175 FSTL1 −4.56735 7.14E−06 0.000143 GAD1 −2.75515 0.006213 0.035514 GATA6 −2.95962 0.003318 0.021907 GDF6 −3.57806 0.000402 0.004089 GINS4 −4.29356 2.35E−05 0.000392 GLIPR1 −5.15516 4.52E−07 1.35E−05 GLIS3 −2.88323 0.004211 0.026349 GNGT2 −2.98368 0.003074 0.02065  GOLGA8F −2.73345 0.006628 0.037306 GOLGA8G −3.33689 0.00095  0.008182 GPR116 −3.23522 0.001347 0.010799 GPR137C −3.77558 0.000191 0.002234 GPR153 −2.70662 0.007174 0.039617 GPR39 −3.10237 0.002096 0.015314 GRM5 −2.83551 0.004876 0.029502 GRM8 −3.15477 0.001764 0.013367 GUCY1A2 −6.22001 1.61E−09 9.91E−08 GXYLT2 −4.60002 6.16E−06 0.000126 HAPLN1 −5.46562 9.50E−08 3.50E−06 HAS2 −4.90104 1.54E−06 3.87E−05 HELLS −3.47233 0.000589 0.005576 HHIPL1 −5.11384 5.54E−07 1.61E−05 HIST1H2AG −5.61991 4.26E−08 1.74E−06 HIST1H2BD −3.40446 0.00075  0.00677  HIST1H2BO −5.44492 1.06E−07 3.84E−06 HIST1H3B −2.8217 0.005085 0.030472 HIST1H4E −3.13256 0.001898 0.014162 HMX1 −3.92309 0.000108 0.001392 HOXA10 −6.33104 8.53E−10 5.68E−08 HOXB9 −4.93878 1.29E−06 3.32E−05 HOXC10 −6.03467 4.54E−09 2.47E−07 HOXC11 −7.25611 3.22E−12 4.05E−10 HOXC4 −6.45736 4.11E−10 2.98E−08 HOXD1 −4.49567 9.81E−06 0.000187 HOXD11 −7.56657 4.40E−13 6.87E−11 HOXD12 −3.76912 0.000196 0.002281 HSPA12A −3.75646 0.000206 0.002373 HSPA2 −2.90069 0.00399  0.02527  IFI44L −3.82079 0.000161 0.001936 IFIT2 −5.41764 1.21E−07 4.33E−06 IFNK −2.63939 0.008725 0.04593  IGF2BP2 −4.72804 3.45E−06 7.71E−05 IGSF6 −3.83708 0.000151 0.001838 INHBA −8.99561 2.40E−17 9.68E−15 ISL2 −2.64672 0.008543 0.045202 ITGA1 −7.22186 3.99E−12 4.90E−10 ITGA3 −4.64266 5.09E−06 0.000107 ITGB6 −3.35809 0.000883 0.007714 KANK4 −3.77904 0.000189 0.00221  KCNJ6 −3.19048 0.001566 0.012169 KCNMB3 −2.69746 0.007369 0.040435 KIAA1644 −4.81971 2.26E−06 5.37E−05 KIF4A −7.37437 1.52E−12 2.07E−10 KIF4B −6.56762 2.16E−10 1.69E−08 KLF7 −5.6146 4.38E−08 1.79E−06 KLHL6 −3.22736 0.001383 0.011029 KRT82 −3.0844 0.002223 0.016034 LAMP3 −3.2309 0.001367 0.010926 LHX9 −3.03305 0.002626 0.01826  LILRB4 −4.07083 5.95E−05 0.000851 LOX −6.21364 1.67E−09 1.02E−07 LPAR4 −2.83169 0.004933 0.029767 LPPR5 −4.05481 6.35E−05 0.000898 LRP8 −2.72484 0.006799 0.038033 LTBP2 −5.09681 6.02E−07 1.73E−05 MAF −3.81931 0.000162 0.001946 MATN3 −7.12045 7.54E−12 8.64E−10 MCTP1 −3.91447 0.000111 0.001432 MELK −7.44867 9.43E−13 1.36E−10 MEST −3.1584 0.001743 0.01324  MFRP −5.76589 1.96E−08 8.89E−07 MKI67 −5.92945 8.10E−09 4.10E−07 MS4A14 −4.53705 8.17E−06 0.00016  MS4A7 −3.29782 0.001088 0.009112 MYL9 −3.42878 0.000688 0.006319 NAV3 −2.68239 0.007702 0.041798 NCAM1 −2.70794 0.007146 0.0395  NETO1 −3.66353 0.000292 0.003161 NEXN −3.58178 0.000396 0.004044 NFE2L3 −3.94766 9.77E−05 0.001284 NLRP10 −2.86328 0.004479 0.027629 NOX5 −2.86268 0.004487 0.027669 NT5E −4.87679 1.73E−06 4.27E−05 NTM −5.75521 2.08E−08 9.34E−07 NTNG2 −3.39489 0.000776 0.006955 NXPH4 −3.73884 0.00022  0.002507 OLFML2A −4.36198 1.76E−05 0.000306 OLR1 −4.27104 2.59E−05 0.000425 OPN1SW −3.45766 0.000621 0.005817 PAG1 −3.60653 0.000362 0.003756 PALM2 −2.6554 0.008331 0.044352 PAPLN −4.68802 4.14E−06 9.01E−05 PAPSS2 −3.26239 0.001228 0.010035 PCDH7 −3.59138 0.000382 0.00393  PDE3A −2.95598 0.003356 0.022103 PDGFC −2.97263 0.003184 0.021221 PDPN −7.85634 6.55E−14 1.24E−11 PGM2L1 −2.79247 0.005556 0.032613 PIF1 −6.4856 3.49E−10 2.58E−08 PIPOX −2.66955 0.007996 0.042999 PLEKHG4B −2.97115 0.003199 0.021299 PPEF1 −9.09764 1.15E−17 4.96E−15 PRKG1 −2.84047 0.004803 0.029159 PRNT −3.87715 0.000129 0.001617 PSMB9 −4.71989 3.58E−06 7.96E−05 PSTPIP1 −3.69793 0.000257 0.002845 RASSF4 −3.99371 8.13E−05 0.001103 RASSF8 −3.45857 0.000619 0.005802 RGS4 −6.88112 3.29E−11 3.20E−09 RRM2 −6.24961 1.36E−09 8.55E−08 RSAD2 −5.2935 2.28E−07 7.47E−06 S1PR5 −5.42557 1.17E−07 4.18E−06 SCARB1 −2.753 0.006253 0.035687 SCUBE3 −2.78515 0.00568  0.033164 SDK2 −3.22341 0.001402 0.011147 SEC16B −3.16386 0.001711 0.013052 SEMA5B −4.28609 2.43E−05 0.000403 SFRP4 −3.75325 0.000208 0.002397 SGCD −2.89289 0.004087 0.025746 SGIP1 −6.2358 1.47E−09 9.16E−08 SH2D7 −3.07003 0.00233  0.016635 SHOX2 −8.26163 4.23E−15 1.06E−12 SIGLEC15 −5.56541 5.66E−08 2.23E−06 SKA3 −5.776 1.86E−08 8.48E−07 SLA −2.83748 0.004847 0.029366 SLC16A1 −6.34778 7.75E−10 5.21E−08 SLC5A12 −2.75131 0.006285 0.035824 SLC8A1 −3.23799 0.001334 0.010719 SLFN11 −3.45125 0.000635 0.005925 SP110 −3.72725 0.00023  0.002598 SPOCK1 −3.93298 0.000104 0.001348 ST3GAL5 −4.39456 1.53E−05 0.000272 ST8SIA2 −5.50708 7.67E−08 2.91E−06 STAMBPL1 −2.89838 0.004018 0.025409 STARD13 −4.93888 1.29E−06 3.32E−05 STON1 −4.12629 4.74E−05 0.000704 STON2 −5.23961 2.98E−07 9.43E−06 SUCNR1 −3.03569 0.002603 0.01814  SULF1 −6.35395 7.48E−10 5.05E−08 SULF2 −6.02724 4.73E−09 2.56E−07 TBX18 −2.61611 0.009329 0.048302 TFRC −2.73493 0.006598 0.037182 THBS2 −5.721 2.50E−08 1.10E−06 TLL1 −3.01924 0.002745 0.018902 TMED7-TICAM2 −4.38401 1.60E−05 0.000283 TMEM229B −3.04848 0.002498 0.017568 TMEM26 −7.48025 7.70E−13 1.13E−10 TNC −4.77772 2.74E−06 6.34E−05 TNFRSF9 −5.19521 3.71E−07 1.14E−05 TNS3 −4.86153 1.85E−06 4.54E−05 TOX2 −6.5378 2.57E−10 1.97E−08 TPM1 −4.57777 6.81E−06 0.000138 TRPC4 −5.32987 1.90E−07 6.38E−06 TSHZ3 −5.25058 2.82E−07 8.99E−06 TTC7B −4.11374 4.99E−05 0.000735 TYMS −5.38473 1.44E−07 5.01E−06 XAF1 −5.34345 1.77E−07 6.01E−06 XRCC2 −5.27422 2.51E−07 8.12E−06 ZIC1 −2.82865 0.004979 0.029979 ZIC5 −6.58899 1.90E−10 1.51E−08 ZPLD1 −5.35131 1.70E−07 5.80E−06

Functional pathway analysis of inversely expressed target genes by IPA identified two of the top cancer disease functions, including cell proliferation (21 mRNAs, p=8.95×10⁻¹⁰) and metastasis (23 mRNAs, p=9.54×10⁻¹²) (Table 15). These networks harbor a diverse repertoire of molecules critically implicated in cancer growth (EGFR, MET, IGF1R, PDGFRB, IRS1, SOCS1, CCNA1), adhesion, migration and invasion (MET, ITGA6, NT5E, SERPINE1), and differentiation (WNT7B/5A, FZD2, CELSR3, CTHRC1). Most of the genes are novel targets of miR-30 and not previously validated by functional characterization.

TABLE 15 mRNAs with inverse relationship to miR-30a-5p expression identified in cancer proliferation and metastasis Prediction (based on Genes in expression ID dataset direction) Slope Findings Proliferation IRS1 IRS1 Affected −2.612 Affects (1) NT5E NT5E Decreased −2.675 Increases (3) EGFR EGFR Decreased −2.693 Increases (33) GLDC GLDC Decreased −2.718 Increases (2) SOCS1 SOCS1 Increased −2.843 Decreases (3) STAT1 STAT1 Increased −2.941 Decreases (5) LOX LOX Decreased −3.093 Increases (3) PDGFRB PDGFRB Decreased −3.155 Increases (2) WNT5A WNT5A Decreased −3.212 Increases (7) CD80 CD80 Increased −3.234 Decreases (1) CCNA1 CCNA1 Decreased −3.392 Increases (5) THBS2 THBS2 Increased −3.489 Decreases (2) IGF1R IGF1R Decreased −3.529 Increases (6) AFAP1L2 AFAP1L2 Affected −3.575 Affects (1) CTHRC1 CTHRC1 Decreased −3.813 Increases (1) MET MET Decreased −4.497 Increases (17) FAP FAP Decreased −4.575 Increases (1) SERPINE1 SERPINE1 Affected −6.147 Affects (5) IL1A IL1A Increased −6.209 Decreases (10) GJA1 GJA1 Increased −6.454 Decreases (2) MYBL2 MYBL2 Decreased −7.837 Increases (1) Metastasis IRS1 IRS1 Affected −2.612 Affects (1) TRIM9 TRIM9 Affected −2.634 Affects (1) NT5E NT5E Decreased −2.675 Increases (7) EGFR EGFR Decreased −2.693 Increases (92) SOCS1 SOCS1 Increased −2.843 Decreases (1) STAT1 STAT1 Affected −2.941 Affects (1) LOX LOX Decreased −3.093 Increases (1) EPB41L4B EPB41L4B Affected −3.152 Affects (2) PDGFRB PDGFRB Affected −3.155 Affects (37) WNT5A WNT5A Increased −3.212 Decreases (7) CD80 CD80 Increased −3.234 Decreases (1) CCNA1 CCNA1 Decreased −3.392 Increases (5) IGF1R IGF1R Decreased −3.529 Increases (1) CTHRC1 CTHRC1 Decreased −3.813 Increases (1) GNRHR GNRHR Affected −4.119 Affects (15) MET MET Decreased −4.497 Increases (22) ITGA5 ITGA5 Affected −5.944 Affects (8) SERPINE1 SERPINE1 Increased −6.147 Decreases (7) IL1A IL1A Decreased −6.209 Increases (1) GJA1 GJA1 Increased −6.454 Decreases (1) ITGA6 ITGA6 Affected −6.763 Affects (2) SLC7A11 SLC7A11 Affected −7.343 Affects (1) MYBL2 MYBL2 Affected −7.837 Affects (1)

To validate regulation of inversely expressed mRNAs the effects of ectopic expression of miR-30a-5p (which is more highly expressed in UM-SCC-46 than miR-30e-5p FIG. 7C) or anti-miR30a on potentially targeted mRNAs in the HNSCC line UM-SCC-46, which expresses relatively reduced miR-30a-5p, were examined After expression of miR-30a-5p, a reduction in mRNA expression was observed for 11 selected mRNAs by qRT-PCR, while expression of anti-miR30a did not suppress or increased these target gene expression (FIG. 5 ). Both bioinformatics analyses and experimental data support the hypothesis of suppressive function of miR30a on several target genes implicated in pathogenesis of HNSCC.

Example 5 Functional Validation of miR-30a-5p Direct Regulation of Target Gene Expression

To further validate direct regulation of selected target genes by miR-30-5p family members, luciferase constructs containing the 3′ UTR of EGFR, MET, IGF1R and IRS-1, which contains that target binding sites for miR-30a-5p, were utilized (FIG. 6A). Vectors with a deletion in the binding site complementary to the seed sequence of miR-30a-5p were also constructed (FIG. 6A). miR-30a-5p, but not anti-miR30a, suppressed reporter activity, and this was abrogated by ΔmiR-30 site deletion (FIG. 6B). The effect on expression of several molecules implicated in growth signaling (EGFR, MET, IGF1R, IRS1), adhesion (ITGA6) and differentiation (FZD2) was also confirmed by Western blot (FIGS. 6C and 6E). As these growth factor receptors stimulate several oncogenic signaling pathways, the functional effect of miR30a-5p on signal phosphorylation upon PI3K/mTOR-AKT (Freudlsperger et al., Expert Opin. Ther. Targets 15:63-74, 2011), SRC (Egloff et al., Semin. Oncol. 35:286-297, 2008), and STAT3 signaling (Mali, Oral Oncol. 51:565-569, 2015) was examined. miR-30a-5p decreased downstream phosphorylation of these signaling molecules (FIG. 6D). These data show the direct regulatory effects of miR-30a-5p on the biological targets overexpressed and implicated in malignant phenotype of HNSCC.

Example 6 miR-30a Inhibits Cell Proliferation, Motility, and Invasion by HNSCC Cells

As multiple miR-30a targets can modulate cell growth, anti-proliferative effects of hsa-miR-30a-5p was confirmed in a panel of 11 HNSCC cell lines. Four cells lines (UM-SCC-11A, 11B, 46, 47) displayed significantly decreased cell density of <50% when compared to controls (FIG. 7A), which corresponded with lower expression of miR-30a-5p in these cell lines (FIG. 7B), however, no growth inhibition was observed in HOK cells. Basal level of miR-30a-5p and miR-30e-5p expression in UM-SCC-1 and UM-SCC-46 cells was measured by qRT-PCR (FIG. 7C). Proliferation was also measured in UM-SCC-1 or UM-SCC-46 cells by an XTT assay. Similar inhibition of proliferation was observed between family members (FIG. 7D).

miR-30a-5p also suppressed colony formation by >50% in UM-SCC-46 cells (FIGS. 7E and 7H). As growth signaling can mediate therapeutic resistance, whether miR-30a-5p can augment effects of cisplatin, the most common chemotherapy drug used to treat HNSCC, was examined Sensitivity to cisplatin was enhanced by ectopic expression of miR-30a-5p (FIG. 7F and FIG. 7I). To test the importance of EGFR in the anti-proliferative effect of miR-30a, a stable cell line of UM-SCC-46 was created over-expressing the EGFR coding sequence without its regulatory 3′UTR in UM-SCC-46. This cell line displayed a significant reduction in the effect of miR-30a-5p on proliferation (FIG. 7G).

Several of the miR-30-5p family targets in HNSCC are also implicated in cell motility and invasiveness, including EGFR (Freudlsperger et al., Expert Opin. Ther. Targets 15:63-74, 2011), MET (Dong et al., Cancer Res. 61:5911-5918, 2001), ITGA6 (Carey et al., J. Cell Biochem. Suppl. 17F:223-232, 1993), and Serpinel (Karbiener et al., RNA Biol. 8:850-860, 2011). Ectopic expression of hsa-miR-30a-5p significantly slowed cell motility in migration assays in two HNSCC cell lines (FIGS. 8A and 8B), and significantly reduced EGF stimulated invasiveness in MATRIGEL coated transwell migration assays (FIGS. 8C and 8D). In summary, increased expression of miR-30a-5p significantly inhibited cell proliferation, colony formation, migration, and invasion, as well as enhanced chemosensitivity in HNSCC.

Example 7 miR-30a Mimic Suppresses Tumor Growth of Human HNSCC Xenografts

A miR-30a-5p mimic was formulated into a cationic liposomal nanodelivery system (scL) bearing single chain antibody fragment (TfRscFv), which targets overexpressed transferrin receptor on tumor cells for delivery (Pirollo et al., Cancer Res. 68:1247-1250, 2008; Pirollo et al., Hum. Gene Ther. 17:117-124, 2006). The scL carriers containing FITC-conjugated control oligonucleotide undergo preferential uptake in HNSCC xenografts, when compared to lung or liver, or are excreted via the kidney (FIG. 9A). Nanoliposome particles complexed with a modified miR-30a-5p mimic (miR-30a-scL) or control miR (60 μg or ˜3 mg/kg) given in 9 doses intravenously (IV) on Monday, Wednesday, and Friday (MWF) for 3 weeks were tested in mice bearing UM-SCC-46 xenograft tumors. A significant tumor growth delay and prolongation of survival was observed with miR-30a-scL treatment (FIGS. 9B-D). Treatment with miR-30a-scL did not cause a significant reduction in weight suggesting the treatment was well tolerated (FIG. 9C). A similar inhibitory effect on tumor growth in vivo was observed in a second HNSCC xenograft model, UM-SCC47, which is HPV positive (FIG. 9E).

Quantitative RT-PCR of six miR-30a-5p target genes was performed and substantially decreased gene expression was observed after treatment by four doses of miR-30a-scL nanoparticles (FIGS. 10A and 10F). Decreased expression of EGFR and MET by immunofluorescent staining was also observed in frozen sections harvested from xenograft tumors after treatment in vivo (FIGS. 10B and 10C). With confirmation both in vitro and in vivo of several target genes of miR-30a-5p, a pathway diagram connecting reported interactions and function in relation to proliferation and migration as predicted by Ingenuity Pathway Analysis was constructed (FIG. 10D). Confirming miR-30a-5p family's anti-proliferative effect, a decrease in ki-67 staining was also observed (FIG. 10E).

Example 8 Genetic Alterations of miR-30 Family Members Associated with Clinical Features of HNSCC

If loss of expression of miR-30 family members is important in pathogenesis of HNSCC, there may be selective pressure for deletion or epigenetic silencing at the genomic level. To address this question, copy number variation of miR-30 family members from the HNSCC TCGA datasets was analyzed (FIGS. 11A and 11B). The MIR30A and MIR30C2 genes are clustered together on chromosome 6, and the MIR30E and MIR30C1 gene are clustered together on chromosome 1, where 19.7% and 14.7% display at least heterozygous loss at these genetic loci, respectively. Integrative analysis supported a trend or significant correlation of heterozygous copy number loss with decreased expression for miR-30a (p=0.15, FIGS. 11A and 11C) and miR-30e (p=0.0006, FIGS. 11B and 11D). We further analyzed if the broader decreased expression of miR-30a/e observed was associated with methylation of putative promoters, and compared average DNA methylation along the MIR30A/C2 promoter and coding region (Table 16). A correlation between increasing DNA methylation of MIR30A promoter and lower expression in a subset of tumor specimens was observed (p=0.00057, FIGS. 11C and 11F).

A high percentage of oral cavity tumors (n=87) displayed reduced miR-30a-5p expression and were significantly correlated by Spearman's correlation test with MIR30A hypermethylation of CPZG sites in the MIR30A promoter (p-value 6.15E-07, FIGS. 11C and 11F; Table 17). Reduced expression of miR-30e-5p was correlated with HPV negative status. Additionally, tumors occurring in the laryngeal site were significantly correlated with reduced miR-30e-5p expression and MIR30E copy number deletion (FIG. 11E and Table 17).

TABLE 16 Correlation of expression and methylation of mir-30 family mean mean mean mean expr. in expr. in meth in meth in unmeth meth unmeth meth Spear-man probe gene group group tstat pval adj. p. val group group corr. cg20815778 hsa-mir-30a 4.634 5.119 −0.227 8.34E−01 8.52E−01 0.086 0.441 −0.064 MIMAT0000087 cg10039188 hsa-mir-30a 6.584 3.957 3.84 1.61E−04 1.23E−03 0.031 0.459 −0.225 cg25210451 hsa-mir-30a 6.567 3.892 3.938 1.11E−04 1.09E−03 0.04 0.499 −0.184 cg15045441 hsa-mir-30a 6.814 4.003 3.79 2.01E−04 1.23E−03 0.052 0.435 −0.225 cg26162616 hsa-mir-30a 6.931 3.977 3.824 1.79E−04 1.23E−03 0.04 0.421 −0.23 cg23281154 hsa-mir-30a 6.685 4.174 3.361 1.02E−03 3.85E−03 0.033 0.382 −0.24 cg22300282 hsa-mir-30a 8.386 3.984 2.256 2.87E−02 5.86E−02 0.077 0.518 −0.199 cg11574469 hsa-mir-30a 8.278 4.066 2.359 2.20E−02 5.10E−02 0.078 0.428 −0.244 cg25141674 hsa-mir-30a 7.363 4.151 2.842 5.35E−03 1.62E−02 0.063 0.495 −0.23 cg24772267 hsa-mir-30a 6.694 4.29 2.359 1.98E−02 4.84E−02 0.077 0.472 −0.122 cg00920327 hsa-mir-30a 7.006 4.052 3.642 3.52E−04 1.92E−03 0.058 0.465 −0.247 cg03318695 hsa-mir-30a 7.396 4.395 1.562 1.25E−01 1.92E−01 0.075 0.487 −0.221 cg20815778 hsa-mir-30a 1.936 1.845 0.081 9.40E−01 9.40E−01 0.086 0.441 −0.073 MIMAT0000088 cg10039188 hsa-mir-30a 2.331 1.351 4.494 1.19E−05 1.46E−04 0.031 0.459 −0.196 cg25210451 hsa-mir-30a 2.303 1.3 4.876 2.52E−06 8.69E−05 0.04 0.499 −0.181 cg15045441 hsa-mir-30a 2.44 1.361 4.62 7.85E−06 1.28E−04 0.052 0.435 −0.216 cg26162616 hsa-mir-30a 2.451 1.336 4.778 3.55E−06 8.69E−05 0.04 0.421 −0.232 cg23281154 hsa-mir-30a 2.386 1.481 3.61 5.22E−04 2.32E−03 0.033 0.382 −0.243 cg22300282 hsa-mir-30a 2.752 1.385 3.396 1.24E−03 4.35E−03 0.077 0.518 −0.222 cg11574469 hsa-mir-30a 2.69 1.43 3.335 1.38E−03 4.50E−03 0.078 0.428 −0.218 cg25141674 hsa-mir-30a 2.602 1.479 3.423 8.09E−04 3.30E−03 0.063 0.495 −0.243 cg24772267 hsa-mir-30a 2.37 1.637 2.132 3.70E−02 7.26E−02 0.077 0.472 −0.138 cg00920327 hsa-mir-30a 2.445 1.454 3.589 4.74E−04 2.32E−03 0.058 0.465 −0.219 cg03318695 hsa-mir-30a 2.521 1.585 2.307 2.41E−02 5.14E−02 0.075 0.487 −0.222 cg22904815 hsa-mir-30b 0.266 0.174 2.449 2.29E−02 5.10E−02 0.078 0.326 −0.151 MIMAT0000420 cg10039188 hsa-mir-30c-2 0.316 0.26 1.875 6.36E−02 1.20E−01 0.031 0.459 −0.132 cg25210451 hsa-mir-30c-2 0.316 0.26 1.814 7.29E−02 1.31E−01 0.04 0.499 −0.034 cg15045441 hsa-mir-30c-2 0.321 0.271 1.451 1.51E−01 2.18E−01 0.052 0.435 −0.095 cg26162616 hsa-mir-30c-2 0.323 0.27 1.69 9.38E−02 1.48E−01 0.04 0.421 −0.072 cg23281154 hsa-mir-30c-2 0.316 0.259 1.438 1.58E−01 2.21E−01 0.033 0.382 −0.109 cg22300282 hsa-mir-30c-2 0.272 0.256 0.438 6.62E−01 7.05E−01 0.077 0.518 −0.025 cg11574469 hsa-mir-30c-2 0.325 0.257 1.726 8.78E−02 1.43E−01 0.078 0.428 −0.099 cg25141674 hsa-mir-30c-2 0.306 0.262 1.368 1.74E−01 2.36E−01 0.063 0.495 −0.084 cg24772267 hsa-mir-30c-2 0.286 0.255 0.801 4.27E−01 4.98E−01 0.077 0.472 −0.016 cg00920327 hsa-mir-30c-2 0.327 0.246 2.55 1.23E−02 3.36E−02 0.058 0.465 −0.101 cg03318695 hsa-mir-30c-2 0.317 0.279 0.871 3.87E−01 4.74E−01 0.075 0.487 −0.077 cg22904815 hsa-mir-30d 5.321 4.432 1.504 1.48E−01 2.18E−01 0.078 0.326 −0.137 MIMAT0000245 cg16167741 hsa-mir-30e 4.234 4.02 0.571 5.69E−01 6.19E−01 0.07 0.549 0.03 MIMAT0000692 cg26783428 hsa-mir-30e 5.041 4.302 0.634 5.68E−01 6.19E−01 0.089 0.519 0.016 cg27386837 hsa-mir-30e 4.655 3.407 2.447 1.69E−02 4.36E−02 0.086 0.46 −0.151 cg13735974 hsa-mir-30e 4.383 3.508 1.82 7.74E−02 1.31E−01 0.085 0.502 −0.149 cg10336144 hsa-mir-30e 4.597 3.372 2.827 5.61E−03 1.62E−02 0.082 0.489 −0.117 cg14796708 hsa-mir-30e 3.92 3.828 0.213 8.32E−01 8.52E−01 0.082 0.429 0.018 cg16167741 hsa-mir-30e 5.153 4.779 0.987 3.25E−01 4.09E−01 0.07 0.549 −0.072 MIMAT0000693 cg26783428 hsa-mir-30e 6.638 5.117 0.957 4.07E−01 4.86E−01 0.089 0.519 −0.034 cg27386837 hsa-mir-30e 5.98 4.76 1.794 7.75E−02 1.31E−01 0.086 0.46 −0.184 cg13735974 hsa-mir-30e 5.932 4.931 1.244 2.22E−01 2.94E−01 0.085 0.502 −0.157 cg10336144 hsa-mir-30e 5.534 4.884 1.131 2.63E−01 3.40E−01 0.082 0.489 −0.189 cg14796708 hsa-mir-30e 4.657 5.054 −0.77 4.43E−01 5.05E−01 0.082 0.429 0.027

TABLE 17 Association of copy number variation, methylation, and expression of miR30A/E with clinical characteristics in HNSCC from TCGA dataset Clinical Features miR30 Alterations P-value miR30A Methylation Tumor site Hyper Hypo Oral 58 115 6.15E−07* Non-oral 9 97 HPV status HPV(+) 3 26 0.0686 HPV(−) 52 163 miR30A Expression Tumor site Low High Oral 87 68 0.00822* Non-oral 35 54 HPV status HPV(+) 11 18 0.117 HPV(−) 111 104 miR30E Copy Number Variation Tumor site Deletion Non-deletion Larynx 18 46 0.00184* Non-larynx 20 160 HPV status HPV(+) 0 29 0.00527* HPV(−) 38 177 miR30E Expression Tumor site Low High Larynx 28 36 0.154 Non-larynx 94 86 HPV status HPV(+) 5 24 0.000121* HPV(−) 117 98

As the prognosis of HPV+ and oropharyngeal cancers is better than HPV− and laryngeal HNSCC, association of miR-30a/e expression with differences in prognosis was examined Lower expression of miR-30e significantly correlated with lower overall survival (FIG. 12A, left panel), consistent with association with HPV-tumors. A trend towards reduced survival was also observed in the subset of patients that displayed copy number loss of the MIR30E loci, supporting the contribution of genomic copy alteration to decreased miR30e expression in a subset of tumors (FIG. 12A, middle panel). Surprisingly, survival analysis for tumor sub-sites revealed that low expression of miR-30e-5p is associated with worst prognosis in oropharyngeal carcinomas (FIG. 12A, right panel), which are predominantly HPV+ and for which genomic alterations associated with worse prognosis and therapeutic targets have not been well defined. This dataset displayed a strong correlation between low miR-30a-5p expression with poorer disease specific survival (p-value 0.024, FIG. 11G) and a similar trend for miR-30e-5p (p-value 0.113, FIG. 11H). These data suggest that reduced miR-30a/e expression is associated with genetic or epigenetic alterations, HNSCC tumor subsites, HPV status, and prognosis of clinical relevance in HNSCC. In addition, lower expression of miR-26a-5p and miR-26b-5p was correlated with lower overall survival (FIG. 12B).

Example 9 Anti-Proliferation Activity of miR-30a in Cancer Cell Lines

The effect of miR-30a on proliferation of additional types of cancer was tested on ME180 (cervical squamous cell carcinoma), HeLa (cervical adenocarcinoma), HCT116 (colorectal carcinoma), DU-145 (prostate carcinoma), PC3 (prostate carcinoma), MDA-MB-231 (breast adenocarcinoma), and Pancl (pancreatic carcinoma) cell lines. Cells were seeded at 2×10³ cells/well in 96 well plates and reverse transfected with 15 nM miR-30a duplex for 48 hours with 0.15 μl of RNAiMAX. Following transfection, media was replaced and cells were incubated for 5 days. Following incubation, cell viability was measured by XTT assay. miR-30a decreased cell viability in all cell lines tested (FIG. 13 ).

Example 10 Modified miR-30a miRNAs

Design and synthesis of several modified precursor hsa-miR-30a mimics and/or mimetics was carried out. Exemplary modified miR-30a nucleic acids are shown in Table 18.

Bases 1, 6, and 20 of the passenger strand were mutated to increase the stability of the resulting duplex. In order to bias strand selection towards the guide strand by RISC a two base overhang was placed on the 3′ end of the passenger strand. To further bias strand selection a 5′ amino C6 modification at the 5′ end of the passenger strand was also tested. It is known that modification of the 2′ position of individual nucleic acids in an oligonucleotide can improve affinity to complementary strands and also confer resistance to nucleases. However it is unknown what effect these modification have on microRNA function. To test this, oligonucleotides that contain 2′ modification of the three bases at the ends of the passenger strand (Passenger strand 7) were synthesized. Consecutive bases between position 7 and 18 were also modified in separate oligonucleotides (guide strands 1-5). The strands were hybridized to create six different duplex mimics of miR-30a that may bias maturation of the 5p strand.

The effect of strand length on the activity was also tested. Guide strand 11, which is two bases shorter but has a 2′ modification of the same bases as guide strand 5, and passenger strand 12, which is also two bases shorter than passenger strand 6 but still contains 2′ modification of the 3 bases at the 3′ and 5′ ends of the oligonucleotide, were synthesized. All strands were combined to create six new mimics (010-015).

TABLE 18 Modified miR-30 constructs SEQ ID Oligo Sequence (5′-3′)* NO: Guide strand 1 (G1) UGUAAACAUCCUCGACUGGAAGCU 37 Guide strand 2 (G2) UGUAAACAUCCUCGACUGGAAGCU 38 Guide strand 3 (G3) UGUAAACAUCCUCGACUGGAAGCU 39 Guide stand 4 (G4) UGUAAACAUCCUCGACUGGAAGCU 40 Guide strand 5 (G5) UGUAAACAUCCUCGACUGGAAGCU 41 Guide strand 11 (G11) UGUAAACAUCCUCGACUGGAAG 42 Guide strand 13 (G13) UGUAAACAUCCUCGACUGGAApsG 43 Guide strand 15 (G15) UGUAAACAUCCUCGACUGGApsApsG 44 Guide strand 16 (G16) UGUAAACAUCCUCGACUGGAAd-mpG 45 Guide strand 17 (G17) UGUAAACAUCCUCGACUGGAd-mpAd-mpG 46 Guide strand 18 (G18) UGUAAACAUCCUCGACUGGAAG 47 Guide strand 19 (G19) UGUAAACAUCCUCGACUGGApsApsG 48 Guide strand 20 (G20) UGUAAACAUCCUACACUCUCAGC 49 Guide strand 21 (G21) UGUAAACAUCCUACACUCUCAGC 50 Guide strand 22 (G22) UGUAAACAUCCUACACUCUCAGC 51 Guide strand 23 (G23) UGUAAACAUCCUACACUCUCApsGpsC 52 Guide strand 24 (G24) UfGUAAACAUCCUACACUCUCApsGpsC 53 Passenger strand 6 (P6) amino C6-AGCUUCCAGUCGGAUGUUUACACG 54 Passenger strand 7 (P7) amino C6-AGCUUCCAGUCGGAUGUUUACACG 55 Passenger strand 12 (P12) amino C6-CUUCCAGUCGGAUGUUUACACG 56 Passenger strand 14 (P14) Amino C6-

AGUCGGAUGUUU

57 Passenger strand 25 (P25) Amino C6-UCCAfGUfCGfGAfUGfUUfUAfCA 58 Passenger strand 26 (P26) Amino C6-UCCAfGUfCGfGAfUGfUUfUAfpsCpsA 59 Passenger strand 27 (P27) Amino C6-UCCAfGUfCGfGAfUGfUUfUAfCd-mpA 60 Passenger strand 28 (P28) Amino C6-UG

GAG

GG

UGUUUAC

61 *underlined residues have 2′OMe modification; ps-phosphorothioate; mp-methyl phosphonate; d-2′ deoxy; f-2′ Fluor; Mutated bases are shown in bold and italics.

Cell viability was assessed in UM-SCC-46 cells transfected with modified miR-30a mimics UMSCC-46 cells were seeded at 2×10³ cells/well in 96-well plates and reverse transfected with 15 nM duplex for 48 hours with 0.15 μL of RNAiMAX. Following transfection media was replaced and cell were incubated for 5 days. Following incubation cell viability was measured by XTT assay. Data represent the mean of 6 replicates. M-miR30a-006 (G5+P7) M-miR30a-014 (G11+P12), and M-miR-30a-016 (G11+P14) had the greatest effect on cell viability (Table 19).

TABLE 19 Effect of modified miR-30a mimics on UMSCC-46 cell viability % viability control Mimic name Strands (15 nM) SEM Unmodified miR30a 0.7545821 0.114837 M-miR30a-001 G3 + P6 0.634257 0.138051 M-miR30a-002 G3 + P7 0.680829 0.164553 M-miR30a-003 G4 + P6 0.773038 0.113855 M-miR30a-004 G4 + P7 0.690925 0.066221 M-miR30a-005 G5 + P6 0.681762 0.152425 M-miR30a-006 G5 + P7 0.331135 0.046659 M-miR30a-007  G3 + P10 na na M-miR30a-008  G4 + P10 na na M-miR30a-009  G5 + P10 na na M-miR30a-010  G3 + P12 0.363122 0.048457 M-miR30a-011  G4 + P12 0.49771 0.035976 M-miR30a-012  G5 + P12 0.385692 0.030329 M-miR30a-013 G11 + P7  0.433616 0.038817 M-miR30a-014 G11 + P12 0.255287 0.043365 M-miR30a-015 G11 + P6  0.424858 0.032783 M-miR30a-016 G11 + P14 0.256281 0.028257

The M-miR30a-006 oligonucleotide was also tested in a mouse model of UMSCC-46 xenograft tumors. Mice with a UMSCC-46 xenograft tumor ˜100 mm³ were injected IV with nine doses of 60 μg (˜3 mg/kg) of complexed miR-30a mimic or control vehicle on MWF for 3 weeks. Mice were treated with 10×2 Gy fractions of radiation therapy daily (20 Gy total) on day 24 (FIGS. 14A-14B).

Example 11 Effect of Combination miRNA Treatment on Cell Proliferation

Cell viability was assessed in nine HNSCC tumor cell lines transfected with a mixture of four miRNAs-M-miR30a-014, miR-145-5p, miR-26a-5p, and miR-375 at 7.5 nM or 15 nM total duplexes (1.875 nM or 3.75 nM of each duplex respectively). In other experiments, cells were transfected with pairs of miRNAs at 7.5 nM or 15 nM total duplexes. Cells were seeded at 1.5-2×10³ cells/well in 96-well plates and reverse transfected with mixture for 48 hours with 0.15 μL of RNAiMAX. Following overnight transfection, media was replaced and cell were incubated for 4-5 days. Following incubation, cell viability was measured by XTT assay as described in Example 1.

The four miRNA mixture decreased cell density in all cell lines (FIG. 15 ), particularly at 15 nM concentration. Similarly, the two miRNA combinations also decreased cell density (FIGS. 16A-16D).

Example 12 Effect of Additional miRNAs on Cell Viability

Cell viability was assessed in UM-SCC-1 or UM-SCC-46 cells transfected with miR27-5p or miR-2b-1-5p duplexes. UM-SCC-1 cells were seeded at 1.5×10³ cells/well and UM-SCC-46 cells were seeded at 2×10³ cells/well in 96-well plates and reverse transfected with 7.5 nM or 15 nM duplex for 48 hours with 0.15 μL of RNAiMAX. Following transfection, media was replaced and cells were incubated for 5 days. Cell viability was measured by XTT assay.

Both miR-27b-5p and miR-29-b-1-5p decreased cell density in both UM-SCC-1 and UM-SCC-46 cells (FIGS. 17A and 17B).

Example 13 Modified miRNAs

Design of several miR mimics and/or mimetics was carried out. Exemplary miR mimics and/or mimetics are shown in Table 20.

TABLE 20 Modified miRs SEQ ID Oligo Sequence (5′-3′) NO: hsa-miR-375 mimic/mimetic Guide strand (G29) UUU GUU CGU UCG GCU CGC GUG A 62 Passenger strand (P30) Amino C6-

CG AGC C

CG 

AC AAA 63 miR-26a-5p mimic/mimetic Guide strand 31 (G31) UUC AAG UAA UCC AGG AUA GGC U 64 Passenger strand (P32) Amino C6-CCU AU

 CCU 

G

 UUA CUU G

A 65 miR-145-5p mimic/mimetic Guide strand (G33) GUC CAG UUU UCC CAG GAA UCC CU 66 Passenger strand (P34) Amino C6-GGA UUC CUG GAA AUA CUG 

C 67 underlined residues have 2′OMe modification; Mutated bases are shown in bold and italics.

Example 14 Treatment of Head and Neck Squamous Cell Carcinoma

This example describes methods that can be used to treat or inhibit HNSCC in a subject. However, one skilled in the art will appreciate based on the teachings herein that methods that deviate from these specific methods can also be used to successfully treat HNSCC. One of skill in the art will also recognize that these methods can also be used to treat or inhibit other cancers in a subject.

In an example, a subject with HNSCC (or another type of tumor) is selected. In some examples, the subject has an HNSCC tumor. In other examples, the subject has an HNSCC tumor that is determined to have decreased expression of one or more miRNAs (such as one or more of miR-30a family member, miR-26 family member, miR-145-5p, miR-338-3p, and miR-375). In other examples, the subject has a tumor with a deletion in the DNA encoding of one or more miRNAs (such as one or more of MIR30 gene, MIR26 gene, MIR145 gene, MIR338 gene, and MIR375 gene). In other examples, the subject has a tumor with increased methylation of the promoter or in the DNA encoding for one or more miRNAs (such as one or more of MIR30 gene, MIR26 gene, MIR145 gene, MIR338 gene, and MIR375 gene).

Following subject selection, an effective amount of an miRNA nucleic acid (such as miR-30a-5p or a mimic or mimetic thereof) or a mixture of miRNA nucleic acids (such as a mixture of miR-30a, miR-145, miR-26a, and miR-375 or a mimic or mimetic of one or more thereof) is administered to the subject. The amount of the composition administered the subject depends on the subject being treated, the severity (such as TNM stage) of the tumor, and the manner of administration of the composition. Ideally, an effective amount of the miRNA(s) is the amount sufficient to decrease one or more signs and symptoms of the HNSCC in the subject without causing a substantial cytotoxic effect in the subject.

In some examples, a decrease in the number and/or size of tumors, number and/or size of metastases, a decrease (or halt) in disease progression, an increase in survival (such as disease-free survival, progression-free survival, and/or metastasis-free survival), or a combination of two or more thereof, indicates the effectiveness of the treatment.

Example 15 Design and Testing of Additional miR-30 Mimics

Additional modified miR-30-5p guide and passenger strands were designed and are shown in Table 21.

TABLE 21 Modified miR-30-5p miRNAs SEQ Oligo Sequence (5′→3′) ID NO: Guide strand 35 (G35) UGUAAACAUCCUACACUCUCAGC 50 Guide strand 36 (G36) UfGUfAAfACfAUfCCfUAfCAfCUfCUfCAfpsGpsCf 73 Guide strand 37 (G37) UGfUAAAfCAUfCCfUAfCAfCUfCUfCAfpsGpsCf 74 Passenger strand 28 (P28) Amino C6-UG

GAG

GG

UGUUUAC

61 f, 2′-fluoro, underlined, 2′-OME, ps, phosphorothioate, Mutated bases are shown in bold and italics.

Cell viability was assessed in UM-SCC-46 cells transfected with modified miR-30a mimics, as described in Example 11. Data represent the mean of 6 replicates (Table 22). The stability of the mimics in serum was tested (FIG. 18 ). The chemical modifications incorporated in M-miR30-018 and M-miR30-019 imparted long term resistant to nuclease with >50× increased stability in human serum (FIG. 18 ). Cell viability was assessed UM-SCC-46 cells transfected with the indicated miRNA duplexes (7.5 nM or 15 nM total duplexes) as described in Example 11 (FIG. 19 ). M-miR30-018 and M-miR30-019 still maintained potency inhibiting proliferation of cancer cells equal to M-006 which is vastly improved over the biological microRNA (FIG. 19 and Table 22).

TABLE 22 Effect of modified miR-30a mimics on UMSCC-46 cell viability % viability control Mimic name Strands (15 nM) SEM M-miR30-017 G35 + P28 0.281711 0.038428 M-miR30-018 G36 + P28 0.363828 0.024757 M-miR30-019 G37 + P28 0.457675 0.100329

Example 16 Additional miR Mimics

Design of additional miR mimics and/or mimetics was carried out. Exemplary miR mimics and/or mimetics are shown in Table 23.

TABLE 23 Modified miRs SEQ ID Oligo Sequence (5′-3′) NO: miR-30 mimics Guide strand 39 (G39) UfGUf AAA CAUf CCfU CfGAf CUfG GfApsAfpsG  75 Guide strand 40 (G40) UfGUf AAA CAUf CCfU CGA CUG GApsApsG  76 Guide strand 41 (G41) UfGUf AAAf CAUf CCfU CfGAf CUfG GfApsAfpsG  77 Guide strand 42 (G42) UfGUf AAfA CfAUf CCfU CfGAf CUfG GfApsAfpsG  78 Guide strand 43 (G43) UfGUf AAfAf CAUf CCfU CfGAf CUfG GfApsAfpsG  79 Guide strand 44 (G44) UfGUf AAfA CfAUf CCfU CGA CUG GfApsAfpsG  80 Guide strand 45 (G45) UfGUf AAA CAUf CCfU CGA CUG GfApsAfpsG  81 Guide strand 46 (G46) UfGUf AAfA CfAUf CCfU CGA CUG GApsApsG  82 Guide strand 47 (G47) UfGUf AAA CAU CCU CGA CUG GApsApsG  83 Guide strand 48 (G48) UfGUf AAA CAU CCU CGA CUG GApsAfpsG  84 Guide strand 49 (G49) UfGUf AAA CAU CCU CGA CUG GApsApsGf  85 Guide strand 50 (G50) UfGU AAA CAU CCU CGA CUG GApsApsGf  86 Guide strand 51 (G51) UfGU AAA CAU CCU CGA CUG GApsAfpsG  87 Guide strand 52 (G52) UfGU AAA CAU CCU CGA CUG GApsApsGf  88 Guide strand 53 (G53) UfGU AAA CAU CfCU CGA CUG GApsApsGf  89 Guide strand 54 (G54) UfGU AAA CAUf CCU CGA CUG GApsApsGf  90 Guide strand 55 (G55) UfGUf AAA CAU CCfU CfGAf CUfG GfApsAfpsG  91 Passenger strand 56 (P56) Amino C6-U

CAfGUfCGfGAUGUfUUf

CA  92 miR-375 mimics Guide strand 57 (G57) UfUUf GUU CGU UCG GCU CGC GUpsGfps A  93 Guide strand 58 (G58) UfUU GUU CGU UCG GCU CGC GUpsGfps A  94 Guide strand 59 (G59) UfUUf GUU CGU UCG GCU CGC GfUpsGfps A  95 Guide strand 60 (G60) UfUUf GUfU CGU UCG GCU CGC GfUpsGfps A  96 Guide strand 61 (G61) UfUUf GUfU CGU UCG GCU CGfC GfUpsGfps A  97 Guide strand 62 (G62) UfUUf GUfU CfGU UCG GCU CGfC GfUpsGfps A  98 Guide strand 63 (G63) UfUUf GUU CGU UCG GCU CGfC GfUpsGfps A  99 Guide strand 64 (G64) UUU GUU CGU UCG GCU CGfC GfUpsGfps A 100 Guide strand 65 (G65) UUU GUU CGU UCG GCU CGfC GfUpsGfps A 101 Guide strand 66 (G66) UfUUf GUfU CfGUf UCfG GfCUf CGfC GfUpsGfps A 102 Guide strand 67 (G67) UfUUf GUU CGU UCfG GfCUf CGfC GfUpsGfps A 103 Passenger strand 68 (P68) Amino C6-

CfG AfGCf C

CfG 

ACf AAA 104 miR-26 mimics Guide strand 69 (G69) UfUCf AAG UAA UCC AGG AUA GGpsCfps U 105 Guide strand 70 (G70) UfUC AAG UAA UCC AGG AUA GGpsCfps U 106 Guide strand 71 (G71) UfUCf AAG UAA UCC AGG AUA GfGpsCfps U 107 Guide strand 72 (G72) UfUCf AAG UAA UCC AGG AUA GfGpsCfps U 108 Guide strand 73 (G73) UfUCf AAfG UAA UCC AGG AUA GfGpsCfps U 109 Guide strand 74 (G74) UfUCf AAfG UAA UCC AGG AUAf GfGpsCfps U 110 Guide strand 75 (G75) UfUCf AAfG UfAA UCC AGG AUAf GfGpsCfps U 111 Guide strand 76 (G76) UfUCf AAfG UfAA UCC AGG AUAf GfGpsCfps U 112 Guide strand 77 (G77) UfUCf AAfG UfAA UCC AGG AfUAf GfGpsCfps U 113 Guide strand 78 (G78) UfUCf AAfG UfAAf UCfC AfGGf AUfA GfGpsCfps U 114 Passenger strand 79 (P79) Amino C6-CCU AfU

 CCfU 

G

 UUfA CfUUf G

A 115 miR-145-5p mimics Guide strand 80 (G80) GfUC CAG UUU UCC CAG GAA UCCps CfpsU 116 Guide strand 81 (G81) GfUCf CAG UUU UCC CAG GAA UCCps CfpsU 117 Guide strand 82 (G82) GfUCf CAG UUU UCC CAG GAA UCfCps CfpsU 118 Guide strand 83 (G83) GfUCf CAfG UUU UCC CAG GAA UCfCps CfpsU 119 Guide strand 84 (G84) GfUCf CAfG UUU UCC CAG GAAf UCfCps CfpsU 120 Guide strand 85 (G85) GfUCf CAfG UfUU UCC CAG GAAf UCfCps CfpsU 121 Guide strand 86 (G86) GfUCf CAfG UfUU UCC CAG GfAAf UCfCps CfpsU 122 Guide strand 87 (G87) GfUCf CAfG UfUUf UCfC CfAGf GfAAf UCfCps CfpsU 123 Guide strand 88 (G88) GfUCf CAfG UfUUf UCfC CfAGf GAfA UfCCfps CpsUf 124 Passenger strand 89 (P89) Amino C6-GGA UfUCf CUfG GAA AUfA CfUGf 

C 125 miR-101 mimics Guide strand 89 (G89) UAC AGU ACU GUG AUA ACU GAA 126 Guide strand 90 (G90) UfAC AGU ACU GUG AUA ACU GpsAfpsA 127 Guide strand 91 (G91) UfACf AGU ACU GUG AUA ACU GpsAfpsA 128 Guide strand 92 (G92) UfACf AGU ACU GUG AUA ACUf GpsAfpsA 129 Guide strand 93 (G93) UfACf AGfU ACU GUG AUA ACUf GpsAfpsA 130 Guide strand 94 (G94) UfACf AGfU ACU GUG AUA AfCUf GpsAfpsA 131 Guide strand 95 (G95) UfACf AGfU AfCU GUG AUA AfCUf GpsAfpsA 132 Guide strand 96 (G96) UfACf AGfU AfCUf GUfG AfUAf ACfU GfpsApsAf 133 Passenger strand 97 (P97) Amino C6-CAG UUA UCA CAG UAC UG

134 Passenger strand 98 (P98) Amino C6-CAG UfUAf UCfA CAG U

C UfG

135 miR-29 mimics Guide strand 99 (G99) GCU GGU UUC AUA UGG UGG UUU AGA 136 Guide strand 100 (G100) GfCU GGU UUC AUA UGG UGG UUU ApsGfpsA 137 Guide strand 101 (G101) GfCUf GGU UUC AUA UGG UGG UUU ApsGfpsA 138 Guide strand 102 (G102) GfCUf GGU UUC AUA UGG UGG UUUf ApsGfpsA 139 Guide strand 103 (G103) GfCUf GGfU UUC AUA UGG UGG UUUf ApsGfpsA 140 Guide strand 104 (G104) GfCUf GGfU UUC AUA UGG UGG UfUUf ApsGfpsA 141 Guide strand 105 (G105) GfCUf GGfU UfUC AUA UGG UGG UfUUf ApsGfpsA 142 Guide strand 106 (G106) GfCUf GGfU UfUC AUA UGG UGfG UfUUf ApsGfpsA 143 Guide strand 107 (G107) GfCUf GGfU UfUC AUA UGG UGfG UfUUf ApsGfpsA 144 Guide strand 107 (G107) GfCUf GGfU UfUCf AfUA UfGGf UGfG UfUUf 145 ApsGfpsA Passenger strand108 (P108) Amino C6-UA

C ACC AU

 UGA AA

 CAG 

146 miR-27 mimics Guide strand 109 (G109) AGA GCU UAG CUG AUU GGU GAA C 147 Guide strand 110 (G110) AfGA GCU UAG CUG AUU GGU GApsAfps C 148 Guide strand 111 (G111) AfGAf GCU UAG CUG AUU GGU GApsAfps C 149 Guide strand 112 (G112) AfGAf GCU UAG CUG AUU GGU GfApsAfps C 150 Guide strand 112 (G112) AfGAf GCfU UAG CUG AUU GGU GfApsAfps C 151 Guide strand 113 (G113) AfGAf GCfU UAG CUG AUU GGUf GfApsAfps C 152 Guide strand 114 (G114) AfGAf GCfU UfAG CUG AUU GGUf GfApsAfps C 153 Guide strand 115 (G115) AfGAf GCfU UfAG CUG AUU GfGUf GfApsAfps C 154 Guide strand 116 (G116) AfGAf GCfU UfAGf CUfG AfUUf GGfU GfApsAfps Cf 155 Passenger strand 117 (P117) Amino C6-GUU CAC 

UC U 156 Passenger strand 118 (P118) Amino C6-GUU CfACf 

UC U 157 Passenger strand 119 (P119) Amino C6-UA

Cf ACfC AU

 UfGAf AAf

 CfAG 

158 f, 2′-fluoro, underlined, 2′-OME, ps, phosphorothioate. Mutated bases are shown in bold and italics.

In view of the many possible embodiments to which the principles of the disclosure may be applied, it should be recognized that the illustrated embodiments are only examples and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims. 

We claim:
 1. A method of treating a subject with cancer, comprising administering to the subject an effective amount of a composition comprising: at least one miR-30-5p mimic or mimetic nucleic acid, wherein the miR-30-5p mimic or mimetic nucleic acid comprises: (a) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position from the ninth 5′ residue to the nineteenth 5′ residue, when that residue is present in the guide strand; or (b) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises 2′-O-methyl-modified nucleotides at every even position residue, 2′-fluoro-modified nucleotides at every odd position residue, or 2′-O-methyl-modified nucleotides at every odd position residue and 2′-fluoro-modified nucleotides at every even position residue; or (c) a guide strand and a passenger strand, wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; or (d) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position from the ninth 5′ residue to the nineteenth 5′ residue, when that residue is present in the guide strand, and wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; or (e) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises 2′-O-methyl-modified nucleotides at every even position residue, 2′-fluoro-modified nucleotides at every odd position residue, or 2′-O-methyl-modified nucleotides at every odd position residue and 2′-fluoro-modified nucleotides at every even position residue, and wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; thereby treating the subject with cancer.
 2. The method of claim 1, wherein the miR-30 mimic or mimetic nucleic acid comprises: any one of SEQ ID NOs: 37-61, a duplex of SEQ ID NOs: 42 and 56, or a duplex of SEQ ID NOs: 42 and 57; any one of SEQ ID NOs: 73-92, a duplex of SEQ ID NOs: 50 and 61, a duplex of SEQ ID NOs: 73 and 61, or a duplex of SEQ ID NOs: 74 and
 61. 3. The method of claim 1, wherein the composition decreases expression of one or more mRNAs listed in Tables 6 to
 14. 4. The method of claim 1, wherein the composition is administered in a liposome composition.
 5. The method of claim 4, wherein the liposome further comprises one or more molecules targeting the liposome to the cancer.
 6. The method of claim 5, wherein the targeting molecule comprises an anti-transferrin receptor antibody or fragment thereof.
 7. The method of claim 1, wherein the cancer comprises a squamous cell carcinoma or wherein the cancer is of epithelial origin and is selected from a group of cervical adenocarcinoma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, and pancreatic carcinoma.
 8. The method of claim 7, wherein the squamous cell carcinoma comprises head and neck squamous cell carcinoma, lung squamous cell carcinoma, or cervical squamous cell carcinoma.
 9. The method of claim 1, further comprising administering one or more additional therapies to the subject.
 10. The method of claim 9, wherein the one or more additional therapies comprise surgery, radiation therapy, and chemotherapy.
 11. A method of treating a subject with cancer, comprising administering to the subject an effective amount of a composition comprising: at least one miR-30-5p nucleic acid, or a miR-30-5p mimic or mimetic nucleic acid wherein the mimic or mimetic nucleic acid comprises: (a) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position from the ninth 5′ residue to the nineteenth 5′ residue, when that residue is present in the guide strand; or (b) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises 2′-O-methyl-modified nucleotides at every even position residue, 2′-fluoro-modified nucleotides at every odd position residue, or 2′-O-methyl-modified nucleotides at every odd position residue and 2′-fluoro-modified nucleotides at every even position residue; or (c) a guide strand and a passenger strand, wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; or (d) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position from the ninth 5′ residue to the nineteenth 5′ residue, when that residue is present in the guide strand, and wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; or (e) a guide strand and a passenger strand, wherein the guide strand is of about 16 to about 27 nucleotides in length and comprises 2′-O-methyl-modified nucleotides at every even position residue, 2′-fluoro-modified nucleotides at every odd position residue, or 2′-O-methyl-modified nucleotides at every odd position residue and 2′-fluoro-modified nucleotides at every even position residue, and wherein the passenger strand is of about 16 to about 27 nucleotides in length and comprises one or more of 2′-O-methyl- and 2′-fluoro-modified nucleotides in any position within the three residues at the 5′ end and the three residues at the 3′ end and a 5′-amino C6 modification; thereby treating the subject with cancer, wherein the cancer comprises a squamous cell carcinoma.
 12. The method of claim 11, wherein the miR-30 mimic or mimetic nucleic acid comprises: any one of SEQ ID NOs: 37-61, a duplex of SEQ ID NOs: 42 and 56, or a duplex of SEQ ID NOs: 42 and 57; any one of SEQ ID NOs: 73-92, a duplex of SEQ ID NOs: 50 and 61, a duplex of SEQ ID NOs: 73 and 61, or a duplex of SEQ ID NOs: 74 and
 61. 13. The method of claim 11, wherein the composition decreases expression of one or more mRNAs listed in Tables 6 to
 14. 14. The method of claim 11, wherein the composition is administered in a liposome composition.
 15. The method of claim 14, wherein the liposome further comprises one or more molecules targeting the liposome to the cancer.
 16. The method of claim 15, wherein the targeting molecule comprises an anti-transferrin receptor antibody or fragment thereof.
 17. The method of claim 11, wherein the cancer further comprises a cancer of epithelial origin and is selected from a group of cervical adenocarcinoma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, and pancreatic carcinoma.
 18. The method of claim 11, wherein the squamous cell carcinoma comprises head and neck squamous cell carcinoma, lung squamous cell carcinoma, or cervical squamous cell carcinoma.
 19. The method of claim 11, further comprising administering one or more additional therapies.
 20. The method of claim 19, wherein the one or more additional therapies comprise surgery, radiation therapy, and chemotherapy. 